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For decades, small molecule modulators of protein function have been vital for advancing both 
understanding of basic biology and therapeutic discovery; however, there are classes of proteins 
for which small molecule discovery has lagged. The majority of the proteins studied in this work 
are transcriptional coactivators, proteins that have great potential as therapeutic targets, yet are 
often classified as “undruggable” because of their atypical structure and mechanism of action. 
Coactivators are highly malleable and their interactions typically occur over broad surfaces areas 
with only moderate affinity, making them difficult to target. Recent advances in protein-protein 
interaction (PPI) inhibitor discovery, exploiting allostery and dynamic substructures within target 
proteins, has led to some success, but selectivity remains a challenge. Selectivity is pivotal for 
candidate probe molecules due to the extensive interaction network of these dynamic hubs. The 
following dissertation addresses the challenges of selectivity and presents small molecules that 
target coactivator interactions. 
A large portion of this work is dedicated to targeting the activator interaction domain (AcID) 
of the coactivator Med25. This domain contains a unique protein fold and is not required for basal 
transcription, but interacts with activators to regulate genes implicated in disease. Previous work 
from the Mapp lab led to identification of promising AcID PPI inhibitors. Here, this work was 
continued with the compound norstictic acid (NA). NA demonstrated high selectivity for AcID 
interactions and, using biochemical techniques in combination with molecular dynamics 
simulations, the mechanism of inhibition was elucidated: covalent modification of lysine residues 
within a dynamic loop leads to both orthosteric and allosteric inhibition of activator binding. NA 
proved useful for studying Med25 in a cellular context, engaging with full length protein from cell 
extracts and inhibiting the interaction between endogenous Med25 and transcriptional 
coactivators. Ultimately NA was used to probe the interaction of Med25 and ETV5, a transcription 
factor linked to metastasis, in a metastatic breast cancer cell line. Dosing with NA was able to 
decrease expression of the Med25•ETV5 regulated gene MMP-2, similarly to what was observed 
with KO of Med25.  
 xix 
Inspired by the iterative screening approach used to discover NA, a new small molecule 
screening method for PPIs was developed, the first method for coactivator targets that directly 
incorporates selectivity at the primary level. A fluorescence polarization assay that simultaneously 
monitors multiple activator•coactivator interactions is presented. This method enables assessment 
of both selectivity and potency of candidate inhibitors in a single screen. A duplex assay containing 
AcID and CBP KIX has been optimized and a pilot screen has been conducted. The pilot screen 
was able to categorize compounds as Med25 AcID-selective, CBP KIX-selective, or dual 
inhibitors. Representative compounds from each subset were evaluated in secondary screening, 
leading to identification of novel inhibitors of both proteins. Ultimately, this approach is applicable 
to other coactivator•activator complexes. 
The final focus of this dissertation is development of a biochemical screen for the human 
serine protease TMPRSS2, which plays a key role in SARS-CoV-2 viral infection. TMPRSS2 is a 
difficult protein target because expression and purification is challenging, thus complicating 
inhibitor screening and in vitro studies. An expression and purification procedure to isolate active 
TMPRSS2 protease domain from E. Coli was developed. Biochemical methods were used to 
characterize the mechanism of known inhibitors, and, through integration with computational 








Selective Modulation of Dynamic Protein Complexes* 
 
1.1 Abstract 
Dynamic proteins perform critical roles in cellular machines, including those that control 
proteostasis, transcription, translation, and signaling. Thus, dynamic proteins are prime candidates 
for chemical probe and drug discovery but difficult targets because they do not conform to classical 
rules of design and screening. Selectivity is pivotal for candidate probe molecules due to the 
extensive interaction network of these dynamic hubs. Recognition that the traditional rules of 
probe discovery are not necessarily applicable to dynamic proteins and their complexes, as well as 
technological advances in screening, have produced remarkable results in the last 2-4 years. 
Particularly notable are the improvements in target selectivity for small molecule modulators of 
dynamic proteins, especially with techniques that increase the discovery likelihood of allosteric 
regulatory mechanisms.  
This chapter focuses on approaches to small molecule screening that appear to be more 
suitable for highly dynamic targets and have the potential to streamline identification of selective 
modulators. First, dynamic proteins are defined and discussed, followed by a review of key 
principles that govern selectivity in binding and function for these proteins and their complexes. 
Additionally, notable recent success stories in small-molecule modulation of these proteins, 
examples that either intentionally or serendipitously mimic natural regulatory mechanisms of 
dynamic proteins, are highlighted.  Finally, we discuss emerging strategies that facilitate the 
discovery of selective chemical modulators of conformationally dynamic proteins. 
 
1.2 Introduction  
Chemical modulation of protein targets with small molecules has been fundamental in the field 
of chemical biology and drug discovery. Chemical modulators, as opposed to genetic or biological, 
                                                
* The majority of this chapter is reproduced from Garlick J.M., Mapp A.K. Selective Modulation of Dynamic 
Protein Complexes. Cell Chemical Biology 2020, 27, (8), 986-997 (DOI: 10.1016/j.chembiol.2020.07.019) 
 2 
can allow for fine-tuned exploration of a specific protein in vitro in order to better understand that 
protein in a broader biological context.1,2 From a drug discovery perspective, small molecule 
chemical probes can be key players in the validation of new molecular targets for a therapeutic 
intervention.3 However, the path to a chemical probe is not well paved for all protein targets. In 
particular, conformationally dynamic proteins and hub proteins (often one in the same), present 
novel challenges to probe discovery that remain unaddressed. Thus, it is not surprising that proteins 
within this class are often deemed “undruggable” and there are few quality chemical probes.4,5 
Thorough analysis of the current research with regards to selective chemical modulation of 
dynamic protein targets is necessary to identify broadly applicable strategies that can facilitate 
probe discovery for these potential drug targets.  
 
1.3 Overview of dynamic proteins and their interactions 
Conformationally dynamic proteins underpin all biological processes, from signaling to gene 
expression. 6–8 These proteins often form short-lived protein-protein interactions (PPIs) that allow 
cellular machines to assemble and disassemble as needed to regulate key pathways and events.9 
Efforts to decipher the principles that govern PPI formation in general have been extensive.10–12 
However, most work has been focused on PPIs between stable, well-defined partners and the 
emergent rules governing assembly, molecular recognition, and modulation of PPIs are not 
generally applicable to dynamic proteins, leading to classification as “undruggable” (Figure 1.1).  
 
Figure 1.1. Comparison of PPI structural order and “druggability.” An example of a stable, well 
defined interaction is that of the BH3 domain of Bax and Bcl2. These proteins are both ordered before 
binding, and interact at a well-defined interface with a high affinity (nM).13 This has allowed for multiple 
inhibitors of clinical relevance to be developed.14,15  The interactions of transcriptional activator Gcn4 with 
the KIX domain of the coactivator Med15 is moderately ordered, but still a challenge for drug discovery 
with current methods. KIX is folded, but part of the larger Med15 protein which contains multiple regions 
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of disorder as well as other PPI interfaces. Gcn4 is disordered until binding, and binding occurs with 
moderate affinity over a larger interface. Both the interaction between CBP/p300 IBiD and ACTR as well 
as Human linker Histone H1 and ProTa are examples extremely challenging PPI targets. IBiD and ACTR 
are both intrinsically disordered and unstructured until binding occurs.16,17 H1 and ProTa are also 
intrinsically disordered, however they continue to remain unstructured even upon interaction, forming an 
extremely fuzzy complex.18 Studies of the PPI interface have revealed that it is so large, barely any specific 
binding site on either protein can be identified.19,20 Figure created using BioRender.  
 
 
While no single definition can be used to identify dynamic proteins, useful metrics for 
successful classification include: 1) the structure and mobility of the protein and/or the individual 
domains; 2) the number of functional roles the protein can fulfill; and 3) the number binding 
interactions the protein can participate in. Dynamic proteins tend to be multifunctional, 
participating in many pathways and performing multiple cellular roles, either through the presence 
of multiple domains or by the formation of dynamic transient complexes that vary in function. The 
functional multiplicity can in part be attributed to the number of binding partners the protein 
engages with, which oftentimes leads to conformational changes either within a single domain or 
domain rearrangement as an entire protein to elicit variable functional effects.  Members of this 
protein class tend to have high flexibility and structural plasticity.21 Malleable structures allow 
them to perform context-dependent regulatory functions and interact with a multitude of binding 
partners. For example, the master coactivator CBP/p300 (Figure 1.2) contains six conformationally 
dynamic domains that interact with hundreds of transcriptional activators, which are linked by 
intrinsically disordered regions, thus increasing the overall flexibility of the protein.22  
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Figure 1.2. The master coactivator CREB binding protein (CBP) analyzed as a 
representative dynamic protein. CBP is highly disordered, with more unstructured and dynamic 
regions than structured domains.22 The protein has high conformational plasticity, as its domains 
are connected by long unstructured linkers. The individual domains within CBP allow it to perform 
multiple functions. For example, CBP has four activator binding domains, KIX, TAZ1, TAZ2, and 
IBiD, that interact with transcriptional activators to regulate gene expression. It also contains a 
histone acetyltransferase domain (HAT) and bromodomain (BD) that it utilizes for perform 
chromatin remodeling functions.23 Each of these individual domains has its own network of 
interactions, summing up to 100s of potential PPIs made by CBP. The KIX domain is shown here 
as an example – it interacts with a suite of 15+ activator proteins, all which can be implicated in a 
variety of diseases.24 Figure created using BioRender.  
 
Dynamic proteins are often observed in higher order cellular machines with a functional need 
to rapidly form and exist only transiently, such as the multiprotein complexes involved in 
chromatin remodeling25 or protein folding.26 Thus, dynamic proteins are often hubs, interacting 
with subunits within a complex as well as other proteins and ligands.27 The composition of a 
dynamic protein complex can dictate enzymatic subunit activity or even change the function of the 
complex. For example, combinatorial assembly of Hsp70 (Figure 1.3) allows the complex to 
switch between a folding system and a degradation complex.28 Transcription is another process 
that relies on dynamic proteins. It is important that individual components of the machinery, such 
as activators, coactivators, general transcription factors, and RNA polymerase, are able to 
assemble efficiently at one promotor and then move on to mediate expression of another gene.29 
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There are extensive reviews regarding the function and composition of these dynamic machines.30–
33 
 
Figure 1.3. The chaperone HSP70 analyzed as a representative dynamic protein. HSP70 contains 
much more secondary structure than CBP. It is comprised of two main domains: the nucleotide binding 
domain (NBD) and substrate binding domain (SBD). These two domains are connected by a small dynamic 
linker.34 Substrate binding can induce domain rearrangement to elicit differental functional effects. HSP70 
itself functions as an ATPase, however it is able to perform many diverse cellular functions by forming 
different multiprotein complexes. For example, Hsp70 in complex with cochaperones Hip and Hop acts as 
a protein folding complex, while Hsp70 in complex with BAG-1 and CHIP functions as a degradation 
complex.28 Finally, Hsp70 complexes also interact with many other proteins. Many regulatory proteins are 
known to be controlled via transient association with Hsp70. Thus, Hsp70 is a potential point of therapeutic 
intervention for conditions such as cancer, autoimmune and neurodegenerative diseases.35 Figure created 
using Biorender.  
 
The qualities that make dynamic proteins and their complexes effective cellular machines also 
make them challenging to target. Due to conformational flexibility, it is often difficult to obtain 
the structural and biophysical data useful for the rational design and/or optimization of chemical 
modulators. The PPIs of dynamic proteins are typically lower affinity, utilize a relatively large 
surface area, and have minimal topology, thus representing a significant challenge for orthosteric 
inhibition.36,37 High throughput screening (HTS) with dynamic protein targets can also be 
challenging due to the difficult expression and isolation of the full-length proteins. Thus, in many 
cases, it is necessary to utilize simplified systems such as isolated domains that may not 
recapitulate the structure, dynamics, and/or activity of the full-length complexes. Finally, selective 
targeting of a particular PPI or specific binding interface is a challenge because dynamic proteins 
typically interact with a multitude of binding partners, which is a challenge that will be focused 
upon in this dissertation.5,38,39 
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Notably, dynamic proteins are often dysregulated in disease and dynamic multiprotein 
complexes often contain specific subunits that are attractive therapeutic targets. For example, the 
tumor suppressor BRCA1, an important target for breast cancer prevention and therapy, associates 
with the Swi/Snf chromatin remodeling complex.40,41 CBP/p300, p53, and other transcription 
factors are all also dynamic proteins that are potential targets for a variety of diseases.42,43 While 
dynamic PPIs do not conform to typical “rules” used for drug discovery, in recent years significant 
achievements have been made when it comes to modulating some of these challenging targets.  
 
1.4 Controlling the interactions and function of dynamic proteins: Lessons from Nature 
As hubs associated with many complex cellular machines, dynamic proteins are precisely 
regulated. These regulatory processes often control the access of binding surface(s) within the 
dynamic protein either directly or indirectly. This can occur through masking of binding surfaces 
via intra- or intermolecular interactions, through induced conformational changes of the protein, 
and, most commonly, combinations of both mechanisms.  
Masking of binding surfaces within dynamic proteins occurs through intra- and intermolecular 
complexes that have a variety of functional outcomes. Masking interactions are common in 
transcriptional activators, where the highly disordered transcriptional activation domain is 
sequestered by a high affinity interaction until needed. Classic and well-studied examples include 
the Gal4•Gal8044,45 and p53•Mdm246 complexes that provide temporal control of the transcription 
factors. Masking of dynamic proteins and/or protein domains is similarly important in many other 
cellular contexts. The scaffolding 14-3-3 protein, for example, regulates the subcellular 
localization and function of Caspase-2 through stabilizing two dynamic regions in individual 
subunits. 14-3-3 masks both the nuclear localization sequence of pro-Caspase2 and the 
dimerization interface, inhibiting pro-Caspase2 activation47 (Figure 1.4). 14-3-3 also regulates 
FOXO transcription factors by masking their nuclear localization sequences.48 In all of these 
examples, the masking interaction provides fine temporal control of the dynamic protein. 
Obstruction of key binding surfaces in a dynamic protein is also associated with spatial control. 
For example, until the unfolded protein response is activated in a cell, the transcription factor ATF6 
is sequestered at the ER membrane. Once the pathway is stimulated, ATF6 is cleaved from the ER 
membrane, enabling its translocation to the nucleus, where its potential binding partners reside.49  
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Figure 1.4. Masking as a mechanism to dictate interaction and function of dynamic proteins. 
Masking particular sequences or binding surfaces on proteins provides control over function, localization, 
and ligand binding. 14-3-3 regulates activity of Caspase-2 by masking its dimerization interface. Without 
14-3-3 bound, Caspase-2 dimerizes and proteolytically cleave other proteins.47 Figure created using 
BioRender. 
 
Emerging data regarding the composition and function of biomolecular condensates indicates 
that masking of dynamic proteins likely plays a crucial role in the compartmentalization that such 
condensates afford.  More recent examples of compartmentalization focus on phase separation, 
which increases the strength and specificity of interactions that otherwise appear promiscuous, 
while still allowing the proteins involved to retain their dynamic nature.50 The transcription factors 
TAZ, OCT4, GCN4, and the estrogen receptor, have been shown to form phase-separated 
condensates with Mediator via its coactivator subunits.51 TAZ has also been observed to form 
nuclear condensates with its DNA binding cofactor TEAD4 as well as the coactivator BRD4.52 In 
all of these cases, unmasked transcriptional activation domains appear necessary for condensate 
formation. However, there is also some evidence to the contrary, suggesting that there is actually 
no correlation between phase separation and regulation of gene expression, rather alternative 
mechanisms such as cooperative chromatin binding and formation of well-defined multivalent 
protein complexes are the driving forces enhancing transcriptional activation.53 
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Posttranslational modifications (PTMs) and distal binding events that influence structure are 
also mechanisms of binding surface control. PTMs occur at many PPI interfaces to promote or 
inhibit binding. For example, phosphorylation of the coactivator p300 at S89 inhibits its interaction 
with peroxisome proliferator-activated receptor γ (PPAR-γ) and retinoic acid receptor (RAR).54 
PTMs can also alter stability, folding, or conformation as a mechanism to regulate dynamic protein 
interactions.55 PTMs, such as ubiquitination, acetylation, phosphorylation, and glycosylation, have 
been observed to be allosteric regulators.56 For example, N-linked glycosylation of interleukin-7 
receptor α allosterically enhances binding to human IL-7 nearly 300-fold.57 In another example, a 
conserved cysteine in the palmitate binding pocket of TEAD proteins undergoes palmitoylation 
that allosterically stabilizes the TEAD-YAP interaction.58 Nature often utilizes a combination of 
PTMs to fine-tune protein function, allowing a single protein to perform diverse cellular roles. A 
recent study of Hsp90, for example, identified a group of conserved PTMs that globally mediates 
dynamics and allosteric communication in the Hsp90 structures.59 
Allosteric crosstalk via inter and intra-molecular interactions can lead to broader 
conformational changes, redistribution of conformers, and alterations in kinetic/thermodynamic 
barriers that also regulate protein interfaces.60,61 For example, the binding of a cognate ligand or 
cofactor can lead to structural changes that influence protein function.62 A classic example of this 
is G-protein coupled receptors (GPCRs). Ligand binding results in a conformational change in the 
GPCR, leading to activation of its associated G protein.63 PPIs can play a similar role. For example, 
the ubiquitinase BAP must interact with another protein, ASXL2, via its nonenzymatic ULD 
domain to allow ubiquitin to bind and be cleaved via its hydrolase (UCH) domain. Thus, allosteric 
changes induced in BAP1 via ASXL2 interaction with the ULD domain are critical for its 
enzymatic function. Biophysical studies suggest that a loop within the UCH domain of BAP1 is 




Figure 1.5. Allostery as a mechanism to regulate dynamic proteins. Allostery, via intra or 
intermolecular interactions, regulates structure and function of proteins. The Polycomb group protein 
ASXL2 interacts with the deubiquitinase BAP1, stabilizing a distal dynamic loop and allowing ubiquitin to 
bind and be hydrolyzed. Without ASXL2 interaction, BAP1 is unable to perform its enzymatic function.64 
Figure created using BioRender.  
 
Allosteric sites often reside within the most flexible regions of a protein. Dynamic proteins and 
the complexes they form rely heavily on unstructured regions such as loops and linkers to influence 
interactions. Loops are often directing components of selectivity and linkers play an important role 
in crosstalk between multidomain proteins. Linkers also can play a key role in multiprotein 
complex assembly and intradomain interactions.65 A flexible glycine rich linker region in NFkB 
allows for the formation of an interaction between the p50 and SWI6/ANK domains to regulate 
intracellular transport.66 Allosteric sites tend to be less conserved between closely related proteins, 
subfamily members, or homologues.67–69 Thus, allosteric inhibitors are a potential route to 
selective targeting of challenging PPIs as well as control over multiprotein, dynamic complexes. 
Perhaps more than any other class of proteins, nature suggests that dynamic proteins are prime 
targets for allosteric regulation. 
 
1.5 Achieving selectivity with chemical probes 
Assessing the native mechanisms that dictate interaction between dynamic proteins and their 
binding partners can illuminate possible routes or methods to target such challenging interactions. 
Natural regulation of dynamic proteins suggests that a possible route to successful modulators of 
their interactions is via allosteric sites. Allosteric modulators have the ability to shift the 
conformational ensemble of proteins to favor the formation of specific complexes or toggle 
active/inactive conformers without the need to directly target the PPI interface. This strategy is 
particularly attractive when it comes to targeting large surface area interactions because orthosteric 
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modulation, particularly with small molecules, is challenging due to the lack of topological 
characteristics that allow for high affinity ligand binding. Allosteric modulation can be achieved -
even for these challenging targets- with small molecules that have more drug-like properties, such 
as lower MW (<600), greater structural rigidity, and hydrophobicity.36 Another advantage that 
comes with targeting allosteric regions of dynamic proteins is that they tend to be less conserved 
between the same protein family and homologous proteins, therefore, suggesting an avenue for 
selective modulation.69–71 Table 1.1 summarizes the allosteric compounds, all published since 
2018, that will be discussed in this section and spotlights their selectivity profiles.  
Table 1.1. Representative allosteric small molecule modulators published in recent years 
 
Allosteric regulators have demonstrated high selectivity for protein targets of many other classes, 
suggesting that similar results are possible with dynamic proteins. For example, the ability to 
selectively target kinases, GPCRS, and bromodomains (BRDs) has improved with our 
understanding of allostery in these systems.72–74 Extensive research on selectivity within kinase 
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families has shown that molecules that bind outside the catalytic domain display high selectivity 
on both a family and subtype level while still functioning as potent inhibitors of enzymatic 
activity.72 Allosteric modulation of GPCRs and the impact on selectivity is also well 
documented.75,76 For example, a group from Merck recently published work on MK-7622 a novel 
positive allosteric modulator of the muscarinic acetylcholine receptor M1 for the treatment of 
Alzheimer’s disease. This compound was highly selective for the M1 receptor, with no potentiation 
or agonism of M2-M4 subtypes in an overexpression model conducted in CHO cells.77 
Furthermore, compounds that are able to distinguish between the most homologous BRDs, 
BRD4/7/9, take advantage of subtle conformational differences in non-conserved regions distal to 
the acetyl lysine binding site.78,79  
Covalent small molecule modulators have been successful at allosterically modifying dynamic 
proteins in a manner that mimics covalent PTMs found in nature. In a study informed by a naturally 
occurring PTM, Bum-Erdene et al. targeted a conserved cysteine residue in TEAD family proteins 
known to undergo palmitoylation in order to stabilize interaction with YAP. Starting with the 
FDA-approved compound flufenamic acid, shown to weakly bind TEAD2 non-covalently near the 
thiol of the conserved cysteine, a chloromethylketone moiety was incorporated to make it a 
covalent inhibitor. This compound, TED-347, allosterically inhibited YAP-TEAD PPIs both in 
vitro and in mammalian cells (Ki = 10 µM). TED-347 also demonstrated selectivity for the TEAD 
family over other related proteins.80 The recently published compound MGH-CP1 covalently 
modifies and inhibits TEAD family proteins similarly to TED-347, but with increased potency. 
MGH-CP1 inhibits autopalmitoylation of TEAD2/4 but does not affect autopalmitoylation of 
ZDHCC family palmitoyl acetyltransferases, suggesting that the compound is selective for TEAD 
proteins.81 The authors also find that TEAD2 adopts similar conformations when bound to 
palmitate or MGH-CP1, further suggesting that mimicking regulation by naturally occurring PTMs 
can be a successful strategy for selectively targeting dynamic proteins.  In another example, 
covalent allosteric inhibitors were designed to selectively target isoforms of protein kinase Akt. 
There are three different isoforms of Akt, each with a unique intracellular location and function; 
thus, highly selective probe compounds are needed to study these proteins. The covalent compound 
borussertib alkylates a cysteine residue located within an interdomain pocket between the PH 
domain and kinase domain of Akt proteins, irreversibly stabilizing the inactive conformation. 
Quambusch et al. observed slight differences around this allosteric pocket between isoforms and 
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designed a library of compounds based on the pyrazinone scaffold of borussertib that could engage 
these subtle sequence changes. With this approach, they were able to identify compounds with 
high selectivity for Akt1 and Akt2.82 This study highlights paths to attain high selectivity and 
potency with allosteric modulators. 
In the previous example, the structural differences exploited by selective small molecules at 
the allosteric site of Akt isoforms mainly occurred within a loop formed by residues 259-273. 
Often the most dynamic components of a protein structure, such as loops, linkers, and flexible 
helices, are effective sites for allosteric modulation and improved selectivity. Recent work 
targeting the dynamic coactivator Mediator subunit Med25 also highlights this point. Henderson 
et al. show that a small molecule, Compound 22, can allosterically regulate binding of 
transcriptional activators to Med25 via covalent modification of a distal cysteine reside. This 
cysteine residue is located adjacent to regions predicted to be highly flexible via structural 
modelling. Additionally, compound 22 influences the flexible substructures within Med25, also 
known to be perturbed by interactions with transcriptional activation domains.83 Thus, by targeting 
dynamic regions of a protein, even large PPI interfaces can be inhibited.  
Another example illustrating that targeting loop modules can improve inhibitor selectivity is 
the discovery of LY3154207, a potent inhibitor of the Human Dopamine receptor, D1, presented 
by Lilly. Classical approaches to targeting D1 receptors have mainly been orthosteric, and 
candidate modulators bind similarly to the natural substrate dopamine.84 However, as D1 and D5 
receptors have high structural similarity, this approach leads to selectivity issues. The authors 
found that LYS3154207 and its analogs bound to a novel binding site in the intracellular loop 2 
(ICL2), allosterically inhibiting binding of dopamine.  Excitingly, this inhibitor was highly 
selective for the D1 receptor over the closely related D5 receptor (>2700-fold). LYS3154207 
demonstrated over 1000-fold selectivity for the D1 receptor when tested against a panel of 40 
additional targets.85 In another recent example targeting a transcription factor, fosfosal, a well-
documented clinical prodrug, was found to inhibit the SH2 domain of STAT5b over its homologue 
STAT5a. Mutational analysis showed this selectivity was dictated by residues within an adjacent 
linker domain rather than within the SH2 domain itself.86 This work illustrates the role that the 
STAT linker region in SH2 domain function, and targeting the linker with small molecules is thus 
an avenue for selective inhibition of STAT PPIs. This same group has identified additional 
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molecules selective for both STAT5a and STAT5b utilizing the same concept (Elumalai et al., 
2015; Gräb et al., 2019).  
 
1.6 Techniques for identification of selective dynamic protein complex modulators  
The examples discussed above demonstrate the power and promise of allosteric regulators for 
modulating dynamic proteins, particularly in terms of selectivity. However, in the majority of these 
examples, the mechanism of action was not the result of the discovery method but rather 
serendipitous. Here we outline emerging techniques and strategies that facilitate screens more 
likely to produce allosteric and ultimately selective inhibitors.  
Inhibitor identification from well-structured proteins allows for easier structural 
characterization and lead compound optimization. Dynamic proteins, by definition alone, provide 
a steep challenge, with many of the common experimental techniques requiring improvements 
before being applied to proteins that are highly mobile and lack definitive structure. Thus, 
advancements in structural biology and biophysics are key when it comes to understanding 
selectivity in dynamic protein complexes. Recent improvements in techniques such as mass 
spectrometry,89 NMR,90 and cryogenic electron microscopy (cryo-EM)91,92 have allowed a high-
resolution view of multiprotein complexes and aided in our understanding of composition as well 
as identification of key PPIs. For example, Khattabi et al. reported a 5.9 Å cryo-EM structure 
mapping the entire mammalian Mediator complex (~4 MDa). This included, for the first time, 
mapping of the exchangeable and conformationally dynamic proteins within the tail region of the 
complex.93 Many of the tail proteins are the primary targets of transcription factors and these 
results provide key insights into how to target this class of proteins successfully. More recently 
and even higher resolution, less than 4 Å, structure of human Mediator bound to the transcriptional 
preinitiation complex has been reported, providing key insights into many key protein 
interactions.94 In another exciting example, time resolved cryoEM was used to obtain a near-
atomic-resolution view of the conformational changes that drive and regulate subunit assembly, 
initiation factor dissociation, and fMet-tRNA positioning during the formation of the 70S 
elongation-competent complex in bacteria.95 This type of approach allows dissection of the 
specific timing and order of conformational changes contributing to the mechanism and regulation 
of large and dynamic multiprotein systems. These examples highlight how improved 
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understanding of dynamic protein complexes using these techniques will allow researchers to 
identify more promising regions to target.  
Increased complexity of an assay system is characteristic of techniques that allow for 
enrichment of selective hits from screening. Grey box screening is a prominent example. In this 
method, multiprotein complexes are reconstituted in vitro and subjected to HTS with the goal of 
identifying compounds that effect biochemical properties, such as enzymatic activity, of the 
complex. This approach has identified specific chemical modulators of dynamic proteins within 
complexes such as Hsp70,96,97 Hsp90,98 and regulators of G-protein signaling.99 This method has 
been thoroughly reviewed in the literature.33,39  Mass spectrometry approaches can also allow for 
multiplexing of protein assays. Collision-induced unfolding (CIU) can distinguish individual 
protein and protein complex ions through their distinct unfolding pathways in the gas phase, 
allowing for analysis of multiprotein and protein-ligand complexes.100 Combining CIU with 
collision induced dissociation (CID) mass spec analysis (Figure 1.6) distinguished ATP 
competitive from allosteric kinase inhibitors of the tyrosine kinase Abl.101 There are also many 
other examples utilizing mass spectrometry to analyze intact multiprotein complexes.89 
Application of these techniques to dynamic targets in high throughput screens can streamline 
identification of selective modulators. Molecules displaying selectivity, as seen with the examples 
in the previous section, often act allosterically, and thus characterization of their effects on target 
proteins will provide insights into allosteric regions to focus on in future studies.  
 
Figure 1.6. Mass spectrometry as a technique for identification of dynamic protein modulators. 
Collision induced unfolding (CIU) can be utilized as a medium-high throughput approach to determine 
binding profiles protein•ligand complexes. If the CIU profile is known for a certain type of protein•ligand 
complexes, for example an allosteric signature or orthosteric signature, a screen can be conducted and 
molecules can be sorted by distinct fingerprints.102 Figure created using BioRender. 
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Classical approaches, such as Forster resonance energy transfer (FRET) and fluorescence 
polarization (FP), can be utilized for HTS of dynamic protein targets where allosteric sites are 
unknown. To assess the selectivity of lead compounds, secondary screening against a selected 
panel of alternate targets is necessary.103 This iterative screening process is highlighted in work 
from Majmudar et al. Hits from a FP-based HTS for inhibitors of CBP KIX were subjected to 
multiple rounds of secondary screening against increasingly relevant PPIs, from non-
transcriptional PPIs to DNA-binding domain•DNA interactions to related coactivator•activator 
interactions. This led to the identification of the CBP KIX selective molecule lobaric acid.104 
Library complexity is also key for screening dynamic proteins. Diversity oriented synthesis and 
DNA Encoded Libraries (DEL) have allowed for the generation of huge billion-trillion compound 
libraries that can be screened in a one pot format.105–107 Other notable library developments with 
the ability to impact dynamic protein probe discovery include diverse natural product focused 
libraries, protein-protein interaction focused libraries, and cheminformatic based design and 
optimization.108–110 
Targeted fragment approaches have been successful in discovering allosteric sites and 
modulators of diverse proteins. Fragment based screening does not rely on identification of a single 
high affinity hit, rather it provides the opportunity to diversify lead scaffolds into directed libraries 
or link together lower affinity binders, acting at unique sites on the target protein, to construct a 
more potent compound.111,112 The Cravatt lab has pioneered cell-based approaches to fragment 
screening, providing the advantage of being able to study a protein of interest in its native 
environment.113,114 This would be particularly useful for dynamic proteins that are challenging to 
work with in vitro. Tethering is a site-directed fragment technique that utilizes a disulfide moiety 
within each fragment to facilitate localization to protein binding sites via covalent bond formation 
with adjacent cysteine residues. Tethering has enabled the identification of allosteric modulators 
for many dynamic protein targets, from enzymes such as PDK1 and Ras to coactivators such as 
CBP and Med25.83,115–117 In a recent example targeting the scaffolding protein 14-3-3 PPI, 
tethering was used to identify orthosteric stabilizers of the 14-3-3•ERa complex. These stabilizers 
were able to enhance the interaction by up to 40-fold while demonstrating selectivity for ERa over 
other 14-3-3 interacting proteins.118 
Screening methods that provide mechanistic insight into small molecule binding have proven 
highly useful for conformationally dynamic proteins, providing the ability to select for molecules 
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that influence desired regions of the target. NMR-based methods, including Protein Observed 
Fluorine (PrOF) and 1H15N HSQC can provide information on both binding site location and 
impact on protein dynamics and structure.119–121 Thus, one can select for compounds during 
screening that show specific alterations in structure and/or dynamics. Because throughput in NMR 
based screening methods can be a limitation, this approach is extremely powerful when coupled 
with computational screening methods. Recent work by Gupta et al. combined computational and 
NMR screening approaches with the goal of targeting known allosteric sites on mutant and 
wildtype KRAS. Gupta et al. started from a virtual library of 76 million compounds and identified 
nine compounds that lead to 1H15N HSQC chemical shift perturbations of residues near the 
functionally responsive switch loop. Although the authors do not analyze the functional effect of 
their lead compound, E22, they find that it binds nearly 100-fold tighter to GNP-bound Ras 
compared to GDP bound Ras and hypothesize that the molecule may affect GEF-mediated 
GDP/GTP exchange, similar to other indole compounds that target KRAS.122 Combinations of 
computational and experimental approaches, as this example illustrates, have and will continue to 
be important for dynamic protein probe discovery. Notably, computational studies of allostery, 
with a focus on identification of allosteric sites and discovery of potent allosteric inhibitors, have 
been extensively performed in recent years with many successes.123–125 
Thermal stability assays, such as differential scanning fluorimetry (DSF), are powerful 
screening options for dynamic protein targets.126–128 While DSF is a technique dating back to 1991, 
it recently has been used to screen some challenging targets such as STAT proteins (STAT1, 
STAT3, and STAT5),129,130, nuclear receptors,131 and chaperone proteins.132,133 Not only is this 
method simple, inexpensive, and amenable to HTS, it provides insights into the effect of a 
compound on the thermal stability of the target protein, making it possible to select for compounds 
with the desired stabilizing or destabilizing effect (Figure 1.7). Thermal stability assays have the 
added benefit of not requiring knowledge of binding partners. Recently, groups have been working 
to improve understanding of the theoretical underpinnings of DSF and further interrogate the 
potential information that can be obtained from DSF melting curves.134,135 This work has made it 
clear that more than just a melting temperature (Tm) emerges from these experiments. For 
example, the shape of the melt curve can provide some insight into ligand binding even if Tm 
shifts are not observed. Additionally, innovations to the technique suggest the ability to multiplex. 
DSF-GFP, a technique pioneered in 2012, involves labelling the target protein of interest with GFP 
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and using the change in GFP fluorescence over a temperature gradient as a readout rather than 
solvatochromic dye.136 This approach allows for the selective measurement of target protein Tm 
in the presence of other proteins.  
 
Figure 1.7. Differential scanning fluorimetry (DSF) as a technique for identification of dynamic 
protein modulators. DSF is a high throughput method for screening proteins. This method monitors 
protein unfolding as a function of temperature. As the protein unfolds, a solvatochromatic dye binds and 
fluorescence increases.  The melting temperature (Tm) of the protein is interpreted as the inflection point of 
the resulting melt curve.128 While allosteric effects of small molecules cannot be determined using this 
method, their effect on protein stability can be determined. In a HTS, molecules can be sorted by their 
ability to increase or decrease protein Tm. Figure created using BioRender.  
 
The cellular thermal shift assay (CETSA) is another technique that interrogates changes in 
protein stability and can also be extremely useful for screening dynamic proteins.137 A benefit of 
this approach is the ability to screen the protein in a more native environment, such as in cell 
lysates. Recent advances to CETSA techniques have allowed for use in HTS. To date, there have 
been multiple HT-CETSA approaches published, all focusing on altering protein detection 
methods to allow for the classic CETSA western blot readout to be adapted to 384 or 1536 well 
format.138 For example, Shaw et al. applied HT-CETSA via AlphaScreen technology to conduct a 
screen for modulators of BRAF and PARP1 through screening 896 and 6288 compounds, 
respectively.139 In a recent success story with a challenging target, a small molecule, NPD10084, 
was found to thermally destabilize PKM2, which can function as both a kinase and a transcriptional 
coactivator. This interaction with PKM2 leads to inhibition of PPIs with STAT3 and beta-catenin 
as well as altered expression of PKM2 regulated genes. Notably, the authors outlined a novel assay, 
which they termed 2D gel electrophoresis-based proteome-wide CETSA, or 2DE-CETSA, that 
allowed for proteome wide screening for small molecule target identification.140 
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1.7 Emergent technologies and alternative approaches to selectivity 
As can be seen from the outlined examples, it is a particularly exciting time for those who 
study and/or target dynamic proteins. Discovery methods that are tailored for the distinct 
biophysical characteristics of dynamic proteins, as well as those that more closely recapitulate the 
native context, have been highly successful. In addition to these screening techniques, thoroughly 
interrogating the selectivity of lead compounds on a global scale will be integral in deriving 
effective biological probes of dynamic protein targets. Techniques such as thermal proteome 
profiling, activity based protein profiling and Drug Affinity Responsive Target Stability (DARTS) 
allow determination of potential off target effects for a chemical probe in a cellular context.141–143 
The resulting generation of more selective and potent small molecule modulators now enable the 
chemical genetic dissection of critical cellular machines. For example, studies with full length 
p300 and other various multidomain constructs show BRD inhibitors can affect HAT activity, 
suggesting interdomain crosstalk does occur.144,145 Interdomain crosstalk has been observed in 
other dynamic systems, particularly in nuclear receptors such as the thyroid hormone receptor and 
ERa, where the DNA binding via the DNA binding domain (DBD) can be enhanced by changes 
in the ligand binding domain (LBD).146 Further exciting studies focusing on the global effects of 
selective dynamic protein modulators on full length proteins or intact protein complexes are sure 
to come in the future and improve our understanding of interdomain communication in these 
systems.  
Another interesting avenue for dynamic proteins that has yet to be fully explored is 
proteolysis targeting chimeras (PROTACs). PROTACs could be particularly advantageous in the 
field of dynamic protein complexes because the starting scaffold does not need to functionally 
affect any interactions, as it can be challenging to find modulators with low IC50s or EC50s for 
certain targets. Additionally, even non-specific inhibitors can be starting points for PROTACS. 
Recent work has shown specificity can be engineered into a PROTAC starting from a multi-target 
warhead by exploiting differences in the interface between the protein of interest and the E3 
ligase.147,148 It is possible that through PROTACS, some of the challenges that come with 
identifying selective modulators can be averted. With regards to dynamic protein complexes, one 
could imagine using a PROTAC to completely alter complex composition or skew complexes to 
favor one exchangeable subunit over others. These and other novel selective mechanisms to 
chemically target dynamic proteins are sure to be on the horizon. 
 19 
1.8 Dissertation Summary 
The overall goal of the research presented in this thesis is to identify novel probes of 
challenging dynamic protein targets. Towards this goal, we begin in Chapter 2 by describing the 
discovery and validation of norstictic acid as the first chemical probe for Med25, a dynamic 
coactivator and subunit of the transcriptional Mediator complex. In Chapter 3, we build off of the 
screening approach used in Chapter 2 and present the development of a multiplex fluorescence 
polarization-based screening method that allows for selectivity to be assessed at the primary 
screening level. This method is then used to uncover additional novel chemical modulators of both 
Med25 and the KIX domain of CBP, another dynamic coactivator protein. In Chapter 4, we apply 
differential scanning fluorimetry to analyze the effects of ligand interactions, both small molecules 
and native peptides, on coactivator thermal stability. We hypothesize that this system will be 
uniquely suited to identify allosteric modulators of dynamic protein complexes. Finally, in Chapter 
5 we develop a biochemical screen for the human serine protease TMPRSS2, which plays a key 
role in SARS-CoV-2 viral infection. TMPRSS2 is a challenging target because expression and 
purification is challenging, as is extensively noted in the literature. We present an expression and 
purification procedure in E. coli to isolate active TMPRSS2 protease domain. Additionally, while 
inhibitors of TMPRSS2 exist, there are no selective chemical probes and thus its broader biological 
roles remain poorly characterized. By integration of biochemical and computational 
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Targeting the Dynamic Coactivator Med25 with a Selective Small Molecule Probe† 
 
2.1 Abstract 
Here we report the results of a high throughput screen that identified the natural product 
norstictic acid as a highly selective, potent (low µM) allosteric inhibitor of Med25 AcID activator 
interactions. Further, we elucidated a unique mechanism of action for the small molecule, showing 
that it preferentially modifies lysine residues within a dynamic loop on one face of the protein 
affecting binding at both faces. Structural models in combination with biochemical data indicate 
that the molecule likely functions via an orthosteric/allosteric mechanism. Norstictic acid also 
engages with cellular Med25, and treatment of mammalian cells with norstictic acid downregulates 
genes known to be regulated by Med25, recapitulating a Med25 KO phenotype. Taken together, 
the discovery of norstictic acid confirms that functionally modulating AcID with small molecules 
by targeting dynamic loop regions of the protein provides selective allosteric modulators that can 
affect cellular function of Med25.  
 
2.2 Introduction 
Transcriptional coactivators play an integral role in the regulation of gene expression, 
serving as hub proteins for transcriptional machinery assembly through interactions with 
transcriptional activators.1–9  Coactivators use conformationally plastic activator binding domains 
 
† The majority of this chapter is reproduced from Garlick J.M., Sturlis S.M., Bruno P.A., Yates J.A., Peiffer A.L, Goo L., Bao 
L.W., De Salle S.N., Tamayo-Castillo G., Brooks C.L. III, Merajver S.D., Mapp A.K. Norstictic acid is a selective allosteric 
transcriptional regulator (DOI: 10.1101/2021.03.26.437253). The research described in this chapter was a collaborative effort. Dr. 
Steve Sturlis and Dr. Paul Bruno conceived and developed the HTS, including Med25 expression, ran the HTS and validated the 
initial hits as covalent binders, identifying the orthophenolic aldehyde as key functional group for binding and function. Dr. Steve 
Sturlis made, characterized, and tested many of the Lys to Arg mutants. He was also consulted on the design and implementation 
of experiments. Julie Garlick carried out full selectivity assessment of NA; expanded Lys to Arg mutant study to exclude all possible 
Lys as sites of modification and tested mutational effects on ETV5 binding and inhibition by NA; developed and implemented 
CETSA and co-IP studies in HeLa lysates; developed and implemented studies of NA in VARI068 WT and KO cell lines. Amanda 
Peiffer conducted MD simulations to construct structural model of NA binding and function. Yeujin Liu carried out synergy 
experiments of NA in MB-MDA-231 cells with lapatinib. Dr. Joel Yates and Laura Goo generated Med25 CRISPR KO cell lines. 
Sam De Salle generated K422R mutant. 
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(ABDs) to interact with a variety of DNA-bound transcriptional activators. This interaction leads 
to recruitment of additional proteins, such as chromatin remodeling enzymes and general 
transcription factors, and ultimately RNA Pol II (Figure 2.1). Alterations in the network of 
coactivator-activator protein-protein interactions (PPIs) contribute to the onset and perpetuation of 
numerous diseases, leading to significant interest in synthetic probes for mechanistic studies and 
therapeutic applications.10–16 This is especially true for coactivators whose function is highly 
context-dependent, required only for a subset of genes or only at particular times or locations in 
the life cycle of an organism.17 Thus, synthetic modulation of such coactivators would also be 
context-dependent, providing an advantageous layer of specificity. The coactivator Med25 falls 
into this category; homozygous deletion of Med25, for example, is nonlethal, impacting 
approximately 900 genes.18 Med25 is a subunit of the Mediator complex. Mediator acts as a 
functional bridge between DNA bound transcriptional factors and RNA Polymerase II. The ABD 
of coactivators, such as Med25, within the tail of the complex, interact directly with the 
transcriptional activation domain (TAD) of activator proteins. As a substoichiometric component 
of the Mediator complex, it is not required for basal transcription. Several lines of evidence 
indicate that dysregulation of the PPI network of Med25 and the ETV/PEA3 transcriptional 
activators contributes to oncogenesis as well as metastatic phenotypes in certain breast and prostate 
cancers, heightening a need for Med25-selective inhibitors.19–22 
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Figure 2.1. Transcriptional activation is mediated by coactivator proteins such as those found in the 
tail of the Mediator complex. A highly regulated network of protein-protein interactions (PPIs) occurs 
at gene promotors between transcription factors and the transcriptional machinery. Specifically, 
interaction between the transcriptional activation domain (TAD) of a DNA bound activators and 
coactivators are fundamental in the process of activated gene expression. The Mediator Complex 
contains multiple coactivator proteins and acts as a functional bridge between transcriptional activators and 
the additional machinery, such as chromatin remodeling enzymes and general transcription factors, that 
ultimately led to recruitment of the RNA Polymerase II preinitiation complex. Figure created using 
BioRender. 
 
The domain of Med25 that interacts with activators is the Activator-Interacting Domain 
(AcID).23–25 This domain contains a 7-stranded beta barrel core flanked with dynamic loops and 
three alpha helices (Figure 2.2). Like other ABDs within coactivators, AcID does not contain 
defined binding pockets but rather uses highly dynamic, largely hydrophobic interfaces to interact 
with transcription factors to regulate gene expression.11 Specifically, Med25 contains two distinct 
binding faces it uses to interact with different TADs (Figure 2.2).19,25,26 This interaction has been 
well studied particularly within the context of AcID•VP16 and AcID•ETV5.19,23,27–29 These 
qualities make AcID, as well as other coactivators, challenging to target selectively. Recent efforts 
by our lab and others have been elucidating successful approaches to target these classically 
“undruggable” proteins20,30–33. The Mapp lab recently reported that dynamic substructures, such 
as helices and loops, within activator binding domains are very important for formation of 
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activator-coactivator complexes and are the driving component of allosteric networks connecting 
binding sites.20 For example, Tethering of a small molecule to a cysteine residue within a loop at 
the base of Med25 AcID, visible in Figure 2.2 (right) on the H1 face highlighted in blue, enhances 
complex formation with transcriptional activators.20 In another unrelated example, a class of small 
molecule inhibitors of the SH2 domain of STAT transcription factors were found to bind at an 
adjacent dynamic linker rather than within the SH2 domain itself.32 The differences in this linker 
region between different STAT proteins, even closely related homologs such as STAT5b and 
STAT5a, could be exploited to influence inhibitor selectivity.34 Thus, we hypothesize that 
targeting the dynamic substructures in coactivators proteins can provide an effective strategy for 
modulation of coactivator protein-protein interactions. Further, because such substructures are 
more likely to access conformations with topologically unique binding surfaces, one might 
anticipate that small-molecule modulators of such sites would exhibit enhanced selectivity 
compared to purely orthosteric ligands.12,35–39 
  
Figure 2.2. Coactivator and hub protein Med25 is a subunit of the Mediator coactivator complex. 
Left: The Mediator complex is comprised of ~30 proteins classified into multiple sections. The variable tail 
portion is known to contain transcriptional coactivators, including Med25. Med25 is made up of two main 
structured domains, the VWA domain which anchors the protein to Mediator, and the Activator-Interacting 
Domain (AcID). Right: AcID forms a PPI network with transcriptional activators using two binding 
surfaces (H1, H2) and in doing so regulates key cellular processes often associated with disease. PDB 2XNF 
used to generate figure. Figure created using BioRender. 
 
This chapter focuses on the identification of norstictic acid as a potent and selective Med25 
inhibitor. The mechanism of action of NA is elucidated, binding and covalent modification of a 
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flexible loop, further suggesting that targeting dynamic substructures leads to allosteric, selective, 
protein modulation.  Finally, NA is validated in as a useful probe of Med25 biological function.  
 
2.3 Results & Discussion 
High throughput screening of Med25 leads to identification of covalent depsidone inhibitors 
To identify inhibitors of Med25 AcID, we utilized a high-throughput fluorescence 
polarization (FP) assay interrogating a complex of AcID and fluorescein-tagged VP16(465-490) 
(Figure 2.3). As previously reported, this VP16 sequence contains the minimal binding sequence 
for interaction with AcID (KD = 0.60 ± 0.06 μM) and interacts with the H1 and H2 binding 
surfaces.20,25 Several commercially available libraries (MS Spectrum 2000, Focused Collections, 
and BioFocus NCC libraries) with a combined total of 4046 compounds were screened using this 
format (Figure 2.3, see Methods for additional details). The primary screening campaign had an 
average Z’ score of 0.87, indicating an excellent assay, and a 1.6% hit rate. Following the primary 
screen, hits were filtered and compounds with known chemically reactive properties as well as 
those compounds that demonstrated native fluorescence greater than ten percent of the 
fluorescence produced by the tracer were removed. Compounds with activity greater than 3 
standard deviations relative to the negative control (DMSO) were subjected to dose-response 
assessment with freshly purchased material, as well as secondary selectivity assays. From this, the 
natural lichen products norstictic acid (NA) and psoromic acid (PA) emerged as the best inhibitors, 
with apparent IC50 values of 2.3 ± 0.1 μM and 3.9 ± 0.3 μM, respectively (Figure 2.3).   
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Figure 2.3. Norstictic acid is discovered as the result of a high throughput screen for inhibitors of the 
AcID•VP16(465-490) PPI. Top: Schematic of HTS fluorescence polarization based screen to identify 
inhibitors of the Med25 AcID PPI network. Bottom left: Campaign view of HTS screening results. 65 hits 
were identified from a 2688 compound screen. Bottom right: after confirmatory screening, two compounds 
emerged as preliminary hits, with low micromolar IC50 values, norstictic acid and psoromic acid. Data 
obtained by Dr. Steven Sturlis. Figure made using BioRender. 
 
Both NA and PA are natural products in the depsidone family containing an orthophenolic 
aldehyde moiety. The presence of a reactive aldehyde functionality suggested a potential covalent 
mechanism of action via imine formation with lysine side chains. Consistent with this hypothesis, 
analysis of NA-treated Med25 AcID using mass spectrometry showed the presence of 
concentration-dependent covalent adduct(s) (Figure 2.4). Treatment with the reducing agent 
NaBH4 led to incorporation of H2 into the adduct, indicating initial formation of a Schiff base 
followed by reduction. Data from a time-course experiment revealed that at 5 minutes, significant 
inhibition is observed, with full activity after 30 minutes (Figure 2.4).  
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Figure 2.4. Norstictic acid is identified as a covalent inhibitor. A) Schematic of covalent bond formation 
with AcID via reaction of the orthophenolic aldehyde of NA with a primary amine group from a lysine 
residue, resulting in an imine. B) Concentration dependent NA adduct formation is observed with AcID (20 
µM) using mass spectrometry. Data was obtained after incubation of Med25 with NA for 30 minutes. X-
axis labels represent the equivalents of NA used compared to protein concentration. Experiments were 
conducted in technical triplicate and the average value is shown with error bars representing the standard 
deviation of the mean. Experiment conducted with Dr. Steven Sturlis. C) The apparent IC50 of norstictic 
acid was determined for inhibition of the VP16(465-490)•AcID interaction at various time points to 
determine how quickly inhibition was achieved. Experiment conducted by Dr. Steven Sturlis.  
 
An examination of related structures indicates that the orthophenolic aldehyde is necessary, but 
not sufficient for either interaction with Med25 AcID or inhibitory activity. Stictic acid, in which 
the phenol is masked as a methyl ether, inhibits Med25 interactions poorly (IC50 > 250 μM). 
Additionally, salicylaldehyde efficiently labels Med25 AcID, but does not impact binding of 
activators (Figure 2.5). These data suggest that noncovalent interactions play essential roles in the 
inhibitor function of NA. 
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Figure 2.5. Salicylaldehyde covalently modifies, but does not inhibit, Med25 AcID. Mass spectrometry 
shows dosing with 50X salicylaldehyde leads to formation of +104 Med25 adduct (left). Salicylaldehyde 
does not inhibit the Med25•VP16(465-490) interaction using fluorescence polarization (right). Curves 
represent the mean values of three independent experiments with vertical error bars representing the 
standard deviation of the fraction of tracer bound at the indicated AcID concentration. Data obtained by Dr. 
Steven Sturlis.  
 
Evaluating the in vitro selectivity of norstictic acid  
ABDs in coactivators are typically hydrophobic and conformationally dynamic to allow 
for interaction with many distinct transcriptional activation domains.9,28,40–42 The implication for 
inhibitor discovery is that molecules discovered as inhibitors of one ABD will most often interact 
with other off target ABDs. It has been suggested that small molecules that take advantage of 
dynamic binding interfaces within coactivator proteins could allosterically modulate the target 
protein while maintain selectivity.20,30,43 We have also found that peptides engaging the beta-barrel 
surface are not very specific for one or the other faces of Med25 (or other coactivators), while 
interaction with loops and helices confers more selectivity– for example, VP16(465-490) interacts 
with both binding surfaces and engages largely with the beta-barrel surfaces. In contrast, the 
ETV/PEA3 activators form specific contacts with dynamic loops flanking the H1 beta-barrel 
surface and are highly selective for that binding site.20 We hypothesized that interaction with the 
dynamic substructures within AcID would confer additional inhibitor selectivity. Screening, via 
competition FP, of a small panel of coactivators comprised of various common motifs showed that 
NA is indeed selective for Med25 AcID (Figure 2.6). The demonstrated selectivity of NA is 
particularly significant because selective targeting of coactivator proteins has remained a challenge 
to date. Notably, NA inhibits Med25 PPIs at both binding surfaces, including those formed with 
transcriptional activators ETV5 (H1 binding surface) and ATF6α (H2 binding surface). 
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Figure 2.6. Norstictic acid is selective for AcID PPIs. NA was tested against a panel of transcriptional 
PPIs using competition FP. Left: Graphical view. Right: Apparent IC50 values obtained after a 30 minute 
incubation of compound with protein. Experiments were performed in technical triplicate, And IC50 values 
are the average with error shows as the standard deviation of the mean.  
 
Selectivity with regards to lysine modification can also be observed with NA. For example, 
CBP KIX and AcID contain a similar number of lysine residues, 8 and 11 respectively; however 
the data clearly demonstrates that NA covalently modifies AcID at a much faster rate (Figure 2.7). 
After incubation for 30 minutes using 1 equivalent NA, 75% of AcID has been covalently modified 
whereas for KIX less than 5% has been modified. Even at 4 equivalents NA after 30 minutes only 
slightly more than 50% of KIX protein is labelled. Similar behavior is observed when dosing a 
mixture of both proteins with NA. Even when there is 4-fold excess KIX protein compared to 
AcID, upon adding NA and incubating for 30 minutes almost exclusively AcID protein is 
covalently modified. Thus, both binding and proper positioning of the lysine residue is key for 


































































Figure 2.7. Comparison of norstictic acid reactivity between AcID and KIX. KIX and Med25 were 
separately dosed with varying concentrations of norstictic acid (0.5-4 equivalents) and subjected to LC-MS 
analysis. The percent of labelled species (any +NA modification) was calculated and plotted. This 
experiment was conducted in technical triplicate and the average value is show with error bars representing 
the standard deviation of the mean.  (top). A mixture of Med25 and KIX was dosed with NA and the percent 
of labelled species (any +NA modification) observed for each protein was calculated. This experiment was 
conducted in technical duplicate and the average value is show with error bars representing the standard 
deviation of the mean (bottom).  
 
Elucidation of NA binding site and inhibitory mechanism   
Several lines of evidence suggested that the engagement site of NA is a lysine-rich dynamic 
loop that borders the H2 binding site.  There are 11 lysine residues within Med25 AcID, 6 of which 
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By mutating these residues to arginine, we are able to remove the ability of NA to covalently 
modify at that particular site while maintaining the same chemical environment (i.e. keeping the 
positive charge). As expected, the lysine to arginine mutations had minimal effects on binding 
with the cognate transcriptional activator binding partners (Figure 2.8).  
 
Figure 2.8. Mutation of dynamic loop lysine residues to arginine has minimal impact on ETV5 
binding. A) There are two dynamic loops containing 3 lysine residues each located on AcID. The residues 
are shown in light blue. PDB: 2XNF B) Direct binding fluorescence polarization experiments with FITC 
labelled ETV5 and AcID show that mutation of residue(s) to arginine has minimal effect on KD. 
Experiments were conducted in technical triplicate with the average shown and error represented as the 
standard deviation of the mean.  
 
Similarly, mutations within the H1 binding surface had minimal impact on both NA binding, 
determined by mass spectrometric analysis, and inhibition in an in vitro binding assay. In contrast, 
mutation of K519, located within a lysine-rich dynamic loop that flanks the H2 face, had a 
profound effect on NA binding and inhibition (Figure 2.9). Mutation of the additional lysine 
residues within the H2 loop to arginine, further impacts NA function, suggesting K518 and K520 
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may also be important. Thus, we can conclude that the molecule inhibits via binding at the H2 
lysine loop, with K519 the primary site of modification. 
 
Figure 2.9. Mutation of lysine residues in H2 loop to arginine impacts NA binding and inhibition. A) 
Mass spec data obtained after incubation of AcID protein with NA for 30 minutes. From the deconvoluted 
data, the fold change in mass abundance of each potential species (parent, +1 NA, +2 NA) was calculated 
for the mutant compared to the WT. Data obtained in technical duplicate with error bars representing the 
standard deviation of the mean. B) Competition FP experiments with NA against FITC labelled ETV5 and 
AcID. Mutants highlighted in gray show a significant decrease in NA inhibitory ability (increase in IC50). 
C) The structure of AcID, summarizing importance of each lysine residue analyzed for NA binding and 
inhibition determined from mass spec and competition FP experiments. 
 
To develop a structural model of NA binding and function, molecular dynamics 
simulations of the covalent NA-Med25 AcID complex in which NA is covalently linked to K519 
were carried out, and the results compared to the case of unbound Med25 AcID. As illustrated in 
Figure 2.10, minimal restructuring in the lysine loop adjacent to the H2 binding interface is 
observed. However, helix a1 shows significant conformational changes, resulting in partial 
unfolding. More surprising, the only detectable dynamical changes in NA binding occur on the H1 
face, with residues in the two loops on that face showing up to 50% reduction in root-mean-square 
fluctuations (RMSF).  
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Figure 2.10. Molecular dynamics of AcID with NA modification at K519. Centroid structure of the most 
populated cluster from molecular dynamics simulations, where norstictic acid binds to the H2 face of 
Med25 and covalently links to K519. (Right) The residues that showed the greatest reduction in fluctuations 
(RMSF) upon activator binding all occur on dynamic substructures on the H1 face. Experiments conducted 
by Amanda Peiffer. 
 
Taken together, the data indicate that NA serves as both an orthosteric inhibitor of H2-binding 
transcription factors (e.g. ATF6α) and an allosteric inhibitor of H1 binding transcriptional 
activators (e.g. ETV5). 
 
Engagement of norstictic acid with Med25 in cells 
Next, the engagement of full-length Med25 by NA was tested, along with the resulting 
impact of PPI formation and function in mammalian cells. Thermal shift assays using freshly 
prepared HeLa nuclear extracts demonstrate that NA stabilizes endogenous Med25 protein, 
indicating engagement with the AcID motif in the context of full-length protein (Figure 2.11). 
Quantification of band density using ImageJ software shows that Med25 is generally stabilized at 
all tested concentrations, with only slight thermal denaturation occurring at the highest temperature 
in the 25 µM condition. To determine an approximate DTm of Med25 + NA from thermal shift 
assays, extended temperature points were tested (Figure 2.11). Ultimately, it was calculated that 
an approximate increase in Tm of 13.3°C occurs from NA binding to endogenous Med25. 
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Figure 2.11. Thermal shift assays profiling NA engagement with endogenous Med25. A) Western blot 
for anti-Med25 in HeLa nuclear extracts heated at various temperature either with or without dosing with 
NA. B) Quantification of relative band densities from Western blot. NA dosed conditions are the average 
of biological duplicate. DMSO data is the average of six biological replicates. Error bars represent the 
standard deviation of the mean. C) NA stabilization of endogenous Med25 tested at extended temperatures 
(up to 86°C). Band density was then plotted against temperature to determine Tm. 
 
The ability of NA to block PPIs formed between endogenous Med25 and cognate activators was 
then assessed.  ETV5 is a member of the ETV/PEA3 subfamily of transcriptional activators, 
comprised of ETV5, ETV1, and ETV4. This transcriptional activator trio has nearly identical 
domains that utilize a PPI with the H1 surface of Med25 for function, and the PPIs are dysregulated 
in cancer through overexpression of one or both of the binding partners.19,44,45 As shown in Figure 
2.12, NA treatment of HeLa cells blocks formation of the Med25-ETV complex, consistent with 
the in vitro binding data of Figure 2D.  
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Figure 2.12. Co-immunoprecipitation of ETV5 with Med25 is inhibited by NA in HeLA cells. Western 
blot against ETV5 in HeLA cells dosed with 25 µM NA or DMSO (right). Relative band density of anti-
ETV5 calculated using ImageJ, normalized to anti-Med25 signal. Values represent the average of biological 
triplicate experiments (right).  
 
The Med25•ETV/PEA3 PPIs regulate proliferation, invasion, and migration pathways and in at 
least a subset of cancers, as demonstrated as part of a tyrosine kinase receptor-driven RAS-RAF-
MEK-MAPK circuit.46,47 Thus, if NA blocks Med25•ETV/PEA3 PPIs, positive synergy with a 
Her2 inhibitor would be anticipated in some systems. To test this, the combination of NA and 
lapatinib was tested for synergy by the isobologram method (Figure 2.13) in MDA-MB-231 breast 
cancer cells, an established model.19 As can be seen, strong synergy was observed, consistent with 
NA engagement of Med25 blocking PPIs formed with ETV/PEA3 activators.  
                                            
Figure 2.13. Isobologram showing synergy between NA and Lapatinib.  NA shows positive synergy 
with an on-pathway kinase inhibitor, lapatinib. IC50 values of fixed dose ratios of NA and lapatinib were 
measured in MDA-MB-231 cells after 2 days of dosing and plotted on an isobologram. Experiment 
conducted by Yejun Liu.  
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This model was further tested in the patient-derived early passage triple negative breast cancer cell 
line VARI068 with robust EGFR expression.48,49 VARI068 cells exhibit approximately 2-fold 
upregulation of Med25 relative to normal-like non-tumorigenic MCF10A cells. Treatment of 
VARI068 cells with NA blocks the Med25•ETV5 complex (Figure 2.14). To further explore the 
effects of Med25 regulation on cancer, CRISPR-Cas9-mediated knockout of Med25 in VARI068 
cells leads to downregulation of Med25•ETV/PEA3-regulated MMP2 (~5 fold) and NA treatment 
leads to substantial down-regulation of MMP2 relative to vehicle (Figure 2.14). Taken together, 
these data are consistent with a mechanism in which NA engages Med25 in cells and alters its PPI 
network with downstream effects on tumor phenotype.  
 
Figure 2.14. NA inhibits Med25 ETV5 interaction in triple negative breast cancer cell line VARI068. 
Co-immunoprecipitation of ETV5 with Med25 dosed with either NA or DMSO (top left). Relative band 
density of anti-ETV5 calculated using ImageJ, normalized to anti-Med25 signal (top right). Analysis of 
MMP2 transcript levels by qPCR indicates that NA treatment decreases MMP2 levels to that of a KO 
variant of the cell line. MMP2 transcript levels are normalized to the reference gene RPL19.  Results shown 
are the average of technical triplicate experiments, conducted in biological duplicate with error bars 
representing the standard deviation of the mean (bottom). 
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In vitro inhibition data indicated that NA would also be a good inhibitor of Med25 
interaction with ATF6. Thus, cellular experiments looking at NA’s ability to regulate 
Med25•ATF6 were also conducted. Importantly, for the Med25•ATF6 to occur in cells, the 
unfolded protein response must be activated. This is accomplished by treating cells with the 
compound thapsigargin to induce ER stress and activate this pathway prior to dosing with inhibitor 
(in this case NA).26,50 Co-immunoprecipitation experiments looking at Med25•ATF6 after 
treatment with thapsigargin and dosing with NA or DMSO revealed that NA inhibited 
Med25•ATF6 (Figure 2.15). To further explore the use of NA as a Med25•ATF6 probe, qPCR 
experiments looking at NA’s effects on HSPA5 expression were conducted. HSPA5 expression 
has been shown to be regulated by the Med25•ATF6 interaction.26  In VARI068 cells, Med25 KO 
decreases stimulated HSPA5 expression by about 3.75-fold. Dosing WT cells with NA led to a 
slightly less than 2-fold decrease in HSPA5 expression (Figure 2.15). Thapsigargin induces the 
unfolded protein response and expression of HSPA5 through multiple pathways,51,52 which could 
explain why dosing with NA has less of an effect on transcriptional output of the gene target 









Figure 2.15. NA inhibits Med25 ATF6 interaction mammalian cells line. A) Co-immunoprecipitation 
of ATF6 with Med25 dosed with either NA or DMSO. B) Relative band density of anti-ATF6 calculated 
using ImageJ, normalized to anti-Med25 signal. Analysis of MMP2 transcript levels by qPCR indicates that 
NA treatment decreases HSPA5 levels in VARI068. C) HSPA5 transcript levels are normalized to the 
reference gene RPL19.  Results shown are the average of technical triplicate experiments with error bars 
representing the standard deviation of the mean. 
 
2.4 Conclusions 
The demonstration of NA as a selective allosteric inhibitor of Med25 function validates the 
importance of dynamic loops in coactivators in molecular recognition and their utility as targets. 
We also provide evidence that modulation of these protein-protein interactions would provide a 
useful tool to study cancer at the bench. Our work suggests that Med25 is a potentially viable 
clinical target, thus justifying the search for a drug-like compound for testing the clinical utility of 
the strategy. We anticipate that NA will be a useful probe compound for dissecting the 
Med25•ETV/PEA3 axis in cancers with Med25 dysregulation. Further, the strategy of targeting 
dynamic substructures within coactivators should be generalizable beyond Med25. This work, in 
line with the information presented in Chapter 1, continues to support the hypothesis that targeting 
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dynamic loops rather than primary binding surfaces (allostery vs orthostery) affords compounds 
with better selectivity.  
 
2.5 Materials & Methods 
Protein expression and purification 
The Med25 expression plasmid, referred to as pAcID(394-543)-His6, was generously 
provided by Prof. Patrick Cramer.27 pAcID(394-543)-His6 mutants, with the exception of K420R, 
were prepared using site directed mutagenesis with the primers listed below. Plasmid sequence 
identity was confirmed via standard Sanger sequencing methods at the University of Michigan 
DNA Sequencing Core and analyzed using SeqMan Pro from the Lasergene DNASTAR software 
suite. 
 
Primers used for SDM: 
pAcID-(K518R)-His6  
F Pr. TCATGCTCCTGTACTCGTCCAGGAAGAAGATCTTCATGGGCCTCATCCC  
R Pr. GGGATGAGGCCCATGAAGATCTTCTTCCTGGACGAGTACAGGAGCATGA  
pAcID-(K519R)-His6  
F Pr. TCATGCTCCTGTACTCGTCCAAGAGGAAGATCTTCATGGGCCTCATCCC  
R Pr. GGGATGAGGCCCATGAAGATCTTCCTCTTGGACGAGTACAGGAGCATGA  
pAcID-(K520R)-His6  
F Pr. TCATGCTCCTGTACTCGTCCAAGAAGAGGATCTTCATGGGCCTCATCCC  
R Pr. GGGATGAGGCCCATGAAGATCCTCTTCTTGGACGAGTACAGGAGCATGA  
pAcID-(KK518RR)-His6  
F Pr. TCATGCTCCTGTACTCGTCCAGGAGGAAGATCTTCATGGGCCTCATCCC  
R Pr. GGGATGAGGCCCATGAAGATCTTCCTCCTGGACGAGTACAGGAGCATGA  
pAcID-(KKK518RRR)-His6  
F Pr. TCATGCTCCTGTACTCGTCCAGGAGGAGGATCTTCATGGGCCTCATCCC  
R Pr. GGGATGAGGCCCATGAAGATCCTCCTCCTGGACGAGTACAGGAGCATGA  
pAcID-(K411R/K413R)-His6  
F Pr. GGGGTCCTGGAGTGGCAAGAGAGACCCAGACCTGCCTCAGTGGATGCCAAC  
R Pr. GTTGGCATCCACTGAGGCAGGTCTGGGTCTCTCTTGCCACTCCAGGACCCC 
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Mutant K420R was made using PCR-driven overlap extension.53 The flanking primers A and D 
were designed to extend into the pET21b vector. Primers B and C contain the mutated codon. The 
primer designs are as follows:  
 
Primer A: 5’-GAA GGA GAT ATA CAT ATG TCA GTC TCC AAT AAG-3’ 
Primer B: 5’-GAT GCC AAC ACC CGA CTG ACG CGG TCA CTG-3’ 
Primer C: 5’ CAG TGA CCG CGT CAG TCG GGT GTT GGC ATC-3’ 
Primer D: 5’-GTG GTG GTG CTC GAG GTT GGT GAT GAC-3’ 
 
WT Med25 and mutants were expressed and purified from heat-shock competent Rosetta 
pLysS cells (Novagen), in Terrific Broth (TB) containing 0.1 mg/mL ampicillin and 0.034 mg/mL 
chloramphenicol, using previously described conditions.20,27 Cells were grown at 37 °C to an 
optical density (OD600nm) of 0.8. Temperature was reduced to 18°C and protein expression was 
induced upon addition of IPTG to a final concentration of 0.5 mM. Post-induction, cells were 
incubated 16 hours at 18°C. Cells were pelleted via centrifugation at 6000xg for 20 mins at 4°C. 
Cell pellets were stored at -80°C prior to purification. The harvested pellet was thawed on ice and 
resuspended in 20 mL of lysis buffer (50 mM phosphate, 300 mM sodium chloride, 10 mM 
imidazole, pH 6.8). Cells were then lysed by sonication on ice and cellular lysates were cleared by 
centrifugation at 9500 rpm for 20 min at 4°C. The supernatant lysate was then added to 750 µL  
Ni-NTA beads (Qiagen) and incubated for 1 hour at 4°C. The resin was pelleted by centrifugation 
at 2500 rpm for 2 min at 4°C and washed with wash buffer (50 mM phosphate, 300 mM sodium 
chloride, 30 mM imidazole, pH 6.8) a total of five times. Protein was then eluted with 2 mL of 
elution buffer (50 mM phosphate, 300 mM sodium chloride, 400 mM imidazole, pH 6.8) a total 
of three times. Eluent was then pooled and purified by cation exchange FPLC (Source 15S, GE 
Healthcare) using a gradient of Buffer B (50 mM phosphate, 100 mM NaCl, 1 mM DTT, pH 6.8) 
in Buffer A (50 mM phosphate, 1 mM DTT). The FPLC purified protein was then dialyzed into 
storage buffer (10 mM phosphate, 50 mM NaCl, 10% v/v glycerol, 0.001% v/v NP-40, pH 6.8) 
overnight, concentrated, aliquoted, and stored at -80°C. Final protein was greater than 90% pure 
as determined by Coomassie stained polyacrylamide gel. Protein concentration was determined by 
UV-Vis spectroscopy using an extinction coefficient, ε = 22,460 M-1 cm-1.  
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CBP KIX (586-672) was expressed in BL21 DE3 E. coli as previously described.30 Cells 
were grown to an optical density (OD 600nm) of 0.8 (37°C, 250 rpm), induced with 0.25 mM 
isopropyl b-d-1-thiogalactopyranoside (IPTG) for 16 hours at 20°C, harvested by centrifugation 
(20 min, 6500xg) and stored at -80°C. Cell pellets were lysed via sonication in lysis buffer (10 
mM phosphate, 300 mM NaCl, 10 mM imidazole, pH 7.2) containing 2-mercaptoethanol and 
cOmplete protease inhibitor (Roche, 11873580001). The Hisx6 tagged protein was affinity 
purified using immobilized metal ion affinity chromatography (IMAC) on a HisTrap HP Ni 
Sepharose column (GE Healthcare). Elution was conducted using an imidazole gradient of 10 mM 
to 600 mM imidazole. An additional round of purification was completed using ion-exchange 
chromatography on a Source S column (GE Healthcare) in phosphate buffer (50 mM, pH 7.2) by 
eluting with a NaCl gradient from 0 to 1M. Purified protein was buffer-exchanged by dialysis 
(overnight, 4°C) into 10 mM phosphate, 100 mM NaCl, 10% glycerol, pH 6.8. Purity was 
determined by Coomassie stained polyacrylamide gel. Protein concentration was determined by 
UV-Vis spectroscopy using an extinction coefficient, ε = 12,950 M-1 cm-1. Purified protein samples 
(>90% pure) were aliquoted      and stored at -80°C.  
 
Med15 (1-345) was expressed and purified by as previously described.43  
 
The expression plasmid for p300 TAZ1(324-423) was generously provided by Prof. 
Paramjit Arora.54 Protein was  expressed in BL21 DE3 E. coli. Cells were grown in LB containing 
0.1 mg/mL ampicillin and 1 mM ZnCl2 to an optical density (OD 600nm) of 0.8 (37°C, 250 rpm), 
cooled to 22°C and induced with 100 µM IPTC for 5 hours. Cells were harvested by centrifugation 
(20 min, 6500xg) and stored at -80°C. Cell pellets were lysed by sonication in lysis buffer (50 mM 
Tris, 150 mM NaCl, pH 6.3) containing cOmplete protease inhibitor (Roche, 11873580001). The 
GST tagged protein was affinity purified using a GSTrap column (GE Healthcare). After initial 
binding of the protein to the column, elution was conducted using a buffer containing 10 mM 
reduced glutathione. An additional round of purification was completed using ion-exchange 
chromatography on a Source S column (GE Healthcare) in phosphate buffer (50 mM, 1 mM DTT, 
pH 7.2) by eluting with a NaCl gradient from 0 to 1M. Purified protein was buffer-exchanged by 
dialysis (overnight, 4°C) into 10 mM Tris, 100 mM NaH2PO4, 10% glycerol, 1mM DTT, 100 µM 
 53 
ZnCl2, pH 6.8. Purity was determined by Coomassie stained polyacrylamide gel. Protein 
concentration was determined by UV-Vis spectroscopy using an extinction coefficient, ε = 49,110 
M-1 cm-1. Purified protein samples (>90% pure) were aliquoted and stored at -80°C.  
 
Synthesis of transcriptional activation domain peptides 
The peptides listed below were prepared following standard FMOC solid-phase synthesis 
methods on a Liberty Blue Microwave Synthesizer (CEM). FMOC deprotections were completed 
by suspending the resin in 20% piperidine (ChemImpex) in DMF supplemented with 0.2 M Oxyma 
Pure (CEM) and irradiating under variable power to maintain a temperature of 90°C for 60 
seconds. Coupling reactions were completed by combining the amino acid (5 eq relative to resin; 
CEM, ChemImpex, and NovaBiochem), diisopropylcarbodiimide (7 eq, ChemImpex), and Oxyma 
Pure (5 eq) in DMF and irradiating under variable power to maintain a temperature of 90°C for 4 
minutes. The resin was rinsed four times with an excess of DMF between all deprotection and 
coupling steps. N-terminal addition of fluoresceine isothiocyanate (FITC) residue was conducted 
by adding 1.2 eq in 5% diisopropylethylamine in dimethyl formamide for 18 hours at RT.  Peptides 
were deprotected and cleaved from the resin for 4 hours in 90% trifluoroacetic acid (TFA), 5% 
thioanisole, 3% ethanedithiol (EDT) and 2% anisole.  Crude peptides were filtered to remove resin, 
dried under nitrogen stream, and precipitated from cold ether.  Peptide suspensions were 
transferred to a 15 mL falcon tube, centrifuged at 4000 g for 5 minutes at 4°C, and ether decanted.  
Crude peptides were resuspended in 20-40% acetonitrile, purified via HPLC on an Agilent 1260 
HPLC using a semi-prep C18 column (Phenomenex).  Pure fractions were collected and 
lyophilized to afford pure peptides. Final purity was determined via analytical HPLC and identify 
was confirmed using mass spectrometry.   Analytical spectra were obtained using an analytical 
C18 column (Phenomenex) on an Agilent 1260 HPLC.  Mass spectra were obtained using an 
Agilent 6230 LC/TOF and an Agilent 6545 LC/Q-TOF.  Analytical spectra of peptides can be 
found in Appendix A.  
 
VP16 (465-490) - Fluorescein isothiocyanate and β-alanine were coupled to the N-terminus to 
produce FITC-βA-YGALDMADFEFEQMFTDALGIDEYGG. A gradient of 10-40% acetonitrile 
over 30 min was used for HPLC purification. 
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ETV5 (38-68) - Fluorescein isothiocyanate and β-alanine were coupled to the N-terminus to 
produce FITC-βA-ALDMADFEFEQMFTDALG. A gradient of 10-40% acetonitrile over 30 min 
was used for HPLC purification 
 
ATF6a (40-66) - Fluorescein isothiocyanate and β-alanine were coupled to the N-terminus to 
produce FITC-βA-DTDELQLEAANETYENNFDNLDFDLDLM. A gradient of 10-40% 
acetonitrile over 30 min was used for HPLC purification 
 
MLL (840-858) – Fluorescein isothiocyanate and β-alanine were coupled to the N-terminus      to 
produce FITC-βA- DCGNILPSDIMDFVLKNTP. A gradient of 10-40% acetonitrile over 30 min 
was used for HPLC purification 
 
myb (291-316) - Fluorescein isothiocyanate and β-alanine were coupled to the N-terminus       to 
produce FITC-βA-KEKRIKELELLLMSTENELKGQQVLP. A gradient of 10-40% acetonitrile 
over 30 min was used for HPLC purification 
 
IBiD (2063–2111) – The N-terminus was acetylated to produce Ac- 
SPSALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVAN. A gradient of 
10-50% acetonitrile over 40 min was used for HPLC purification. 
 
ACTR (1041-1088) – Fluorescein isothiocyanate and β-alanine were coupled to the N-terminus      
to produce FITC-βA- 
PSNLEGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQAL. A gradient of 10-
50% acetonitrile over 40 min was used for HPLC purification. 
 
HIF1a (786-826) - Fluorescein isothiocyanate and β-alanine were coupled to the N-terminus      to 
produce FITC-βA-SMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN. A gradient 





Direct binding and competition experiments  
Direct binding and competition experiments were performed using fluorescence 
polarization as previously described.20 Low volume, non-binding, black 384-well plates (Corning) 
were used and fluorescence polarization was measured using a PHERAStar plate reader with 
polarized excitation at 485 nm and emission intensity measured through a parallel and 
perpendicularly polarized 535 nm filters.  
Data was analyzed using GraphPad Prism. For direct binding experiments, a binding 
isotherm accounting for ligand depletion (assuming a 1:1 binding model) was fit to the obtained 
polarization values as a function of protein concentration to obtain the equilibrium dissociation 
constant, Kd:  
 
“a” and “x” are the total concentrations of fluorescent peptide and protein, respectively, “y” is the 
observed anisotropy at a given protein concentration, “b” is the maximum observed anisotropy 
value, and “c” is the minimum observed anisotropy value. Each data point is an average of three 
independent experiments with the indicated error representing the standard deviation the mean.  
For competition experiments, curves were fit with a non-linear regression using the “log(inhibitor) 
vs response – variable slope” equation, allowing calculation of IC50. 
 
AcID•VP16 High-throughput screening 
Assays were performed in a final volume of 20 µL in low volume, non-binding, black 384-
well plates (Corning) and read by plate reader (Pherastar) with excitation at 485 nm and emission 
intensity measured through parallel and perpendicularly polarized 535 nm filters. Optimization of 
fluorescence polarization assay for high throughput was conducted by testing stability of the 
VP16(465-490)•AcID interaction (Kd) over time, with combinations of DMSO and NP-40 (for 
more details see the dissertation of Dr. Steven Sturilis: http://hdl.handle.net/2027.42/120661). The 
assay shows little variance in affinity over time, up to 20 hours as well as tolerance to DMSO (5%) 
and NP-40 (0.001%). 4046 compounds were tested from the MS Spectrum 2000, Focused 
 56 
Collections, and BioFocus NCC libraries, which include known bioactive molecules, secondary 
metabolites, natural products, and FDA approved drugs. 200 nL of each compound in DMSO was 
first plated, followed by addition of 10 µL FITC-VP16(465-490). The compounds were then tested 
for fluorescence quenching before 10 µL of Med25 AcID protein was added. Plates were incubated 
for thirty minutes at room temperature and read by plate reader, as described above with gain 
settings determined based on a well from columns 23-24 (tracer only).  Final concentration of 
AcID protein was 850 nM, final concentration of FITC-VP16(465-490) was 20 nM, and 
compounds were assayed at a concentration of 20 µM with a final DMSO concentration of 1% 
v/v. Data was published to and analyzed using MScreen (http://mscreen.lsi.umich.edu). Conducted 
by Steven Sturlis; published at http://hdl.handle.net/2027.42/120661. 
 
Mass spectrometry analysis of covalent adducts 
Protein (Med25 WT and mutants) was diluted to a concentration of 20 µM using storage 
buffer (10 mM phosphate, 50 mM NaCl, 10% v/v glycerol, 0.001% v/v NP-40, pH 6.8). Norstictic 
acid was added to the protein to give a final concentration of 20 µM (1 equivalent, unless otherwise 
noted). Samples were incubated for 30 minutes at room temperature with gentle mixing on an 
orbital shaker. Analysis was conducted by mass spectrometry using an Agilent QToF LC/MS 
equipped with a Poroshell 300SB C8 reverse-phased column with a gradient of 5-100% acetonitrile 
with 0.1% formic acid in water with 0.1% formic acid over five minutes. Analysis of data was 
completed using the Agilent Qualitative Analysis Program with background subtraction and 
deconvolution settings for an intact protein of 10,000- 30,000 Da.  
 
Molecular dynamics simulations 
Modeling was performed using the NMR structure of Med25 AcID (PDB 2xnf). The 
norstictic acid was parameterized using CGENFF, which was then covalently linked to Med25 
K519 through a PATCH that was created in CHARMM, with the molecules oriented out in space 
to allow for full, unbiased exploration around the protein before binding. The system was solvated 
using TIP3P water molecules as well as 100 mM NaCl using the MMTSB toolset so that the linked 
complex was in a cubic box with a minimum cutoff distance being 10 Å from the box edges. 
Simulations were unbiased molecular dynamics simulations using the CHARMM36 and CGENFF 
force fields for 100 ns of sampling at 298 K after allowing for 2ns of equilibration of the system. 
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The simulation was run in the NVT ensemble using the Langevin dynamics algorithm with a 
friction coefficient of 5 ps-1. The SHAKE algorithm was used to fix bond lengths during 
simulations. PME and vswitch were used for nonbonded interactions with a 12 Å cutoff. All 
molecular dynamics simulations were performed using GPUs through the CHARMM compatible 
OpenMM interface. Five independent trials of simulations were performed for each molecule. 
Conducted by Amanda Peiffer.  
 
Cell Culture 
HeLa cells were purchased from ATCC (HTB-55). VARI068 cells were derived from a 
patient-derived xenograft orthotopically implanted in NSG mice first and subsequent passaged 
through nude mice. HeLa cells were grown in DMEM (Gibco, 11965-092) supplemented with 
10% FBS (R&D, S11150). VARI068 cells were grown in DMEM (Gibco, 11965-092) 
supplemented      with 10% FBS (R&D, S11150), and 1X Antibiotic-Antimicotic. Both cell lines 
were grown at 37C with 5% CO2.  
 
Thermal shift assays 
HeLa cells were grown, counted, and harvested using standard protocols (300,000 cells per 
temperature). Pelleted cells were resuspended in 1 mL cold PBS and transfered to a 1.5 mL 
Eppendorf tube on ice. Cells were again pelleted by centrifugation at 1500 G for 3 minutes at 4°C. 
Nuclear extracts were generated using a NE-PER kit (Thermo Scientific, 78833) and 
manufacturer’s protocol. After isolating the nuclear extract, a buffer exchange into PBS was 
conducted using a Zeba Spin Desalting Column 7K MWCO (Thermo Scientific, 89882). Prepared 
nuclear extracts were split into 2 epitubes. Norstictic acid (dissolved in DMSO) was added to one 
tube and an equivalent volume of DMSO was added to the other. Final concentration of DMSO 
was 0.1% v/v. Dosed nuclear extracts were incubated at room temperature for 30 minutes. After 
incubation, samples were alliquoted into thin-walled PCR tubes (15 µl per tube, the equivalent of 
300,000 cells per tube).   
 A Labnet Multigene OPTIMAX PCR was used to heat each sample for 3 minutes.  Six 
temperature points were tested, 54, 58, 62, 66, 70, and 74C. Contents were transferred to epitubes 
and centrifuged at 17000 g for 1 minute at 4°C to remove precipitated proteins. Contents of each 
epitube were carefully transferred to a clean epitube, leaving precipitated protein behind. LDS 
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loading dye was added and samples were boiled for 5 minutes at 95°C. 10uL of each sample was 
loaded onto a 4-20% mini-PROTEAN TGX gel (BioRad, 4561096) gel was run at 180V for 45 
minutes.  Protein was transferred from gels to PVDF membrane using a BioRaD TransferBox 
Turbo following the standard protocols. Membrane was blocked for 1 hour at room temperature 
using Super Block (Thermo Scientific, 37515). Med25 antibody (Novus biologicals, NBP2-55868) 
was added to membrane (1:1000 dilution in Super Block) and incubated overnight at 4°C with 
gentle shaking. After removal of primary antibody and three washes with PBST, Secondary 
antibody (Santa Cruz SC-2004, 1:20,000 in Super Block) was added to membrane and incubated 
at RT for 1hr with shaking. After removal of secondary antibody with three washes with PBST, 
HRP substrate (Thermo Scientific, 34095) was added and after 1 minute Western blot was 
visualized using Chemiluminescence on an Azure Biosystems c600 imager. Analysis was 
conducted using ImageJ software.  
 
Co-Immunoprecipitation experiments 
Med25 antibody (Santa Cruz, sc-393759) was chemically crosslinked to Dynabeads 
Protein G (Invitrogen, 10004D) using Bis(sulfosuccinimidyl) suberate (BS3). Briefly, 20 µL 
Dynabeads Protein G were washed with 250 µL PBST 3 times. Med25 Santa Cruz antibody (24 
µL, 4.8ug) in 400 µL PBST was added to beads and incubated on with rotation at 4°C for 1hr. 
Antibody coupled beads were washed twice with conjugation buffer (20mM sodium phosphate, 
150 mM NaCl, pH = 7.5), resuspended in 250 µL of 5mM BS3 (Thermo Scientific, 21580), and 
incubated at RT with rotation. After 30 minutes, 12.5 µL quenching buffer (1M Tris HCl, pH 7.5) 
was added and beads were incubated an additional 15 min with rotation. Crosslinked beads were 
washed three times with PBST and immediately used or stored at 4°C in PBST and used within 24 
hours.  
Mammalian cells were harvested as described in 1-9. Nuclear extracts were generated from 
mammalian cells using a NE-PER kit (Thermo Scientific, 78833). Extracts were buffer exchanged 
into PBS using Zeba Spin Desalting Column 7K MWCO (Thermo Scientific, 89882). Extracts 
were dosed with either Norstictic acid (dissolved in DMSO) or an equivalent volume of DMSO 
(0.1% v/v). After washing crosslinked beads with PBS, nuclear extracts were added and incubated 
for 3 hours at 4°C with rotation. Flowthrough was collected and saved, and beads were washed 3X 
with PBST. LDS sample buffer (Invitrogen, NP0007; 2X final concentration) was added to beads 
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and incubated at 95C for 10 minutes to elute immunoprecipitated proteins. Samples were run on 
4-20% mini-PROTEAN TGX gels (BioRad, 4561096). Transfer and blotting was conducted using 
standard protocols (see cellular thermal shift assay protocol). ETV5 antibody (Proteintech, 13011-
1-AP) diluted 1:2000 in SuperBlock for use.  
 
Quantitative polymerase chain reaction experiments 
For endogenous gene expression analysis, HeLa cells were seeded into a 24-well plate 
(1x105 cells/well) and allowed to adhere overnight. Media was removed and replaced with 
OptiMem media containing vehicle (DMSO) or compound delivered (in DMSO, 0.5% v/v) at the 
indicated concentrations. After 6 h, the media was removed and total RNA was isolated using 
RNeasy Plus RNA isolation kits (Qiagen) according to manufacturer’s instructions. Each RNA 
sample was used to synthesize cDNA using iScript cDNA synthesis kits (Bio-Rad). RT-qPCR 
reactions were carried out in triplicate on an Applied Biosystems StepPlusOne instrument using 
SYBR green master mix and primers for:  
 
human RPL19 Forward. 5’:ATGTATCACAGCCTGTACCTG:3’  
human RPL19 Reverse. 5’:TTCTTGGTCTCTCTTCCTCCTTG:3’ 
MMP-2 Forward. 5’:CATTCCAGGCATCTGCGATGAG:3’ 
MMP-2 Reverse. 5’:AGCGAGTGGATGCCGCCTTTAA:3’ 
 
RT-qPCR analysis was carried out using the comparative CT Method (ΔΔCT Method) to estimate 
MMP-2 mRNA levels relative to the reference RPL19 mRNA levels. Experiments were conducted 
in biological duplicate, technical triplicate.  
 
Synergy experiments with lapatinib (performed by Yejun Liu) 
Cell culture: MDA-MB-231 cells were purchased on ATCC website. Cells were seed at 
3000 cells per well in 96 well plates and cultured in DMEM(Gibco) with 10% FBS and no 
antibiotics. After 24 hours, cells were adhered on the plate. Medium was changed from 10% FBS 
to 1% FBS and at the same time, added appropriate amount of compound (Keep DMSO at 1%). 
After 24 hours, old medium was removed and new 1% FBS DMEM medium and compounds were 
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added to each well. The day after this treatment, cell viability was measured by Cell Proliferation 
Kit (MTT) from Roche following the manufacturer’s instructions. 
Calculation of synergy: All calculations were performed in Graphpad Prism and Microsoft 
Excel 365. Isobolograms were generated based on the dose fractions calculated by the IC50s of 
either Norstictic acid, Laptinb alone or combination of them in different ratios. In this case, dose 
fraction is defined as the IC50 of one component (Norstictic acid or Laptinb) in a combination 
divided by the IC50 of that component in isolation required to exert the same effect. The dose 
fractions of Norstictic acid and Laptinb represent the x/y coordinates on the isobologram. 
Combination index (CI) is the sum of two dose fractions. For single agent, CI is 1 and for 
combination, synergy effect is present when CI<1. 
 
Dose fraction of Compound A for combination AB = IC50(A in AB) / IC50(A in isolation) 
Dose fraction of Compound B for combination AB = IC50(B in AB) / IC50(B in isolation) 
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High-Throughput Method to Identify Selective Modulators of Activator•Coactivator 
Interactions 
3.1 Abstract 
The protein-protein interactions (PPIs) that regulate transcription are often dysregulated in 
disease and therefore make attractive pharmacological targets. However, a major challenge facing 
the discovery of small-molecule modulators of transcriptional coactivator•transcription factor 
complexes has been selectivity. High-throughput screening (HTS) methods have most often relied 
upon binding inhibition against the activator•coactivator complex of interest alone. This approach 
is prone to discovery of compounds that act as nonspecific mimetics of the transcriptional activator 
and thus interact with multiple coactivator proteins, limiting their utility as biological probes. An 
iterative approach involving several rounds of selectivity screening against multiple PPIs has led 
to more potent and selective inhibitors. Still, this approach considers selectivity after primary 
screening and initial triage has been conducted, risking exclusion of slightly less potent but 
selective scaffolds. To address this, a fluorescence polarization-based assay that simultaneously 
monitors multiple activator•coactivator interactions has been developed by simultaneously 
evaluating different protein complexes using peptide tracers tagged with spectroscopically distinct 
fluorophores. This method enables assessment of both selectivity and potency of candidate 
inhibitors in a single screen. To demonstrate the utility of the method, a duplex assay containing 
the coactivators Med25 AcID and CBP KIX has been optimized and a pilot screen has been 
conducted. The pilot screen was able to categorize active compounds as Med25 AcID-selective, 
CBP KIX-selective, or dual inhibitors. Representative compounds from each subset were further 
evaluated in secondary screening. We observed that for compounds retaining activity in secondary 
screening, selectivity profiles from the primary screen are replicated. Ultimately, this approach led 
to the identification of a highly selective compound that displays in vitro inhibition of the 





 As highlighted in the previous chapter, the interactions between activators and coactivators 
are fundamental in the process of activated gene expression. 1–4  Further elucidation of this network 
of PPIs is crucial for insights into the compositionally and conformationally plastic complexes that 
govern transcriptional regulation.5 Additionally, dysregulation of the protein-protein interactions 
involved in transcription is characteristic of many human diseases including cancer.4 Thus, 
transcriptionally relevant PPI’s are potentially attractive therapeutic targets and there is great 
interest in expanding the suite of chemical tools used to study these systems.6–10 
 A significant hurdle for studying these interactions has been the task of discovering 
chemical modulators due to the dynamic nature of activator and coactivator proteins. Coactivators 
use conformationally plastic activator binding domains (ABDs) to interact with a variety of 
activators.11–13 For example, the KIX domain of the coactivator CBP regulates transcription via 
interaction with more than 15 distinct transcription factors using only two binding interfaces.14 
Further, ABDs adopt distinct complex conformations upon interaction with different binding 
partners.11,15,16 This has been highlighted in work analyzing the unique structural changes that 
occur when KIX interacts with different TADs or small molecules ligands.14,17–21 Additionally, 
transcriptional activators interact with many different proteins using only short recognition motifs 
within their transactivation domains (TADs).22,23 Most activators are intrinsically disordered and 
only adopt secondary structural elements upon binding to a coactivator while others retain 
conformational heterogeneity even after binding, forming “fuzzy” complexes (Figure 3.1).13,24 
Considering the structural and functional complexity of the proteins involved in these PPIs, the 




Figure 3.1. Coactivator•activator interactions are classically a challenge to target selectively. A) 
ABDs and TADs form transient, conformationally heterogeneous, complexes (often referred to as “fuzzy”). 
Both members of this complex also interact with a separate network of proteins, including other TADs or 
ABDs, to regulate alternate functions. B) Coactivator activator interactions are classified among the most 
challenging to target with inhibitors due to the attributes of the PPI interface - lower affinity occurring over 
a large surface area. 
 
The previous chapter demonstrated that an iterative in vitro screening platform can be 
successfully applied to determine potent inhibitors of difficult to target ABDs. In addition, two 
natural product inhibitors of CBP/KIX interactions, lobaric acid and sekikaic acid, were discovered 
using this approach.25 However, a significant limitation of the iterative workflow is performing 
separate screens to determine potency and selectivity. Depending on library size and screening 
capabilities, it is possible that promising selective scaffolds of moderate potency are filtered out 
early on in the screening process and never pursued. In addition, many high potency hits identified 
in a HTS for ABD inhibitors mimic the structure of the bound TAD and thus compete for binding 
to the ABD. Because TAD peptides often interact with multiple binding partners, these 
amphipathic mimetics are highly nonspecific for the profiled interaction and can affect many other 
PPIs.26 For example, this can be seen with the isoxazolidine mimetics, utilized due to their 
chemical similarity to natural transcriptional activators.27 This class of molecules was found to 
interact with more than 10 different coactivators,28,29 underscoring the unique challenge of 
selectivity when screening for coactivator•activator modulators. Thus, the current HTS strategy 
has room for improvement, as the maximum amount of information is not currently obtained 
during initial triage of a large compound library.  
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The work outlined in this chapter focuses on the development and implementation of a 
HTS platform for PPIs that improves the ability to detect selective hits from the primary screening 
level. This is particularly useful for dynamic coactivator•transcription factor complexes because 
of the outlined challenges with regards to inhibitor selectivity. A fluorescence polarization (FP) 
based assay that simultaneously monitors multiple activator•coactivator interactions is presented. 
With this method, each protein complex can be individually evaluated using peptide tracers 
labelled with spectroscopically distinct fluorophores. This method enables characterization of both 
selectivity and potency of candidate inhibitors in a single screen. 
 
3.2 Results & Discussion 
Development of duplex fluorescence polarization assay with Med25 AcID and CBP KIX 
HTS affords excellent opportunities to identify chemical scaffolds that can target unique 
conformations of activator-coactivator interactions. A common primary screening methodology 
selected for HTS protein-protein interactions is fluorescence polarization (FP). FP is an attractive 
HTS technique due to its low cost, rapid readout, and amenability to a high throughput format.30,31 
With an activator-coactivator system, FP reports on the binding of a synthetic activator TAD 
peptide to the ABD motif of a coactivator. This approach was used in Chapter 2 to identify 
norstictic acid as a potent and selective Med25 inhibitor. As some TAD•ABD interactions can be 
highly specific, we hypothesized it would be possible to multiplex an FP based assay, 
incorporating multiple TAD•ABD pairs, with the fluorescent tracers labeled with 
spectroscopically distinct fluorophores. This would allow for information on specificity and 
potency of compounds to be determined in a single primary screen. In addition, multiple PPIs can 
be screened against a library of compounds simultaneously. 
The KIX domain of the coactivator CBP and the AcID domain of Med25 were chosen as 
candidate ABDs to utilize in the development of a duplex FP assay due to their structural and 
biological relevance (Figure 3.2). KIX is a prototypical three-helix bundle, a motif associated with 
many ABDs.14,32,33 AcID, as described in the previous chapter, is structurally unique, containing a 
central seven-stranded beta barrel surrounded by three alpha helices.34 Additionally, both AcID 
and KIX are implicated in interactions that influence transcription in diseases such as diabetes and 
cancer.35–39 
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Figure 3.2. Overview of first generation duplex screen proteins Med25 AcID and CBP KIX. Structures 
of the two activator binding domains are shown with the corresponding PDB codes. Qualities of these 
proteins that made them attractive candidates for the first-generation duplex assay are listed.39–42 
 
The format of the duplex screen expands upon the FP technique we and others have used for 
screening transcriptional PPIs.  A typical assay profiles the direct interaction of a single ABD and 
a fluorescently-labeled peptide derived from the transcriptional activation domain (TAD) of an 
activator as the tracer. The duplex FP format incorporates two different ABD•TAD pairs into one 
screen, each labeled with a distinct fluorophore. Based upon their distinct spectral properties, 
fluorescein (FITC) and Texas Red (TR) were selected for tracer labelling.43 For development of 
an AcID•ETV5/KIX•MLL duplex assay, a FITC-labelled peptide of the ETV5 TAD (residues 38-
68) and a Texas-Red labelled peptide of the MLL TAD (residues 840-858) were synthesized as 
the tracers (Figure 3.3).  
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Figure 3.3. Description of first generation duplex screen fluorescence polarization assay. A) Overview 
of assay concept with KIX•TR-MLL and AcID•FITC-ETV5. In this example, low fluorescence polarization 
in the Fluorescein channel and high fluorescence polarization in the Texas-Red channel would indicate an 
AcID selective inhibitor. B) Advantages to using the duplex screening approach. More data at the primary 
screening level allows for more thorough refinement of hits. C) This method allows for rapid classification 
of ligand selectivity.  
 
For the proposed screen to accurately report on activity of a small molecule, it must be 
demonstrated that any observed decrease in polarization is due to direct inhibition of the activator 
peptide-coactivator protein interaction. Direct binding experiments of FITC-ETV5 and TR-MLL 
tracers were performed in isolation, with KIX or AcID, and in duplex, with both KIX and AcID. 
As shown in Figure 3.4, the dissociation constants of the tracers were unaffected in the duplex 
format. Additionally, each tracer shows at least 10-fold selectivity for the cognate ABD. The Z 
factors for AcID•FITC-ETV5 and KIX•TR-MLL in the duplex screen were determined to be 0.9 
and 0.65, respectively, indicating an excellent assay for HTS.44 
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Figure 3.4. Direct binding experiments under duplex conditions accurately represent interaction of 
the cognate ABD•TAD pairs. Left: TR-MLL. Right: FITC-ETV5. Fluorescence polarization data for each 
concentration point was obtained in technical triplicate, with the average plotted and the error shown as the 
standard deviation of the mean.  
 
  To further assess the dynamic range of the assay, as well as to probe its ability to distinguish 
the binding profiles of small molecule ligands, inhibitors previously identified in the Mapp 
laboratory were examined with this method (Figure 3.5). Lobaric acid is a CBP/p300 KIX-
selective inhibitor reported in 2012.25 Norstictic acid is a Med25 AcID-selective inhibitor 
(presented in Ch. 2) and garcinolic acid is an inhibitor with good activity for both AcID and KIX 
(unpublished work from Dr. Meg Breen). Competition experiments were performed by adding a 
mixture of the pre-formed AcID•FITC-ETV5 and KIX•TR-MLL complexes at 50% bound tracer 
to serially diluted small molecule solution aliquots in 384-well plates and incubating at RT for 30 
min. Fluorescence polarization measurements were obtained using both the fluorescein and Texas 
Red channels on a Pherastar plate reader. The inhibition curves obtained accurately reflect the 
known activity of the molecules for their specific targets. These measurements were performed in 
triplicate on different days and produced an average percent coefficient of variability (%CV) of 
8.6%, consistent with a reproducible assay.45 
TR-MLLCBP KIX direct binding
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Figure 3.5. Duplex assay can accurately characterize the selectivity of known inhibitors lobaric acid, 
norstictic acid, and garcinolic acid. A) Competition fluorescence polarization was conducted for each 
inhibitor with Med25 AcID, CBP KIX, or under duplex screen conditions. Plots of KIX inhibition are 
shown in the first column (red – in isolation, blue – under duplex conditions. Plots of AcID inhibition are 
shown on the second column (green – in isolation, blue – under duplex conditions). Assays were conducted 
in technical triplicate, and the average polarization value was plotted with the error shown as the standard 
deviation of the mean. B) IC50 values (shown in µM) calculated from the inhibition curves shown in A. 
 
Pilot screen of small library using duplex assay   
With the duplex assay validated against known inhibitors of both the KIX•MLL and 
AcID•ETV5 interactions, a pilot screen of 2,846 compounds (NIH Clinical Collection and 
MicroSource 2400) was completed with the Center for Chemical Genomics to test the suitability 
 74 
of the duplex format for high-throughput screening. A mixture of AcID (0.6 μM final 
concentration) and KIX (2 μM final concentration) was plated in 384-well format and treated with 
compound (20 µM final concentration). The fluorophore-labeled tracers were added (20 nM final 
concentration, leading to 50% bound complex) and the plates incubated for 30 minutes at room 
temperature before fluorescence polarization in the fluorescein and Texas Red channels were 
measured using a PheraStar plate reader. Percent inhibition for each compound was determined 
using wells treated with DMSO as a negative control and wells containing fluorophore-tagged 
peptide alone as a positive control. Each plate contained 32 negative control wells, containing the 
protein-tracer complex mixture dosed with DMSO, and 32 positive control wells, containing tracer 
only. The assay demonstrated excellent performance with Z factors of 0.88 and 0.64 for the 
AcID•FITC-ETV5 and KIX•TR-MLL measurements, respectively.44 The initial activity threshold 
was set at a polarization value greater than 3 S.D. below the average signal of that of the negative 
controls, leading to the identification of 26 molecules as hits against the AcID•ETV5 interaction 
(0.91% hit-rate) and 94 compounds as hits against the KIX•MLL interaction (3.3% hit-rate). A 
comparison of the individual data sets revealed that 6 compounds inhibited both interactions above 
the 3 S.D. cutoff, leading to their preliminary classification as dual inhibitors. 
Figure 3.6. Duplex assay can accurately characterize the selectivity of known inhibitors lobaric acid, 
norstictic acid, and garcinolic acid. Campaign view of primary screen conducted with duplex assay; 
percent inhibition for each data point. Red dots represent positive controls (100 % inhibition, tracer only), 
blue dots represent negative controls (0% inhibition, tracer + protein), and green dots represent tested 
compounds. The red line represents the 3SD, 20% inhibition, threshold used to determine hits. Data for 
Med25 AcID is shown on the top, CBP KIX is shown on the bottom. 94 compounds were identified as hits 
and immediately sorted for selectivity based on this data. 
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Confirmatory screening using dose-response (8 different concentrations, from 120 µM to 
3.3 µM) in duplicate was conducted with the 114 hit compounds. Additionally, at this step known 
fluorophores such as calcein and fluorescein that appeared as hits were excluded. As an additional 
measure to check for artifacts, the order of addition was switched for the assay components (tracers 
first, protein second). The top three active compounds from each category were selected for further 
profiling via purchase of fresh material (Figure 3.7). 
 
Figure 3.7. Lead compounds selected for follow up screening. Structures, names, and selectivity profiles 
are shown. AcID selective molecules = blue panel, KIX selective molecules = pink panel, inhibitors of both 
proteins = purple panel.   
 
Upon purchase, these compounds were tested in competition FP assays with the individual 
duplex screen ABD•TAD pairs to obtain full inhibition curves and IC50 values (Figure 3.8). At this 
stage, the fluorophore pairs were swapped to test if the fluorophore was not having an effect on 
the inhibition data as FITC is negatively charged whereas Texas Red is neutral. Previous work has 
shown that FITC does increase the binding affinity of the TAD peptide for the ABD, and 
fluorescein shows up as a Med25 binder in high throughput screens. Thus, it is possible that would 
add some bias to the screening method.  
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Figure 3.8. Inhibition curves of representative duplex screen hits. Competition FP was conducted for 
each compound using AcID•TR-ETV5 and KIX•FITC-MLL in isolation. The average polarization from 
assays conducted in technical triplicate is plotted with error bars representing the standard deviation of the 
mean. Calculated IC50 values for compounds showing activity are shown in Table 3.1.  
 
Only five compounds still displayed activity: fumarprotocetraric acid, garcinolic acid, 
purpurogallin, pamoic acid, and agaric acid (Table 3.1). The most potent inhibitor of CBP KIX 
was garcinolic acid, which was not surprising because it had already been identified in a KIX 
targeting screen of the same library conducted by a previous lab member. However, this screen 
also classified garcinolic acid as a dual inhibitor, which was confirmed in secondary screening. 
Agaric acid, with a similar IC50 value to garcinolic acid, was determined to be the most potent and 
selective inhibitor of CBP KIX, showing greater than 10-fold selectivity for KIX over AcID. 
Fumarprotocetraric acid (FPA) stood out as the best Med25 AcID inhibitor, with a low µM IC50 
as well as greater than 10-fold selectivity for AcID over KIX. As shown in Table 1, the five 
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compounds retaining activity maintained the same selectivity profiles from the primary screen, 
illustrating the reliability of the selectivity assessment obtained from the duplex assay.  
Table 3.1. Summary of KIX and AcID inhibition by duplex screen lead molecules 
 
Additional selectivity profiling of lead compounds from pilot screen 
To further analyze selectivity, the five lead compounds were tested against additional 
coactivators, p300 CH1 and CBP IBiD (Figure 3.9). IBiD is known to be intrinsically disordered 
and unstructured until interaction with an activator protein occurs, when it becomes structured into 
a prototypical three helix bundle.46–48 CH1, also known as TAZ1, is a three-helix bundle, however 
it is unique in the fact that it requires specific coordination of three zinc ions for proper folding 
and function.49 The sequences of TADs that interact with both of these coactivators are published, 
and thus these coactivators are readily adaptable to FP assay.46,50–53  The CH1•HIF1a interaction 
plays a key role in transcribing proteins that promote cancer cell survival under the hypoxic 
condition of tumor environment, thus targeting this interaction could be an effective anti-cancer 
strategy.50,54,55 IBiD is the most conformationally dynamic of the CBP/p300 ABDs, only adopting 
its three-helix bundle structure upon ligand binding.46–48 While IBiD has been implicated in cancer 
progression, interacting with p53 as well as the activator for thyroid hormone and retinoid 
receptors (ACTR) domain of the p160 nuclear-receptor co-activator, no small molecule inhibitors 
have been reported.47,53,56 Thus these are interesting targets to test with regards to selectivity for 
multiple reasons, first due to both their structural similarities as three helix bundles, and 
differences, one as an intrinsically disordered protein and CH1 as a zinc coordinating protein.  
Additionally, since they are both domains within the master coactivator CBP/p300, like KIX, they 
would be likely present and able to compete for small molecule binding in a cellular 
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environment.56,57 
Figure 3.9. Competition FP looking at inhibition of CH1 and IBiD by duplex screen lead compounds. 
Assays were conducted in technical triplicate and the average for each data point is shown with error bars 
representing the standard deviation of the mean. 
 
Most of the compounds were able to inhibit the CH1•HIF1a interaction. Notably, 
purpurogallin had a much lower IC50 for this interaction than the other compounds tested, at 0.29 
± 0.02 µM. Purpurogallin also inhibited this interaction much better than any other interaction, 
with its next best IC50 at 26 ± 2 µM. Purpurogallin is a known metal chelator, and part of the 
polyphenol family of natural products, which have been well characterized for their antioxidant 
properties.58–60 Therefore, it is likely that this compound inhibits CH1 not by direct PPI inhibition, 
but by removal and sequestering of the zinc ions necessary for proper folding and TAD binding. 
This inhibitory mechanism has been thoroughly characterized in the context of other CH1•HIF1a 
inhibitors.61–63 Garcinolic acid demonstrated single digit µM IC50 values against all interactions 
tested, further confirming it as a nonspecific inhibitor of multiple coactivators. Pamoic acid, while 
a more modest inhibitor of KIX at 35 ± 2 µM, had some selectivity for its target (>2 fold). Out of 
all compounds tested, FPA stood out as the most useful hit, with a low µM IC50 value for 
Med25•ETV5 and also the greatest selectivity for its target (Figure 3.10).  
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Figure 3.10. Selectivity profiling of fumarprotocetraric acid. Assays were conducted in technical 
triplicate and the average for each data point is shown with error bars representing the standard deviation 
of the mean. Left: calculated IC50 values for each interaction and fold selectivity based on AcID•ETV5 
inhibition. Right: Inhibition curves obtained from competition FP experiments and used to calculate IC50 
values  
 
FPA is a member of the depsidone family of natural products and like NA, discussed in the 
previous chapter, contains an orthophenolic aldehyde, suggesting the ability to covalently modify 
protein targets. However, NA inhibits AcID•ATF6a better than AcID•ETV5 while FPA showed 
modest facial selectivity at the H1 face, inhibiting AcID•ETV5 2-fold better than AcID•ATF6a. 
Thus, while these molecules have high structural similarity, they may bind to unique sites on AcID 
or, alternatively, bind at similar sites yet have distinct effects on conformational tuning. The main 
difference between FPA and NA is the presence of a fumarate functionality on FPA (Figure 3.11). 
Further interrogation of the binding mechanism of FPA will be necessary to fully understand 
inhibition. However, this preliminary data suggests that fine tuning of coactivator targeting 
inhibitors could provide even selectivity at the individual PPI level for those proteins with multiple 
binding interfaces.  
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Figure 3.11. Comparison of FPA(left) and NA(right). The non-orthophenolic aldehyde containing 
benzene ring of FPA is differently substituted than the corresponding ring of NA. Most notable is the 
presence of the fumarate moiety (red), although there are additional subtle changes (blue). Potentially 
significant, NA contains two aldehydes, while FPA only contains one.  
 
Optimization of duplex assay for IBiD  
With the successes of this approach using AcID•ETV5 and KIX•MLL, the duplex approach 
was tested with another ABD of interest, IBiD. Direct binding experiments of TR-ETV5 and FITC-
ACTR tracers were performed in isolation, with IBiD or AcID, and in duplex, with both IBiD and 
AcID. As shown in Figure 3.12, the dissociation constants of the tracers were unaffected in the 
duplex format. Additionally, each tracer shows high selectivity for the cognate ABD (>10 fold).  
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Figure 3.12. Development of duplex assay utilizing Med25 AcID and CBP IBiD. A) Direct binding 
fluorescence polarization data was obtained in technical triplicate, with the average plotted and error bars 
representing the standard deviation of the mean. B) Calculated binding constants (Kd), shown in µM, for 
each peptide tracer under the various conditions tested. The Kd for IBiD•TR-ETV5 and AcID•FITC-ACTR 
could not be determined because it is greater than ½ the maximum protein concentration used in this assay. 
 
Conditions for competition experiments were optimized for signal-to-noise, with best results 
obtained with AcID•TR-ETV5 at 50% bound and IBiD•FITC-ACTR at 80% bound. With these 
conditions, the Z’ factors are 0.86 for IBiD and 0.68 for AcID. Thus, the duplex screen platform 
appears to be a generalizable strategy for coactivator protein inhibitor discovery.  
 
3.4 Conclusions 
Taken together, the results shown here demonstrate that the duplex FP format is a viable 
HTS platform for activator•coactivator interactions. Further, considering selectivity throughout 
the screening process streamlines discovery of selective small molecule modulators. Demonstrated 
here, using this approach with Med25 AcID and CBP KIX, screening of a small pilot library 
resulted in identification of a novel Med25 inhibitor, fumarprotocetraric acid, that demonstrated 
enhanced selectivity for AcID•ETV5 over a panel of other related coactivators and interactions. 
Additionally, while this approach was validated with Med25 AcID and CBP KIX, preliminary data 
suggests that this would be applicable to any set of coactivators, if there is demonstrated specificity 
of the selected TAD tracers.  
 
3.5 Materials & Methods 
Protein expression and purification 
Proteins were expressed and purified as described in Chapter 2. 
 
Synthesis of transcriptional activation domain peptides  
The synthesis of peptides FITC-MLL(840-858), FITC-ETV5(38-68), FITC- ATF6a(40-
66), FITC-myb(291-316), FITC-HIF1a(786-826), FITC-ACTR(1041-1088), and Ac-IBiD(2063-
2111) were described in the previous chapter.  
To generate Texas-Red labelled peptide tracers of ETV5(38-68) and MLL(840-858), first 
the peptides sequences were synthesized following standard FMOC solid-phase synthesis methods 
on a Liberty Blue Microwave Synthesizer (CEM), with the addition of an N-terminal β-alanine (as 
described in depth in Chapter 2). Because Texas-Red sulfonyl chloride was used and hydrolysis 
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of the sulfonyl-chloride group can easily occur leading to poor yields, only dry reagents were used. 
Briefly, peptides still on resin were washed 5x with dry dichloromethane (DCM). For coupling, a 
slight excess (1.2 equivalents) of Texas-Red was dissolved in 1.9 mL dry DCM with 100 µM 
diisopropylethylamine and added to a foiled reaction vessel containing the peptide on resin. 
Coupling occurred for 18 hours on a rotator at RT. Peptides were deprotected and cleaved from 
the resin for 3 hours in 95% trifluoroacetic acid, 2.5% ethanedithiol, 2.5% water. Crude peptides 
were filtered to remove resin, dried under nitrogen stream, and precipitated from cold ether.  
Peptide suspensions were transferred to a 15 mL falcon tube, centrifuged at 4000 g for 5 minutes 
at 4°C, and ether decanted.  Crude peptides were resuspended in 40% acetonitrile, purified via 
HPLC on an Agilent 1260 HPLC using a semi-prep C18 column (Phenomenex).  A gradient of 
15-65% acetonitrile over 50 minutes was used, collecting fractions based on absorbance at 590 
nm. Pure fractions were collected and lyophilized to afford pure peptides. Final purity was 
determined via analytical HPLC and identify was confirmed using mass spectrometry.   Analytical 
spectra were obtained using an analytical C18 column (Phenomenex) on an Agilent 1260 HPLC.  
Mass spectra were obtained using an Agilent 6545 LC/Q-TOF.  Analytical spectra of peptides can 
be found in Appendix A.  
 
Fluorescence polarization assay protocol – direct binding and competition.  
Fluorescence polarization assays were conducted as described in Chapter 2.  
 
Duplex HTS protocol 
The pilot screen of 2,846 compounds was completed in the Center for Chemical Genomics. 
AcID (0.6 μM final concentration) and KIX (2 μM final concentration) were plated in 384-well 
format and treated with 20 µM (final concentration) of each library compound. The fluorophore-
labeled tracers were added (20 nM final concentration; leading to 50% bound complex) and the 
plates incubated for 30 min at room temperature before fluorescence polarization measurements 
in the fluorescein and Texas Red channels were made using a PheraStar plate reader. Percent 
inhibition for each compound was determined using wells treated with DMSO as a negative control 
and wells containing fluorophore-tagged peptide alone as a positive control. Each plate contained 
32 negative control wells, containing the protein-tracer complex mixture dosed with DMSO, and  
32 positive control wells, containing tracer only. The assay demonstrated excellent performance 
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with Z’ factors of 0.88 and 0.64 for the AcID•FITC-ETV5 and KIX•TR-MLL measurements, 
respectively. Using an initial activity threshold a polarization value >/= 3 S.D. below the average 
signal of that of the negative controls, 26 molecules were identified as hits against the AcID•ETV5 
interaction (0.91% hit-rate) and 94 compounds were identified as hits against the KIX•MLL 
interaction (3.3% hit-rate). A comparison of the individual data sets revealed that 6 compounds 
inhibited both interactions at the 3 S.D. cutoff, leading to their preliminary classification as dual 
inhibitors. 
For preliminary development of the IBiD and AcID duplex screen, the final concentration 
of protein per well found to be optimal for the assay was 100 nM and 530 nM respectively. To 
determine the Z-Score, protein was plated followed by addition of TR-ETV5 and FITC-ACTR 
tracers (final concentration 20 nM; representing 50% bound complex for AcID•ETV5 and 80% 
bound complex for IBiD•ACTR). Protein and tracer were incubated for 30 min at room 
temperature before fluorescence polarization measurements in the fluorescein and Texas Red 
channels were made using a PheraStar plate reader. 48 negative control wells and 48 positive 
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Targeting the Transmembrane Serine Protease TMPRSS2 to Prevent SARS-CoV-2 
Infection‡ 
4.1 Abstract 
The COVID-19 pandemic has highlighted the need for new antiviral targets, as many of the 
currently approved drugs have proven ineffective against mitigating SARS-CoV-2 infections. The 
host transmembrane serine protease TMPRSS2 is a highly promising antiviral target, as it plays a 
direct role in priming the spike protein before viral entry occurs. Further, unlike other targets such 
as ACE2, TMPRSS2 has no known biological role but is implicated in infectivity of many 
additional viruses. There are few published TMPRSS2 inhibitors, and those that exist are not ideal 
biological probe compounds or drugs. Thus, TMPRSS2 is an attractive therapeutic target and there 
is a need for novel inhibitors. In this chapter, an in vitro biochemical platform with which 
TMPRSS2 protease can be studied and novel inhibitors can be identified is developed. Ultimately, 
this approach is used in combination with in silico screening to identify a set of TMPRSS2 
inhibitors from already approved drugs. Characterization of lead compounds and known inhibitors 
is conducted, providing insight into their TMPRSS2 inhibitory mechanism. Additional preliminary 
screening data of multiple libraries is presented.  
 
4.2 Introduction 
The emergence of COVID-19 in late 2019 and the rapid transmission of the disease around the 
globe has prompted an urgent need for effective treatments.1 As with many coronoviruses, 
 
‡ The majority of this chapter is reproduced from Peiffer A.L*, Garlick J.M.*, Wu Y., Soellner M.B., Brooks C.L. 
III, Mapp A.K. TMPRSS2 inhibitor discovery facilitated through an in silico and biochemical screening platform 
(DOI: 10.1101/2021.03.22.436465). The research described in this chapter was a collaborative effort. Julie Garlick 
and Amanda Peiffer conceived the project, targeting TMPRSS2 as an anti-SARS-CoV-2 strategy. Julie Garlick led 
experimental approach on the biochemical side. Amanda Peiffer led experimental approach on the computational side. 
Julie Garlick and Amanda Peiffer developed expression and purification protocols for TMPRSS2 protease. Julie 
Garlick conducted all assay development, mass spec experiments, and screening. Amanda Peiffer constructed the 
homology model as well as interpreted computational results, such as analysis of docked structures. Yujin Wu 
developed the flexible docking protocol and scoring functions, and used them to conduct in silico screening. Tessa 
Epstein curated the guanidinium screening library. 
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infection with SARS-CoV-2 requires host cell cooperation; the spike (S) protein located on the 
viral coat requires priming by TMPRSS2, a human transmembrane serine protease, for viral entry 
via the receptor ACE2 (Figure 4.1).2–5 While many groups are focusing on blocking the 
interactions between ACE2 and the S protein, ACE2 also plays an important role in healthy cell 
function by counterbalancing ACE to lower and maintain healthy blood pressure.6 Alternatively, 
there is little known about the biological function of TMPRSS2, with data suggesting it is likely 
functionally redundant.7,8 TMPRSS2-/- knockout mice have little phenotypic differences compared 
to wild-type animals, yet conferred resistance to viral infections, suggesting that the protein is not 
essential.9  Inhibiting transcription of TMPRSS2 via BET inhibitors leads to decreased infectivity 
of SARS-CoV-2 in human lung cells, further suggesting the viability of TMPRSS2 inhibition as 
an antiviral strategy.10 Besides its role in viral infection, the other documented functions of 
TMPRSS2 are related to prostate cancer.11–13 TMPRSS2 expression is regulated in an androgen 
dependent manner, and has been shown to be overexpressed in prostate cancer, and potentially 
linked to cancer progression and metastasis.11,12,14 However, it is unclear if TMPRSS2 
overexpression is functionally significant, or its overexpression is just the result of the real issue, 
misregulation of the androgen receptor. In addition, translocations of the ETS transcription factor 
genes to the TMPRSS2 promotor is known to occur. This leads to over expression of the ETS 
transcription factors, now regulated by the androgen receptor.15,16 Thus at this point TMPRSS2 is 
only known to have detrimental functions in humans, aiding in viral infection and cancer 
metastasis. Additionally, as a human protein target rather than a viral protein target, TMPRSS2-
targeting therapeutics should be less susceptible to drug-resistance due to viral mutation. Taken 
together, this information indicates that TMPRSS2 is a desirable drug target for preventing SARS-
CoV-2 infection.   
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Figure 4.1. TMPRSS2 aids in SARS-CoV-2 viral infection. A) TMPRSS2 primes the viral S protein 
(SARS-2-S), which promotes membrane fusion and ultimately viral entry. TMPRSS2, part of the type II 
transmembrane serine protease family and hepsin/TMPRSS subfamily, is anchored at the cell membrane.4 
The protein is mostly extracellular, with a small intracellular cytosolic domain. The extracellular portion of 
the protein is composed of a LDLR class A domain, an SRCR domain, and finally the peptidase S1 domain 
required for catalytic activity.17 B) The peptidase S1 domain of TMPRSS2 cleaves SARS-2-S at the S2’ 
cleavage site.18,19 Figure created using BioRender.  
 
To date, there are few reported TMPRSS2 inhibitors. Camostat, a compound initially 
discovered as a Matriptase 2 inhibitor, also inhibits TMPRSS2.4,20 Nafamostat and gabexate have 
also been reported to inhibit TMPRSS2. However, camostat, nafamostat, and gabexate lack 
TMPRSS2 specificity and inhibit a wide range of serine proteases. Additionally, camostat is 
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metabolized in mammals to structures with poorly defined activity. 21–23 Further, these compounds 
have only recently been explored for clinical applications with SARS-CoV-2, and the underlying 
inhibitory mechanism of action is still being investigated.20,22 It has been reported that each of 
these compounds form a covalent bond with the active site serine of serine proteases via the central 
ester, also a site of metabolic breakdown (Figure 4.2).24,25 Additionally, molecular modeling 
studies on TMPRSS2 supports covalent bond formation with both camostat and nafamostat, as 
well as the camostat metabolite FOY 251.26 Thus, TMPRSS2 inhibitors with less reactive 
architectures are highly desirable. 
 
Figure 4.2. The molecules that have commonly been cited as TMPRSS2 inhibitors. All four inhibitors 
contain a reactive ester, which can form a covalent bond with the activated catalytic serine. Highlighted are 
the adducts that would form. Camostat, nafamostat, and FOY 251 all form the same adduct (blue). Apparent 
IC50 values for the four inhibitors against TMPRSS2 after 30 minutes incubation time are shown. 
 
TMPRSS2 is part of the type II transmembrane serine protease family and hepsin/TMPRSS 
subfamily. The protein, anchored at the cell membrane, is mostly extracellular, with a small 
intracellular cytosolic domain. The extracellular portion of the protein is composed of a LDLR 
class A domain, an SRCR domain, and finally the peptidase S1 domain, which is required for 
catalytic activity (Figure 4.1).4,17 Thus, the most obvious site for TMPRSS2 inhibition is the active 
site of the peptidase itself, and indeed this is where prior efforts have been focused.11,27–29  The 
classic triad of His/Asp/Ser is present (H296, D345, S441) in the active site, and mutating any of 
these residues abrogates activity in vitro.17 Determining the endogenous substrates and function of 
TMPRSS2 has been challenging, with even complete knockout in mice producing no measurable 
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effects histopathologically and phenotypically.7 A few studies exist looking at the substrate scope 
of TMPRSS2, for example matriptase and PAR2 have been shown to undergo TMPRSS2 mediated 
activation in prostate cancer proliferation and migration pathways, and positional scanning data is 
available for P1-P4 substrate peptides.12,30,31 These data indicate that TMPRSS2 strongly prefers 
Arg as the P1 residue.11 In addition, results from substrate-based inhibitors suggests analogues 
with hydrophobic D-configuration P3 residues are the most successful for TMPRSS2 inhibition.28 
However, further studies will be necessary to define chemotypes that are particularly potent and 
selective for TMPRSS2.  
The most significant roadblock in TMPRSS2 inhibitor discovery is the well-documented 
challenge of obtaining catalytically active enzyme, full-length or the peptidase domain;33,35,40 even 
commercial sources of TMPRSS2 exhibit low to no activity, making it difficult to carry out 
extensive screening campaigns.43 This chapter begins with design of a novel expression construct 
which eliminates the need for multiple rounds of purification. In addition, re-folding conditions 
were optimized, leading to isolation of sufficient TMPRSS2 peptidase domain for a full screening 
and follow-up campaign for up to 5000 compounds with a single 1-L expression.48 This allowed 
for biochemical characterization of known TMPRSS2 inhibitors as well as identification of novel 
active-site inhibitors, including two new TMPRSS2 inhibitor architectures, using a hybrid in 
silico/in vitro screening platform. 
 
4.3 Results & Discussion 
Recombinant expression of TMPRSS2 Peptidase S1 domain in E. coli 
Like other serine proteases, TMPRSS2 is natively expressed as a zymogen; activation occurs 
via autocatalysis of the peptide bond between Arg-255 and Ile-256, leaving the N-terminal portion 
of Ile-256 to undergo a conformational change to stabilize the active state.32–34 Careful 
consideration was taken when designing the gene fragment for recombinant expression and 
purification of the TMPRSS2 peptidase domain (residues 256–492). C-terminal affinity tags 
appear to disrupt catalytic activity; thus, an N-terminal affinity tag is required but must be removed, 
leaving residue Ile-256 with a free N-terminus. Previous approaches to expression and purification 
in bacteria have utilized an orthogonal protease to allow for cleavage directly N-terminal to Ile-
256, such as the TAGzyme system.28 We hypothesized that utilizing a construct with an extended 
N-terminal portion would be enough to promote enzyme autocatalysis, removing any N-terminal 
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affinity tag as well as yielding the necessary free isoleucine without the need for multiple rounds 
of purification and introduction of an orthogonal cleavage site. Thus, a gene fragment for the 
catalytic domain of TMPRSS2 was constructed (see Methods), called TMPRSS2(247–492), with 
an N-terminal 6xHis tag for purification (Figure 4.3).  
 
Figure 4.3. Proposed construct for TMPRSS2(256-492) peptidase expression in E. Coli. The proposed 
amino acid sequence was inserted into pET28a+ vector with a kanamycin resistance cassette. Autocleavage 
of the peptide bond between R255 and I256 (highlighted in red and denoted with an arrow) should allow 
for removal of the 6xHis purification tag once the protein is activated.   
 
Overexpression of the TMPRSS2(247–492) construct in E. coli led to protein aggregation in 
insoluble inclusion bodies, which enabled simple separation from the remaining cell lysate. 
Solubilizing the inclusion bodies required denaturing the aggregates utilizing 8 M urea. The N-
terminal 6xHis tag was used to remove the denatured, unfolded protein from remaining impurities 
by batch binding with Ni-NTA resin. Purified, denatured TMPRSS2 was then subjected to 
refolding by rapid dilution in 1:100 refolding buffer. Development of a modified refolding 
procedure using a syringe pump for slow and controlled dilution proved to be instrumental in 
producing active protein, likely due to providing a more optimal environment for the three internal 
disulfide bonds to correctly form. Concentration (10-fold) and subsequent dialysis into a 50 mM 
Tris 500 mM NaCl 0.01% NP-40 pH 8 buffer led to activation of the enzymatic activity 
demonstrated by the autocatalytic cleavage of the 6xHis tag (Figure 4.4).  
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Figure 4.4. Expression and purification of TMPRSS2 peptidase domain. A) Protein is expressed and 
purified by expression in inclusion bodies (labeled denatured), purified by batch binding to Ni-NTA resin, 
refolded, and dialyzed into assay buffer. Silver staining shows purity and protein levels at each step 
(TMPRSS2, ~26kDa). Western blot with TMPRSS2 antibody raised against the protease domain confirms 
the identity of the 26 kDa protein observed with silver staining as TMPRSS2. B) Western blot for 6xHis 
tag at various stages of TMPRSS2 purification. Significant signal is seen after denaturation and at various 
time points during refolding. A small amount of His-tagged protein is observed immediately after exchange 
of concentrated refolding solution into activation buffer, but ultimately no signal is observed, indicating 
autocleavage and removal of 6xHis tag, in the final active product. Experiments conducted with Amanda 
Peiffer.  
 
Activity of TMPRSS2 peptidase domain  
The canonical trypsin substrate Boc-QAR-AMC has been reported as a TMPRSS2 substrate, 
which we used to confirm activity of the purified protein (assay overview in Figure 4.7).11,21 To 
determine approximate concentration of active protein, we measured TMPRSS2 activity while 
titrating in the covalent protease inhibitor FPR-chloromethylketone (also known as PPACK).35–37 
This inhibitor reacts with the histidine in the catalytic triad of serine proteases to irreversibly 
alkylate and inactivate the enzyme, in a 1:1 complex (Figure 4.5). We determined the KM to be 5.1 
± 0.4 μM  
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Figure 4.5. Inhibition curve of TMPRSS2 activity obtained with increasing [FPR-cmk].  The IC50 
obtained here is 0.32 ± 0.09 nM, allowing us to approximate 100% inhibition at about 0.64 nM. Thus, 
assuming 1:1 complex formation of protein and inhibitor, we can determine the protein concentration of 
this sample to be about 0.64 nM. Data points represent the average of technical triplicate data points with 
error bars indicating the standard deviation of the mean.  
 
with TMPRSS2, which is comparable to the KM for trypsin with this substrate, 7.8 ± 0.7 μM (Figure 
4.6). Experimental conditions for high throughput screening (HTS) in 384-well plates were 
optimized using 2.5 μM substrate and 0.5 nM TMPRSS2. The concentration of substrate in this 
assay was set below the KM to enable identification of competitive inhibitors. After incubation at 
room temperature for 30 min, endpoint fluorescence was determined (ex: 355 nm, em: 450 nm). 
At 30 min, less than 20% of the substrate was cleaved as determined by comparing fluorescence 
to that of 2.5 µM free AMC (i.e. 100% substrate conversion), enabling inhibition to be monitored 
while activity is still within the linear range. The S:B and Z factor were calculated to be 10.6 and 
 






















Figure 4.6. Boc-QAR-AMC as a substrate for TMPRSS2 and Trypsin. The KM of Boc-Gln-Ala-Arg-
AMC is determined for TMPRSS2 (left) and Trypsin (right) by plotting initial velocity, calculated as the 
slope of the kinetic trace at less than 10 percent substrate cleavage, vs substrate concentration. Data was fit 
to the Michaelis-Menten equation using GraphPad Prism. Individual data points are kinetic experiments 
conducted in duplicate with error bars as the standard deviation of the mean.  
 
0.79, respectively, indicating an excellent HTS assay (Figure 4.7). This biochemical assay was 
then utilized to test the apparent IC50 of known inhibitors camostat, nafamostat, and gabexate, 
where the compounds were incubated with TMPRSS2 for 30 min before substrate was added 
(Figure 4.7). IC50 values for these compounds agree with previously reported values obtained using 
similar biochemical approaches.21 Notably, the IC50 values for these compounds are very low, 









































KM = 7.8 ± 0.7 µM 
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Figure 4.7. Development of biochemical TMPRSS2 activity assay. A) Schematic of the biochemical 
assay used to monitor TMPRSS2 activity. Cleavage of the peptide bond between Arg and AMC in the 
substrate results in release of the AMC fluorophore, for which fluorescence can be monitored. B) TMPRSS2 
activity assay was adapted to 384 well format with the Z factor indicating an excellent assay. Negative 
controls correspond to protein + substrate, while positive controls correspond to substrate only. C) 
Inhibition of TMPRSS2 by compounds camostat, nafamostat, FOY 251, and gabexate, with 30 minutes 
preincubation of protein and inhibitor. Data points represent the average of technical triplicate with error 
bars indicating the standard deviation of the mean. IC50 values are listed in Figure 5.2. 
 
Analysis of covalent TMPRSS2 inhibitors  
While it has not been confirmed experimentally, others have suggested that the inhibitors 
camostat and nafamostat covalently modify TMPRSS2 with a similar mechanism to other 
proteases.26 This involves initial binding, acylation, and ultimately hydrolysis. While it would be 
ideal to validate formation of a covalent adduct with TMPRSS2 using mass spectrometry, the 
purification of the protease domain yields low concentrations of active protein that is very sensitive 
to buffer conditions, making mass spectrometric analysis intractable. However, we demonstrate 
covalent adduct formation via mass spectrometry using trypsin (Figure 4.8). With equimolar 
protein and compound, an increase in mass of 161 Da is observed for camostat, nafamostat, and 
FOY 251. Gabexate requires 10X compound compared to protein for adduct formation to be 




Figure 4.8. Camostat, nafamostat, FOY 251, and gabexate covalently modify Trypsin. A-D) 
Deconvoluted LC-MS data of trypsin (A), incubated with equimolar camostat (B) nafamostat (C), or FOY 
251 (D). After 30 minutes incubation, a mass increase of about 161 Da is observed, indicating covalent 
adduct formation. E) Trypsin incubated with 10 equivalents gabexate. After 30 minutes incubation, a mass 
increase of about 155 Da is observed, indicating covalent adduct formation. No mass change was observed 
after 30 minutes incubation with equimolar inhibitor 
 
dependent decrease in apparent IC50 is observed with camostat in biochemical activity assays for 
both trypsin and TMPRSS2 (Figure 4.9). This shift in IC50 vs. time fits to an equation for one phase 
decay, with the IC50 values approaching the limiting concentration of the protein used in the assay, 
suggesting that covalent bond formation is occurring at the active site (Figure 5A). Thus, while 
these compounds exhibit low nM IC50 values in vitro, this is likely due to the covalent mechanism 
of action.  
 
Figure 4.9. Decreasing IC50 values for camostat with increased incubation time for trypsin (A) and 
TMPRSS2 (B) is consistent with covalent inhibition. Left: IC50 curves of camostat obtained at after 
varying incubation times with protein. Values plotted are the average of triplicate data points with the error 
represented as the standard deviation of the mean. Right: Plot of camostat IC50 vs incubation time, fit to an 
equation for one phase decay. 
 
It is important to note that in a cellular context camostat has a very short half-life, <1 min.38 
Rapid hydrolysis to (4‐(4‐guanidinobenzoyl‐oxy)phenylacetic acid), also known as the protease 
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inhibitor FOY 251, occurs both in vitro in serum as well as in vivo.39–41 We observed similar 
potencies of FOY 251 and camostat in our biochemical assay, with apparent IC50 = 4.3 ± 0.9 nM 
and 2.7 ± 0.4 nM, respectively (Figure 4.2). The half‐life of FOY 251 is longer than camostat, 
though it is metabolized to 4-guanidinobenzoic acid, which shows minimal TMPRSS2 
inhibition.39 Thus, it would be advantageous to identify novel inhibitors that have alternative 
molecular scaffolds.  
 
Combined in silico and biochemical screening leads to identification of novel inhibitors 
Virtual screening methods have greatly improved over the past two decades, leading many 
drug discovery campaigns by filtering out thousands/millions of molecules before testing them in 
vitro.42–46 However, such studies require a structural model in which to dock compounds into the 
active site. Because no crystallographic or NMR-based models exist for TMPRSS2, we developed 
a homology model for the active soluble domain starting from prediction using the SWISS-
MODEL web-interface (Figure 4.10).47–51 This structure was built based on sequence homology 
of hepsin (PDB 5CE1). The structure showed high homology with the TMPRSS2 peptidase 
domain (34% sequence similarity with 70% sequence coverage) and also contained the bound 
ligand 2-[6-(1-hydroxycyclohexyl)pyridin-2-yl]-1H-indole-5-carboximidamide, which served as 
one of the templates for pharmacophore-based docking of putative ligands. Full descriptions of 






Figure 4.10. TMPRSS2 homology model. The catalytic triad is highlighted in lime green. D435, key for 
substrate recognition, is shown in red. Experiment conducted by Amanda Peiffer. Figure generated using 
BioRender. 
 
A total of 134,109 molecules were collected from multiple databases (ZINC, SweetLead, and 
the Center for Chemical Genomics) and subjected to initial screening, leading to 4,307 Level 1 
candidates which were ranked by a novel scoring function developed by Yujin Wu. The virtual 
screen was successful on many fronts. MD-based flexible docking identified residues near the 
active site that are conformationally dynamic to accommodate different ligands. Specifically, 
residues Gln-438 and Lys-342 show the greatest conformational change upon ligand binding, 
suggesting that they participate in stabilizing bound compounds. The known inhibitors camostat, 
nafamostat, and gabexate ranked in the top 5 compounds, and all adopted poses that demonstrate 
how the catalytic serine residue positions itself to ultimately react with the inhibitors while the 
guanidinium functionality forms a salt-bridge interaction with the active site Asp-435. Upon 
substrate binding in the active site of a serine protease, the active site serine is deprotonated by the 
histidine in the catalytic triad, turning it into a reactive nucleophile. This is key for the mechanism 
of covalent inhibition by compounds such as camostat. Thus, we performed a subsequent docking 
experiment using the three molecules with these charge changes (Figure 4.11). For all three 
molecules, the deprotonated serine allows for more advantageous position in the active site for 
nucleophilic attack the carbonyl carbon to occur. For instance, the distance between the serine 
oxygen and camostat carbonyl carbon decreased from 4.9 Å to 3.5 Å, and the distance for gabexate 
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decreased from 5.9 Å to 3.3 Å. While nafamostat appears to be further away from the reactive 
carbon (4.4 Å to 4.8 Å), the molecule flips so that the carbonyl is positioned for reactivity.    
 
Figure 4.11. Docked poses of camostat, nafamostat, and gabexate in the TMPRSS2 active site with 
the proton transfer from Ser-441 to His-296 that occurs after substrate binding. Shown in red is D435, 
which resides at the bottom of the S1 binding pocket, and lime green corresponds to the catalytic triad (His-
296, Asp-345, Ser-441). Dashed lines shown here indicate the distance between the catalytic serine oxygen 
and the carbonyl carbon of each inhibitor (camostat = 3.5 Å, nafamostat = 4.8 Å, gabexate = 3.5 Å). 
Experiments done by Yujin Wu and Amanda Peiffer.  
 
Several clinically approved drugs emerged as top ranked compounds in the virtual screen, and 
these were selected for initial testing in the biochemical assay and validation of the platform. Like 
the covalent inhibitors, pentamidine, propamidine, and debrisoquine all contain a guanidinium 
moiety and docked into the active site of TMPRSS2 with the positive charge pointing towards 
Asp-435 (Figure 4.12). Biochemically, all three molecules inhibited TMPRSS2 activity with 
varied potencies, with debrisoquine being the least potent (Figure 4.12). The docked poses of 
pentamidine and propamidine show both compounds are positioned to block the active site 
residues, whereas debrisoquine does not fully span the catalytic triad, which likely correlates to 
the differences in potency. Pentamidine and propamidine are of similar size to camostat and 
nafamostat, typical of small molecule inhibitors (>350 MW), while debrisoquine is quite small, at  
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Figure 4.12. Profiling of clinically approved drugs identified as top hits from computational 
screening. A) Inhibition of TMPRSS2 in biochemical activity assay. Raw inhibition values used to obtain 
IC50 curves. Data is the average of duplicate experiments conducted in technical triplicate. B) Structures of 
hits, calculated IC50 values, and ligand efficiencies (LE). C) Docking results for the three drugs identified 
as hits both in the virtual screen and the in vitro assay. All three molecules fit into the active site (Asp-435 
at the bottom of the pocket shown in red). Pentamidine and propamidine obstruct access to the catalytic 
triad (shown in lime green), whereas the fragment debrisoquine only partially reaches these residues. 
Experiments conducted with Yujin Wu and Amanda Peiffer.  
 
175.2 MW, classifying it as a fragment rather than a small molecule. However, debrisoquine has 
the greatest calculated ligand efficiency (LE) at 0.42 compared to pentamidine and propamidine, 
which are 0.33 and 0.31 respectively. Thus, for its small size debrisoquine binds well to 
TMPRSS2. Furthermore, a LE = 0.42 is suggestive of an excellent starting point for fragment 
expansion efforts. It is worth noting that each of these molecules also inhibit trypsin activity 
(Figure 4.13). However, the fragment debrisoquine has modest selectivity for TMPRSS2 over 
trypsin (~3 fold). As observed with the covalent inhibitors (camostat, nafamostat, and gabexate; 
Figure 4.11), the docking studies with the noncovalent compounds showed significant structural 
rearrangements for the two non-catalytic residues, Lys-342 and Gln-438 (Figure 4.12). While Gln-
438 is conserved across the serine proteases tested here as well as those used to construct the 
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homology model (i.e. TMPRSS2, trypsin, hepsin; lysine residue in human plasma kallikrein), Lys-
342 only appears in TMPRSS2. In fact, the entire loop where this residue resides greatly differs in 
length and conformation among the four proteases.  Thus, derivatization of a fragment like 
debrisoquine towards Lys-342 may confer additional selectivity across similar serine proteases. 
 
Figure 4.13. Inhibition of Trypsin by pentamidine, propamidine, and debrisoquine. Inhibitors were 
preincubated with protein for 30 minutes before addition of substrate. Data points represent the average of 
technical triplicate with error bars indicating the standard deviation (left). Calculated IC50 values (right). 
 
Curated libraries based on guanidinum functionality 
As previously discussed, a commonality of the TMPRSS2 inhibitors identified thus far is the 
presence of one or more guanidinum groups. Thus, an attractive approach to TMPRSS2 inhibitor 
identification would be to create a TMPRSS2-directed library, comprised of compounds all 
containing this moiety. Prof. Alison Narayan’s lab, through utilizing enzymes in the biocatalytic 
pathway of saxitoxin synthesis, has the ability to generate compounds that fall into this 
category.52,53 An initial screen was conducted of a small library of compounds made by Narayan 
lab members using the enzyme Saxitoxin G (library collated by Tessa Epstein). When tested at 10 
µM, two compounds showed >15% inhibition of TMPRSS2 activity, indicating that these would 
be good starting points to further derivatize for increased potency (Figure 4.14).  


















debrisoquine 220 ± 30 
pentamidine  2.6 ± 0.4 
propamidine 7 ± 1 
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Figure 4.14. SxtG fragment screening results. Fragments were preincubated with protein for 30 minutes 
before addition of substrate. Single concentration points (10 µM) of each fragment were tested in triplicate 
and are represented in green. Camostat, in orange, was tested on the same plate as a control at both 10 µM 
and 10 nM, both in triplicate. The positive control, substrate only, representing 0% substrate conversion, 
was tested in 6 replicate wells. The negative control, substrate and protein, representing 100% substrate 
conversion, was tested in 12 replicate wells. Data points represent the average with error bars indicating the 
standard deviation. The two lead fragments with >15% inhibition are shown on the right.  
 
Covalent inhibitors of TMPRSS2 
As shown with camostat and related compounds, covalent inhibition can lead to extremely 
potent small molecule inhibitors. Additionally, covalent chemical probes have many advantages, 
such as allowing for proteome-wide target identification and increasing specificity among related 
enzymes.54,55 Serine proteases utilize an activated serine residue to cleave substrate amide bonds 
via a covalent acyl-enzyme intermediate.56–58 Thus, this same reaction can be exploited to lead to 
inhibition of the active site serine via formation of a covalent bond. Importantly, the active site 
serine is not “activated” until substrate binding occurs, leading to rearrangement of the catalytic 
triad and subsequent deprotonation of the active site serine by histidine.34 Based on this 
mechanism, even with a covalent warhead a small molecule must bind at the active site for bond 
formation to be possible, which may be advantageous for selectivity. Serine proteases in general 
have been thoroughly studied in the literature, and thus potential chemical warheads that can react 
with the active site serine are well documented.55,59–63 A library of serine focused covalent 
fragments, 1280 compounds, was purchased from enamine for screening against TMPRSS2. 
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Functional groups within this library included sulfonyl fluorides, epoxides, β-Propiolactone; γ-
butyrolactone; β-lactams, boronic acids, piperidines and piperazines.  
For high-throughput screening, the compounds were plated at 25 µM concentration 
followed by addition of TMPRSS2 protein. Compound and protein were incubated for 1 hour at 
room temperature to allow for covalent bond formation. After 1 hour, Boc-QAR-AMC substrate 
was added and endpoint fluorescence was read after 30min, at which 16% substrate conversion 
had occurred in the negative control. The Z factor was calculated to be 0.7, indicating an excellent 
assay. A cutoff of 3 SD above the mean of the negative control (zero percent inhibition), was used 
to determine hits and with this criteria 45 hit compounds were identified (Figure 4.15, full 
screening data available through MScreen). Of these 45 compounds, 38 displayed greater than 
20% inhibition. A subset of structures from the top 45 compounds are shown in Figure 4.15 The 
hits contained a variety of warheads, with sulfonyl fluorides being the most common (25), with 
aldehydes (8) and boronic acids (5) also appearing multiple times. Further chemoinformatic 
analysis will be necessary to determine if these functionalities are enriched based on the library 
composition. Additionally, follow up screening for both time and concentration dependence as 





Figure 4.15. Enamine library screening results. A) Campaign view of HTS. Green dots represent 
compounds, red dots represent the positive controls (substrate only), and blue dots represent the negative 
controls (protein and substrate). The red line indicated the 3SD cutoff used to determine hits. Figure 
generated on MScreen. B) Representative structures from the top 45 hits. Compounds were selected to 
emphasize chemical diversity, and covalent functionality is highlighted in red.  
 
4.4 Conclusions 
With new strains of SARS-CoV-2 emerging, and the significance of TMPRSS2 in viral entry 
for multiple coronaviruses, it is pivotal that we uncover novel strategies to inhibit TMPRSS2 
protease activity.64,65 However, TMPRSS2 provides obstacles in multiple areas of the discovery 
pipeline. For instance, the lack of an experimentally solved structure makes docking studies a 
challenge, relying instead on the use of a homology model developed based on other serine 
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protease domains. Biochemically, the protease domain of TMPRSS2 has proven difficult to purify 
and refold recombinantly in E. coli, which has stalled many high-throughput screening efforts. 
This chapter has demonstrated that combined computational and experimental techniques can be 
used to identify new TMPRSS2 protease inhibitors. Having identified promising scaffolds with 
high ligand efficiencies, future work will be dedicated towards improving potency and selectivity 
of these inhibitors. While we have developed an effective expression and purification protocol for 
the TMPRSS2 peptidase domain, it remains a challenge to obtain high yields of active protein. 
Thus, the combined virtual and biochemical screening approach presented here is attractive 
because it enables an initial triage through large compound libraries before testing a smaller 
number of molecules, more likely to be functionally relevant, in an assay. Current efforts are 
directed toward testing more hits prioritized from the computational screen for biochemical 
activity. The results of the two primary fragment screens presented here are currently being tested 
for concentration response and in secondary screening to identify additional lead scaffolds. 
 
4.5 Materials & Methods 
Mass spectrometric analysis of trypsin  
Trypsin (Sigma, T9201), 10 µM, was incubated with compound, 10 µM, for 30 minutes at 
room temperature in assay buffer (50 mM Tris, 500 mM NaCl, 0.001% NP-40, pH 7.5) before 
being subjected to analysis by mass spectrometry using an Agilent QToF LC-MS equipped with a 
Poroshell 300SB C8 reverse phase column. A 5-100% gradient of acetonitrile with 0.1% formic 
acid in water to 0.1% formic acid over five minutes was used. Raw data was deconvoluted (intact 
protein of 20,000-25,000 Da) using BioConfirm software with background subtraction.  
 
Vector design 
Plasmids were constructed by Twist Bioscience by inserting the gene for protease domain 
of TMPRSS2, specifically amino acids 247-492, into the pET28a+ vector using the NdeI_XhoI 
restriction enzyme cut-sites.  
 
Protein expression  
The pET28a+ plasmids containing the TMPRSS2 genes were transformed into BL21(DE3) 
and plated on LB agar with kanamycin. The bacteria were grown in small 5 mL LB (+ kanamycin) 
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cultures overnight at 37 °C. The 5 mL starters were used to inoculate 1 L LB (+ kanamycin) 
cultures, which were grown to OD = 0.8 at 37 °C with shaking at 250 rpm. Expression was induced 
using 1 mM Isopropyl β-d-1-thiogalactopyranoside (IPTG), which we let grow for 5 hours. The 
cells were then spun down at 9,500 x g for 15 min. The pellets were collected, flash frozen and 
stored at -80 °C.  
 
Chemical lysis and denaturing 
Before lysing, the cell pellet was first fully thawed until it reached room temperature. 
Chemical lysis was performed by resuspending the pellet using B-PER reagent (Fisher, PI78243) 
with lysozyme (Fisher, 90082) and DNase I (Fisher, 90083) following manufacturer’s protocols. 
The cells were then spun at 15,000 x g for 5 minutes, and the cell lysate was collected and saved. 
The insoluble portion, which contained inclusion bodies of TMPRSS2, was resuspended / washed 
using lysis buffer containing detergent (50 mM Tris HCl, 150 mM NaCl, 1% Triton X-100, pH 
7.5) and then spun at 15,000 x g for 5 minutes. After removing the supernatant, the pellet was 
washed once more with a lysis buffer that did not contain detergent (50 mM Tris HCl, 150 mM 
NaCl, pH 7.5) and then spun at 15,000 x g for 5 minutes.  
The pellet was resuspended and the inclusion bodies were denatured by adding 20 mL 
denaturing buffer (8 M urea, 10 mM Tris, 100 mM sodium phosphate, pH 8.0) plus reducing agent 
(1:1000 BME). Denaturing occurred at room temperature with rotation for at least 30 minutes. The 
concentration of protein was determined via nanodrop, and additional denaturing buffer was added 
to reduce the concentration to below 1mg/mL. Denaturing occurred at room temperature on a 
rotator for at least 30 minutes before being spun down and decanted (20,000 x g, 15 minutes).  
 
Batch binding    
Ni-NTA agarose (Qiagen, 30210) was prepared by washing 3 times with binding buffer (8 
M urea, 10 mM Tris, 100 mM sodium phosphate, pH 8.0). Denatured protein was added to Ni-
NTA resin (750 µL) and incubated at 4 °C on a rotator for 1.5 hours. Resin was pelleted by 
centrifugation at 2500 x g and flowthrough was removed. Resin was washed 3 times with wash 
buffer (8 M urea, 10 mM Tris, 100 mM sodium phosphate, 20 mM imidazole, pH 6.5), followed 
by addition of elution buffer (8 M urea, 10 mM Tris, 100 mM sodium phosphate, 500 mM 
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Imidazole, pH 6.5). Eluting was performed on a rotator at 4 °C for 30 minutes. The resin was again 
pelleted by centrifugation at 2500 x g, and the sample was collected.   
 
Refolding 
The denatured sample was diluted 1:100 into refolding buffer (50 mM Tris, 0.5 M arginine, 
20 mM CaCl2, 1 mM EDTA, 100 mM NaCl, 0.01% NP-40, 0.05 mM GSSG, 0.5 mM GSH, pH 
7.5) at room temperature using a syringe pump (flow rate 1 mL/min) while allowing the solution 
to gently stir.  The refolding protein was left at 4 °C for 3 days with gentle stirring.  
The sample was concentrated 10-fold using Amicon Stirred Cells with 10 kDa 
Ultrafugation disks (Millipore, UFC801024). Once concentrated, the sample was dialyzed 
overnight into assay buffer (50 mM Tris, 500 mM NaCl, 0.001% NP-40, pH 7.5) at 4 °C.  
 
Protein gel and silver staining  
LDS loading dye was added to protein samples and samples were boiled for 5 minutes at 
95 °C. 10uL of each sample was loaded onto a 4-20% mini-PROTEAN TGX gel (BioRad, 
4561096) and run at 180V for 45 minutes. Total protein was visualized using a Pierce Silver 
Staining Kit (Thermo, PI24612) following manufacturer’s protocols. 
 
Western Blot 
After running gel as described above, protein was transferred to PVDF membrane using a 
BioRaD TransferBox Turbo following the standard protocols. Membrane was blocked for 1 hour 
at room temperature using Super Block (Thermo Scientific, 37515). TMPRSS2 antibody (Novus 
biologicals, NBP1-20984) was added to membrane (1:1000 dilution in Super Block) and incubated 
overnight at 4C with gentle shaking. After removal of primary antibody and three washes with 
TBST, HRP conjugated secondary antibody (abcam, ab6741, 1:20,000 in Super Block) was added 
to membrane and incubated at RT for 1hr with shaking. After removal of secondary antibody with 
three washes with TBST, HRP substrate (Thermo Scientific, 34095) was added and after 1 minute 






Assays were conducted on a Molecular Devices Spectramax Spectrophotometer using 96-
well plates (Fisher, 12-565-501). Protein was first plated, followed by addition of substrate, Boc-
QAR-AMC (Bachem, 4017019.0005) at concentrations to give the indicated final concentration 
in a 100 µL volume. After addition of substrate, fluorescence was immediately read (Ex: 380, Em: 
460nm), taking measurements every 30 seconds for 20 minutes. Active protein was quantified by 
titrating in the known active site protease inhibitor FPR-CMK (Haematologic Technologies). To 
determine the KM the initial fluorescence data, at less than 10% substrate conversion, was fit to a 
linear equation and the slope was determined, V0. V0 was plotted vs substrate concentration and 
the data was fit to the Michaelis Menten equation using GraphPad Prism.  
 
Fluorescence endpoint assays for IC50 determination 
Assays were conducted in 384 well black plates (Costar, 4514) using an Envision plate 
reader, ex. filter 350 nm and em. filter 450 nm. The compounds were first plated (10 µL, at various 
concentrations) followed by addition of TMPRSS2 protein (8 µL, 0.5 nM final concentration). 
After 30 minute incubation (unless otherwise specified) at room temperature, substrate (2 µL, 2.5 
µM final concentration) was added. At 30 minutes, corresponding to less than 20% substrate 
cleavage as measured by comparing fluorescence of the negative control to free AMC (Millipore, 
257370), fluorescence was read. Wells containing no TMPRSS2 protein (substrate only) served as 
positive controls. Wells containing no inhibitors (TMPRSS2 and substrate only) served as negative 
controls.  Fluorescence readout was plotted against the log of inhibitor concentration and fit to 
log(inhibitor) vs response - variable slope equation in GraphPad Prism. Fluorescence endpoint 
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Conclusions and Future Directions 
5.1 Conclusions  
The work presented in this dissertation focuses on selective inhibitor discovery for dynamic 
protein targets. While in the past these targets have been considered “undruggable,” Chapter One 
includes some of the advancements that have led to identification of successful chemical 
modulators, bringing the emergence of general principles for drug/probe discovery for dynamic 
proteins. One such principle is that dynamic proteins often operate through allosteric mechanisms, 
providing opportunities to discovery or develop allosterically active small molecules. For this 
reason, screening methodologies that are geared toward identification of allosteric inhibitors, 
rather than relying on serendipitous identification, would help streamline selective inhibitor 
identification.  
In Chapter Two we set out to target the transcriptional coactivator Med25 with the 
hypothesizes that due to the unique structure of its activator binding domain, only found in one 
other protein to date,1 Med25 AcID could be selectively targeted with a small molecule. In 
addition, known binding partners of Med25 are implicated in various disease related pathways, 
such as viral infection,2,3 the unfolded protein response,4,5 and metastasis,6–8 making it a potentially 
viable therapeutic target. The natural product norstictic acid (NA), was discovered as a potent and 
selective inhibitor of AcID PPIs. Utilizing a combination of mutational analysis, mass 
spectrometry, and inhibitory studies, we discovered that NA covalently modifies lysine residues 
within a dynamic loop, leading to inhibition in a mixed orthosteric/allosteric mode, and concluded 
that this mechanism of action contributes to its unique selectivity. Finally, we showed that NA 
engages with cellular Med25, inhibiting endogenous PPIs as well as decreasing mRNA levels of 
the Med25 regulated gene MMP-2. The demonstration of NA as a selective allosteric inhibitor of 
Med25 function complements the discussion in Chapter 1, suggesting that targeting dynamic 
substructures rather than primary binding surfaces (allostery vs orthostery) affords compounds 
with better selectivity, and this strategy should be generalizable beyond Med25. Additionally, this 
work supports the hypothesis that dynamic substructures are key attributes for molecular 
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recognition in coactivator proteins, complimenting other recent publications coming from the 
Mapp lab.9–12 Our work suggests that Med25 is a potential therapeutic target in metastatic breast 
cancer, justifying the search for drug-like compounds and further exploration of the phenotypic 
effects of Med25 PPI inhibition.  
In Chapter Three, a duplex fluorescence polarization based assay was developed as a 
primary screening method for transcriptional PPI inhibitors. We hypothesized that by looking at 
multiple interactions simultaneously, selective scaffolds could be prioritized immediately in the 
inhibitor discovery process. A pilot screen conducted with AcID-ETV5 and KIX-MLL illustrated 
the utility of this method for rapidly classifying both the potency and selectivity of chemical 
scaffolds for a given target. Additionally, this led to identification of novel inhibitors for both 
interactions, including fumarprotocetraric acid (FPA), which showed facial selectivity for Med25 
PPI inhibition, with more potent inhibition of AcID•ETV5 than AcID•ATF6a. These results 
demonstrate that the duplex FP format is a useful high-throughput screening platform for 
activator•coactivator interactions, allowing selectivity to be assessed during the first step of the 
inhibitor discovery process. This approach should be applicable to any set of coactivators, if there 
is demonstrated specificity of the selected TAD tracers. Further, considering selectivity throughout 
the screening process streamlines discovery of selective small molecule modulators.  
In Chapter Four, we hypothesized that targeting the human serine protease TMPRSS2 would 
be an effective strategy to prevent viral infection. Studies with TMPRSS2 suggest its primary 
function in healthy cells is redundant,13–15 however it aids in the priming of multiple viral coat 
proteins, including SARS-CoV-2, to facilitate receptor binding and cellular entry.16–19 We 
recognized that there was a lack of selective TMPRRS2 probes in the literature and hypothesized 
that we would be able to find inhibitors of protease activity using high-throughput screening. An 
expression and purification method was developed using E. coli and produced active protein for 
use in an optimized biochemical assay. Characterization of the known TMPRSS2 inhibitors 
camostat, nafamostat, and gabexate confirmed the hypothesis presented by us and others20–23 that 
these molecules have such low IC50 values due to their covalent mechanism of action, which occurs 
with multiple other serine proteases.24,25 Multiple curated libraries were screened, including a 
subset of molecules identified from in silico docking method using a homology model of 
TMPRSS2, demonstrating that combing computational and experimental techniques is an effective 
strategy to identify new inhibitors. Further, for dynamic proteins that prove challenge to express 
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and purify in high yields, a similar approach could streamline inhibitor discovery because it 
enables initial triage through large compound libraries before testing a smaller number of 
molecules, requiring less protein than a typical HTS. Ultimately, we identified promising scaffolds 
with good affinity and high ligand efficiencies, providing starting points for development of potent 
and selective antivirals.  
 
5.2 Future Directions 
The conclusions from this dissertation have provided key insights towards chemically targeting 
dynamic proteins and presents them as tractable therapeutic targets. Future efforts will build upon 
these results and methods presented, leading to an improved model of selectivity, frameworks of 
molecular recognition, and a better understanding of the targets presented, specifically Med25 and 
TMPRSS2, in a physiological context. 
A few general considerations will be key for future work. First, the in vitro studies presented 
here were conducted with simplified protein constructs, single domains. As allosteric mechanisms 
are likely significant for selectivity, increasing the complexity of the proteins constructs used in 
these studies, for example, utilizing full length Med25 and multi-domain constructs of TMPRSS2, 
will make the in vitro models more closely resemble the protein in a native context and improve 
inhibitor discovery. Second, continued advancement of the screening approaches presented here 
will help develop enhanced models of selectivity. And finally, utilizing the chemical probes 
identified in this thesis and beyond to better understand how dynamic targets function in a native 
context will enhance future inhibitor discovery efforts.  
 
Targeting Med25 with NA and beyond 
 While NA demonstrated excellent selectivity towards AcID in vitro and the ability to 
engage with Med25 in a cellular context, global selectivity of the molecule remains unknown. To 
better understand the utility of NA as a Med25 probe and the extent of its selectivity, it would be 
beneficial to conduct whole cell proteomics. Since NA is a covalent molecule, this affords a unique 
opportunity where specific signs of protein-NA adduct formation could be identified using 
MS/MS. Proteomics has successfully led to specificity mapping with other covalent inhibitors and 
other bioactive small molecules.26–28 Alternatively, there are other means to profile selectivity such 
as drug affinity responsive target stability (DARTS)29,30 or thermal proteomic profiling (TPP)31,32 
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that do not rely on covalent adduct identification. CETSA could also be used to look at thermal 
stability of hypothetical off targets.33,34 We have already observed that NA is able to modify CBP 
in vitro (both the KIX and TAZ1 domain), thus there is the potential that this could occur in cells 
and a simple experiment would be to look at the effect of NA on endogenous CBP thermal stability. 
Also, analysis of NA’s effect on typical benchmark proteins, such as GAPDH, Tubulin or Actin 
using CETSA could provide insights into the extent of NA selectivity. If NA global selectivity can 
be verified, it would also be beneficial to look at how proteins and total RNA levels are effected 
by NA, that would pinpoint additional gene and protein targets regulated by Med25 AcID. A 
combination of RNAseq analysis and proteomics would allow this information to be gleaned.  
 Ultimately, there is still a lack of knowledge with regards to Med25 biology. For example, 
when analyzing Med25 using Western blot, two potential species are observed: one with a lower 
MW (~70 kDa) which is expected of full length Med25, and one that is a higher MW (~90 kDa). 
When looking at cytoplasmic components vs nuclear extracts, the lower MW form is observed 
primarily in the cytoplasm, whereas the higher MW form is the main form in the nucleus (Figure 
5.1).  
 
Figure 5.1. Western blot comparing Med25 localization in HeLa (H) and VARI068 (V). Two bands 
occur when blotting for Med25, one that appears between the 75 and 100 kDa marker on the ladder and one 
that appears directly below the 75 kDa marker. In both cell lines the higher MW form of Med25 is highly 
abundant in the nucleus, while the lower MW form is almost exclusively in the cytoplasm. 
 
At this point it is unclear if these two proteins are both Med25. However, as a coactivator Med25 
must be located in the nucleus, thus the 92 kDa band likely corresponds to functional Med25. 
Indeed, when Med25 was first identified via a pulldown experiment with the VP16 TAD, it was 
called Arc92 because the observed protein was around 92 kDa.35,36 Thus, there is a discrepancy 
between the posited size of Med25 based on the amino acid sequence and that observed in cellulo. 
I hypothesize that this size difference could indicate a PTM occurs (or multiple PTMs) on Med25, 
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potentially linked to its function as a coactivator. For example, a small ubiquitin like modifier 
(SUMO), typically 12-14kDa, is close to the size of the observed MW difference.37 An online 
SUMOylation predictor, based on protein amino acid sequence, identified multiple sites within 
Med25 of potential modification.38 Interestingly, the two most probable sites are within the AcID 
domain (Figure 5.2). Additionally, the tool PhosphoSite reports multiple potential PTMs within 
Med25 from published proteomic datasets (Figure 5.2).39   
 
Figure 5.2. Potential PTMs within Med25. Online predicting tools identify potential sites of Med25 
modification. Top: SUMOylation predictor shows two sites within AcID that have a high confidence score 
(>5), indicative of a hypothesized sumo modification. Bottom: PhosphoSite reveals the potential for a 
variety of PTMs at multiple sites. Blue dots indicate phosphorylation, orange dots ubiquitination, gray 
methylation, and green acetylation. Of note, K197 ubiquitination is the only PTM with >5 reference datasets 
supporting the modification. K484 ubiquitination has 4.  
 
Ubiquitin, while smaller than SUMO proteins at 8.6 kDa, is often added as a chain 
(polyubiquitination) and thus could account for the change in observed mass.40 Full 
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characterization of Med25 PTMs using proteomics would be extremely beneficial. Not only would 
this potentially solve the issue of the multiple species observed via western blot, this could point 
to novel points of modulation with small molecules. As detailed in Chapter 1, PTMs have been 
identified as critical to stabilize other coactivator protein-protein interactions, and effective small 
molecules have been developed to exploit this mechanism.  
 To date, Med25 has only been studied mechanistically in the context of the AcID domain. 
There are substantial differences between studying a single domain in isolation compared to the 
full-length protein. Future work to express and isolate full length Med25, using either insect cells 
or mammalian cells, will be key to understand if the conclusions made by studying AcID are 
applicable in a biological context. Preliminary data comparing the thermal stability between the 
AcID domain purified from E. coli and endogenous Med25 (see Appendix B for more details) 
have already shown discrepancies. There is a difference in the Tm observed for AcID using 
differential scanning fluorimetry (DSF) (~70°C) compared to full length Med25 using CETSA 
(~65°C). Most surprisingly, ligands binding to the AcID domain lead to a decrease in the Tm 
observed using DSF. This includes NA (Figure 5.3), which using CETSA was shown to stabilize 
Med25 by >10°C.  
 
Figure 5.3. NA leads to dose dependent decrease in AcID thermal stability.  Melting curves (left) and 
the first derivative (change in fluorescence over time) of the melting curves (right) obtained using DSF are 
shown. The maximum change in Tm is observed when concentrations of NA in greater than 3-fold excess 
of AcID protein are used. Largest DTm observed with NA: -5 °C. 
 
Elucidation of chemical scaffolds selective for ABDs 
Chapter 3 presented the first generation of a screening method that enabled rapid identification 
of selective modulators of specific ABD-TAD interactions. At the end of the chapter, this 
workflow was adapted for use with a disordered domain, IBiD, for which there have been no 
inhibitor discovery efforts to date. Thus, we plan to use the duplex method to screen a library of 
Med25 + Norstictic Acid 























compounds available through the center of chemical genomics to identify the first inhibitors of 
IBiD.  
Further, secondary screening elements are being added to this workflow to enable fine-tuned 
profiling of chemical scaffold selectivity. DSF has already been adapted for use with multiple 
coactivator proteins, included AcID and KIX (See Appendix B).  We hypothesize that DSF will 
allow us to distinguish molecular phenotypes that are found to engage ABDs broadly from those 
that are coactivator-specific. We will further expand the DSF approach presented in Appendix B  
into an array format utilizing select fluorescent dye reporters to further differentiate inhibitor 
mechanisms. In addition to SYPRO orange, other dyes used in DSF such as ANS, Nano Orange, 
4-(dicyanovinyl)julolidine (DCVJ), Nile Red, bis-ANS, the rotor dye DASPMI (4-(4-
(dimethylamino)styryl)-N-methylpyridinium iodide , and thiol-reactive dyes such as BODIPY-Fl 
cysteine. will be tested(86, 88)(89).41–44 Dye sensor arrays have been used for chemical 
fingerprinting in a variety of contexts,45–47 with application to PPIs and small-
molecule•intrinsically disordered protein (IDP) interactions representing an innovative direction. 
By analyzing the sensor array perturbations recorded across the high-throughput screening (HTS) 
hits and ABDs from different coactivators in combination with orthogonal binding and structural 
information, future screening work will identify chemotypes that favor particular binding modes 
for each ABD. Ultimately this would enable the development of pharmacophore models for 
selective, pan-selective and non-specific inhibitors of activator-ABD complexes. 
 
Targeting TMPRSS2: profiling mechanism and identifying selective scaffolds 
With expression, purification, and activity assay protocols now developed for TMPRSS2 
peptidase domain, work in the immediate future will be dedicated to continued identification of 
novel inhibitor scaffolds with a particular emphasis on selectivity. From the work presented here, 
we have some natural starting points for novel inhibitor discovery. Since our first efforts in 
inhibitor discovery for TMPRSS2 were focused on molecules that were already in drug 
development pipelines or readily available to us, we will begin by screening the remained of the 
computationally curated libaray (~4000 compounds). This will lead to the identification of novel 
TMPRSS2 inhibitor scaffolds. The preliminary hits from the enamine covalent library will also be 
pursued in secondary screening and evaluated in a time and concentration dependent manner. It 
will be necessary to optimize TMPRSS2 for mass spectrometry, as efforts to date have failed likely 
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due to low concentration of protein as well as high buffer and salt components that lead to ion 
suppression. Lead covalent fragments will provide great starting points for derivatization and 
structure activity relationship (SAR) campaigns. Additionally, debrisoquine was identified as a 
scaffold suitable for elaboration and SAR, with a LE of 0.42. The docking studies with inhibitors 
presented in Chapter 4 using the TMPRSS2 homology model suggest a potential mechanism to 
improve these fragments. Ligand binding at the active site led to structural rearrangement of a non-
catalytic residue, Lys-342, within a proximal dynamic loop. Lys-342 appears to be unique to 
TMPRSS2 and not conserved in other similar serine proteases such as human plasma kallikrein, 
hepsin, and trypsin (Figure 5.4). In fact, the entire loop where this residue resides differs greatly 
in both length and conformation among the four proteases.  Thus, building the fragments presented 
in this chapter to interact with Lys-342 or engage that unique dynamic loop may confer additional 
selectivity for TMPRSS2 across serine proteases.48,49  
 
Figure 5.4. Enhancing potency and selectivity of TMPRSS2 targeting fragments. A) Proposed 
schematic to generate debrisoquine analogs. Starting with 6- and 7-amino-1,2,3,4-tetrahydro-N-Boc-
isoquinoline will enable a route for rapid synthesis. Coupling a carboxylic acid to the isoquinoline, followed 
by guanidinylation will afford a novel scaffold for TMPRSS2 inhibitors. B) Comparison of Lys-342 (circled 
in red) containing loop in TMPRSS2 among similar serine proteases. Structure shown with debrisoquine 
docked. Loops in the superimposed structures are colored to match the protease name listed next to the 
amino acid sequence. 
 
There are also a number of published analogs of the pentamidine and propamadine scaffolds that 
could be further explored for selectivity and potency.50 Further profiling of the identified 
inhibitors, as well as derivative scaffolds, against a panel of representative serine proteases (for 
example: Factor Xa, Matriptase 2, Plasma Kallikrein, Kallikrein 12, Plasmin, Thrombin A, hepsin) 
will be conducted, as the work presented in this dissertation only used trypsin as a point of 
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comparison. This is pivotal, since the inhibitor discovery work flow is currently geared towards 
identification of active site inhibitors, which are classically more promiscuous, and novel selective 
TMPRSS2 inhibitors are desired.  
Another important future direction will be identification of non-active site allosteric 
inhibitors. For this work, a larger construct of TMPRSS2, including the SRCR and peptidase 
domain, will need to be used. Expression protocols in S. cerevisiae have been reported, providing 
a starting point for optimization.51 Additionally, we currently are working with the Center for 
Structural Biology to develop and expression protocol for this construct in insect cells. There is 
evidence that the SRCR domain of TMPRSS2 can influences the activity of the peptidase motif. 
For example, the peptidase is inactive until cleavage occurs at Arg-255 between the two domains 
but the SRCR domain remains associated via a disulfide bond.52,53 Additionally, there are a number 
of TMPRSS2 variants with mutations that exhibit altered peptidase activity (Figure 5.5).54 Seven 
mutations appear to be particularly deleterious for TMPRSS2 function (Val160Met, Gly181Arg, 
Arg240Cys, Gly259Ser, Pro335Leu, Gly432Ala, and Asp435Tyr), three of which are located in 
the SRCR domain (Figure 5.5).54,55 Interrogating the effects of these mutations on TMPRSS2 
enzymatic function will be important to understand if there are potential sites that could be 
exploited for allosteric inhibition with a small molecule. Additionally, development of orthogonal 
screening methods such as thermal stability assays or fluorescence active site labelling and 
quenching56 will facilitate identification of allosteric inhibitors.  
 
Figure 5.5. Common TMPRSS2 variants know to elicit a decrease enzymatic function. Residues in 
magenta affect the peptidase domain via unknown mechanism and would provide excellent starting point 
for mutational analysis. The catalytic triad is highlighted in lime green. 
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The inhibitors presented in this thesis as well as inhibitors emerging from future studies 
will need to be tested in a biological context. Well-established protocols exist for SARS-CoV-2 
pseudotype particle entry assay in Calu-3 cells, thus this would provide a good starting point for 
testing the ability of the molecules to effect viral infectivity.16 Additionally, through a 
collaboration with Dr. Jonathan Sexton and the Center for Drug Repurposing, inhibitors will be 
assessed for anti-SARS-CoV-2 activity.57,58 Other biological experiments will also be conducted 
for evaluation of TMPRSS2 target engagement. Specifically, others have shown it is possible to 
identify different components of TMPRSS2 via Western blot,16,55,59 thus with thermal shift 
experiments using TMPRSS2 expressing cells such as Calu-3, we should be able to determine if 
our inhibitors are stabilizing the active peptidase domain (post-autocleavage), the full-length 
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Characterization of Synthesized Peptides 
 
This appendix contains the analytical HPLC chromatograms of transcriptional activation domain 







































Analytical HPLC UV/Vis trace of FITC-ETV5 (38-68) monitored at 480 nm. 
 
 




























Analytical HPLC UV/Vis trace of FITC-ATF6a (40-66) monitored at 495 nm. 
 
 
Analytical HPLC UV/Vis trace of FITC-HIF1a (786-826) monitored at 495 nm. 
 
Analytical HPLC UV/Vis trace of FITC-ACTR (1041-1088) monitored at 440 nm. 
































Analytical HPLC UV/Vis trace of Ac-IBiD (2063–2111) monitored at 254 nm. 
 
 
Analytical HPLC UV/Vis trace of FITC-Myb (291-316) monitored at 425 nm. Obtained by Dr. 
Stephen Joy  
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Analytical HPLC UV/Vis trace of Ac-Myb(291-396)  monitored at 280 nm. Obtained by Dr. 
Stephen Joy. 
	










Differential Scanning Fluorimetry to Profile Dynamic Coactivators and Their Complexes 
 
This appendix summarizes preliminary data using differential scanning fluorimetry to study 


























Differential scanning fluorimetry (DSF) is a classic technique that allows for the effect of small 
and large molecule ligands on thermal stability of protein targets to be measured. We hypothesize 
that this technique will be uniquely suited to identify allosteric modulators of dynamic protein 
complexes. Towards that end, DSF is used to characterize the effects of ligands, both small 
molecules and peptides, on the thermal stability of coactivator proteins.  
 
B.2 Introduction 
Differential scanning fluorimetry (DSF) is a robust, rapid, and high-content technique that 
measures ligand binding to a protein of interest and the resulting effect on thermal stability.1–3 The 
unfolding of a protein is measured by subjecting the sample to a temperature gradient in the 
presence of a solvatochromic dye, which has affinity to specific parts of the protein that are 
revealed as the protein unfolds (Figure B.1). The most common dyes used in these experiments 
have affinity for hydrophobic parts of the protein, such as bis-ANS or SYPRO orange (Figure 
B.1).4–7 
 
Figure B.1. Use of a reporter dye is a key component of DSF. Left: Overview of dye binding and effects 
on fluorescence as protein unfolding occurs over a temperature gradient. Right: The structure of two 
solvatochromic dyes commonly used in DSF. 
 
These dyes have low fluorescence in an aqueous environment, such as the buffer in which a protein 
sample is stored, and high fluorescence in non-polar environments, such as the hydrophobic sites 
on unfolded proteins. SYPRO orange is most often the dye of choice because, compared to others, 
it has the greatest fluorescence quantum yield in a non-polar environment, meaning only a minimal 
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concentration is needed to elicit a large fluorescent signal.8 This results in a good signal to noise 
ratio for screening. Additionally, SYPRO orange excites near 500 nm, which is far from the 
wavelengths common for small molecules in screening libraries, decreasing the chances that a 
small molecule would interfere with the optical properties of the assay and lead to fluorescence 
quenching.  
The data readout for DSF experiments is temperature-dependent fluorescence intensity. 
Typically, fluorescence intensity is normalized to the maximum value obtained for a sample, 
giving relative fluorescence units (RFU).2 Plotting RFU as a function of temperature generates a 
sigmoidal curve that, for most proteins, can be described by a two-state transition.9,10 The inflection 
point of the curve corresponds to the protein melting temperature (Tm), or the temperature at which 
the concentrations of folded and unfolded protein are equal and the Gibbs free energy of unfolding 
is zero.9 Tm can be calculated from the melting curve by fitting to the Boltzmann equation.2 
Alternatively, the first derivative of RFU vs temperature can be calculated and plotted, and the Tm 
can be identified as the temperature at which the maximum of the first derivative is observed. 
There are also multiple online resources available for analysis of raw DSF data.    
 DSF is an attractive technique to identify and characterize inhibitors, particularly when 
complemented with experiments such as competition fluorescence polarization or FRET. 
Identifying a functional effect from inhibitor binding is important, however IC50 values do not 
provide much mechanistic insight. To determine mechanism, experiments such as NMR or 
stopped-flow kinetics can be utilized. However, due to the low throughput of these methods, 
typically only a few lead molecules are typically profiled. To date, DSF has been successfully 
applied to a wide range of protein targets11–14 including transcription factors.15,16 Others have 
proposed that DSF can be used to obtain more information than just melting temperature, such as 
inhibition constants, thermodynamic paramaters, and even mechanistic information on ligand 
binding.17–19 Thus, DSF has may have the potential for detecting the small conformational 
differences in ABDs in complex with small-molecule or cognate activator binding partners. 
Profiling the changes in thermal stability that occurs upon binding of validated inhibitors and TAD 
ligands will provide insight into properties desirable for future ligand discovery. This may be 
especially relevant considering a potential mechanism of coactivator PPI inhibition is altering the 
distribution of conformational states away from those that can participate in TAD binding.20  
B.3 Results & Discussion 
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Development of DSF method for Med25 AcID and CBP KIX 
To develop a method for screening AcID and KIX, it was first necessary to ensure that the 
Tm could be easily calculated for these proteins. This meant testing that the selected fluorescent 
reporter, SYPRO orange, was effective with these proteins and that the concentration of protein 
used in the assay was optimal for signal to noise. Typical DSF protocols recommend using a 
protein concentration of 75 μg/mL for accurate Tm calculation, so a range of concentrations around 
75 μg/mL were tested for both KIX and Med25. This translates to 7 µM for KIX and 4 µM for 
AcID, so concentrations both higher and lower were tested (Figure B.2). DSF with AcID shows a 
classic melt curve, with low initial fluorescence that eventually increased to a maximum, followed 
by a short decrease at the higher temperatures, indicative of unfolded protein aggregation and/or 
precipitation which prevents dye binding. Notably, there appears to be two separate unfolding 
events occurring, as the melting transition is not smooth. Similar melting is observed  via CD with 
AcID, and is hypothesized to be a result of initial helix fraying at lower temperatures, where  
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Figure B.2. Initial melting temperature calculations for Med25 AcID (A) and CBP KIX (B) using 
DSF. Melting curves are shown as processed from the qPCR (see Methods). Colors of correspond to as 
follows: red = blank, from lowest to highest concentration = yellow, green, turquoise, light blue, dark blue. 
Tm values were calculated by manually determining the temperature at the maximum of the first derivative 
plot provided by the qPCR software.  
 
the beta barrel is still stable, then eventual melting of the entire structure at higher temperatures 
(Figure B.3). The Tm determined for AcID using DSF agrees with the Tm determined using CD, 
70 ± 1 °C compared to 69.3 ± 0.4 °C. Interestingly, the Tm determined for full length Med25 
extracted from HeLa lysates using CETSA was lower, 64.8 ± 0.1 °C (see Chapter 2). This could 
be due to a few different reasons. First, the reporters used in the assays are not the same. CETSA 
utilizes antibody, which binds to a consensus sequence on the protein of interest whereas DSF 
utilizes a dye, which binds to hydrophobic areas. Second, CETSA utilizes endogenous, full length 
Med25, containing other domains in addition to AcID and unstructured interdomain regions and 
possibly PTMs. These additional elements likely change the thermodynamics of unfolding, leading 
to a different observed Tm. For assay development, this data indicates that 4-8 µM AcID would be 
effective for small molecule screening. Because AcID is easy to express and purify in high yields, 
8 µM was selected as the optimal screening concentration. KIX is a protein that gives high initial 
fluorescence in DSF. This trend is observed at all concentrations and even at the highest 
concentration tested, 25 µM, the initial fluorescence is slightly greater than the fluorescence at 
100% unfolded. However, the signal to noise comparing the minimum that occurs at ~ 45 °C to 
the max at ~ 65 °C should be acceptable for small molecule screening at concentrations >15 µM.  
 
Figure B.3. CD thermal melt of Med25 AcID. Data obtained at 214 nm.  
 
Med25 AcID WT


















Because compounds are typically screened in 5 to 10-fold excess, it is beneficial to select a lower 
concentration of protein, thus 15 µM was selected for DSF with KIX. 
 
Analysis of small molecule effects on Med25 AcID thermal stability 
From Chapter 2, it is already known that norstictic acid (NA) engages with and thermally 
stabilized endogenous Med25. Additionally, in unpublished data from Dr. Meg Breen, garcinolic 
acid (GA) has been shown to thermally stabilize endogenous CBP, and from Chapter 3, GA was 
also identified as a Med25 AcID inhibitor. Thus, these two compounds should be great tools for 
initial validation of DSF to look at the effects of inhibitors on coactivator thermal stability. Upon 
incubating AcID with 5X NA or GA in technical triplicate, a decrease in AcID Tm was observed 
(Figure B.4). This was repeated multiple times with the same result, with both compounds leading 
to a change in Tm of -5 °C. 
 
 
Figure B.4. DSF data for Med25 AcID and known ligands Garcinolic acid and Norstictic acid. Data 
was obtained in technical triplicate, and the average fluorescence is shown. Tm was calculated using 
GraphPad Prism. IC50 values are shown from experiments reported elsewhere in this thesis.  
 
Theoretically, “destabilization” upon ligand binding is not possible - the free energy contribution 
of ligand binding results in an increase in the Gibbs free energy of unfolding of a protein. However, 
observed decreases in Tm are sometimes observed using DSF, and thought to be due to ligand 
binding to and stabilization of a less populated state.9 In other words, the ligand preferably binds 
to a state other than the most populated, shifting the ensemble away from the “higher Tm” and 
instead stabilizing a conformer that has a lower Tm.  
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While a similar DTm was observed, each inhibitor leads to a unique change in the shape of 
the melting curve. For example, GA broadens the melt curve whereas NA sharpens the transition 
from folded to unfolded. This can also be seen with the first derivative plot: the value of the 
maximum of the first derivative is higher with NA and lower with GA. While more experimental 
evidence would be needed to confirm, this could reflect the way in which each small molecule 
inhibitor alters the number of accessible AcID conformations. Since the melting curve and Tm are 
representative of an ensemble of protein conformers, a broader melting curve could mean that 
there are more possible states being accessed and less specific interactions, while a sharp transition 
would indicate narrowing down of accessible populations and more specific interactions. 
Alternatively, this could be reflective of the binding mechanisms; NA is covalent whereas GA is 
noncovalent. We know that NA binds, via a specific mechanism mostly at one site on AcID. It is 
possible that GA binds to multiple sites on AcID, leading to an increase in potentially accessible 
substrates and a broader melting transition. However, further experiments would be necessary to 
test this hypothesis. 
The stability of proteins is known to increase with addition of ligand in a dose dependent 
way, indicating that the thermal stability of the protein is proportional to the concentration of the 
ligand. Dosing AcID with concentrations of NA from 1X-5X led to a dose dependent decrease in 
Tm (Figure B.5). Not only did increasing [NA] lead to a more significant change in Tm, it also led 
to a sharper slope in the melting curve (as seen by higher values for the maximum of the first 
derivative). In addition, this experiment shows that maximum stabilizing effects of NA are 
obtained with 3X compound. The melt curves obtained at 3X, 4X, and 5X are identical, suggesting 
that at 3X NA compared to AcID maximum occupancy is obtained. DSF experiments looking at 
titration of ligands with ABDs could be useful in the future for testing compound concentrations 
at which to attempt protein crystallization. 
  
Med25 + Norstictic Acid 























Figure B.5. Concentration dependence of NA on AcID Tm. Data was obtained in technical triplicate, and 
the average fluorescence is shown, with error bars representing the standard deviation of the mean.  
 
While the results showing AcID destabilization via DSF are replicable, since observed Tm 
decreases upon ligand binding are rare, looking at the effects of NA and GA on AcID thermal 
stability using an alternate method was of interest. Inspired by the thermal shift assays conducted 
with NA in Chapter 2, a similar assay was developed utilizing purified AcID rather than nuclear 
extracts. After dosing AcID with NA and subjecting samples to various temperatures, the samples 
could be run on a protein gel and protein visualized via coumassie staining. For both GA and NA, 
a decrease in thermal stability was observed using this method, similar to the decrease observed 
with DSF (Figure B.6). To accurately determine the Tm using this method, an extended  
 
 
Figure B.6. Protein gel based thermal shift assay using purified Med25 AcID and small molecules.  
 
temperature range was tested with NA (Figure B.7). The DTm for AcID with NA was determined 
to be about -6 °C, similar to the DTm calculated using DSF. Two different methods showing NA 
leads to a decrease in thermal stability of AcID validates this result.  
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Figure B.7. Protein gel based thermal shift assay using purified Med25 AcID and NA. The gel images 
shown on the right were analyzed using ImageJ software. Relative band densities were plotted in GraphPad 
Prism and fit to a sigmoidal dose response equation to determine the Tm.   
 
 
Analysis of TAD ligand effects on Med25 AcID thermal stability 
 Profiling of known TADs with DSF could provide additional insights into coactivator 
inhibitor discovery. With two known AcID inhibitors showing a decrease in Tm via DSF, it was 
initially hypothesized that the natural ligands would increase AcID Tm because they bind 
orthosterically. Since ATF6a and ETV5 have defined binding sites on different faces of AcID, 
they were selected as the primary ligands to test. Unexpectedly, both ATF6a and ETV5 binding 
led to an observed decrease in AcID Tm (Figure B.8). Additionally, both ligands led to an increase 
the slope of the melting curve. Notably, ATF6a led to a larger decrease in Tm as well a more 
significant change in the melting curve slope and shape. 
 
   







































Figure B.8. DSF data with Med25 AcID and TAD peptides. Data was obtained in technical triplicate, 
and the average fluorescence is shown. Tm was calculated using GraphPad Prism. KD values were obtained 
from fluorescence polarization experiments. 
 
To confirm the results observed using DSF, the effects of ATF6a and ETV5 on AcID Tm were 
also tested using the previously described gel-based thermal shift assay (Figure B.9). Again, the 
results of the gel-based assay were similar to those observed via DSF: all ligands tested with AcID 
led to a decrease in thermal stability. Here a construct of VP16 that could interact with both binding 
faces simultaneously was also tested, with the hypothesis that engaging both binding faces would 
thermally stabilize AcID. However, this was not the case, and analysis of the gel images using 




Figure B.9. Protein gel based thermal shift assay using purified Med25 AcID and TAD peptides. 
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Analysis of known ligand effects on CBP KIX thermal stability using DSF 
With the unexpected observation that no tested ligands increase thermal stability of AcID, 
it was important to analyze other ABDs to determine if this was unique to AcID or widely 
observed. Analysis of KIX via DSF may provide some additional insights. While AcID has not 
been thoroughly characterized using thermal stability based methods, there is data in the literature 
on the influence of ligands on KIX thermal stability.21 Additionally, allostery and cooperativity in 
the KIX system has been thoroughly studied.22–27 First, a small panel of known ligands were tested 
with KIX using DSF (Figure B.10). A wide variety of DTm values were observed, both positive 
and negative. Incubation with MLL led to an increase in thermal stability, which is not surprising 
given data from the literature suggesting the MLL binding stabilizes KIX structure.22,27 The most 
dramatic increase in thermal stability was observed with the inhibitor MybLLtide, a bivalent 
peptidic inhibitor comprised of the MLL and Myb TADs connected by a PEG linker (created by 
Dr. Stephen Joy). This large increase in thermal stability had previously been observed using CD. 
The remaining ligands tested all led to an observed decrease in thermal stability. Data with agaric 
acid appeared to show the most dramatic change in thermal stability; however there is likely some 
assay interference due to dye binding to the small molecule, as agaric acid is very hydrophobic. A 
control experiment testing a sample containing only agaric acid and SYPRO orange confirmed 
high background fluorescence. The data with KIX and garcinolic acid was also challenging to 
interpret. The melting curve was almost completely flattened, and the first derivative plot shows 
that at no point does the melt curve even have a positive slope. Like GA, Myb has a flattening 





Figure B.10. DSF data with CBP KIX and ligands. Data was obtained in technical triplicate, and the 
average fluorescence is shown. Tm was calculated using GraphPad Prism. KD and IC50 values were obtained 
from fluorescence polarization experiments. 
 
DSF as a tool to analyze KIX ternary systems  
CBP KIX is one of the most well studied ABDs. Further, there is an abundance of 
experimental and computational data published on ligand binding. KIX has two binding sites that 
interact with distinct TADS, and allostery between these two interfaces is well documented, 
particularly with regards to formation of the ternary complexes with transcriptional activators. KIX 
binds both the mixed lineage leukemia (MLL) transcription factor and the proto-oncogene 
transcription factor Myb in a cooperative manner, with ternary complex formation critical for 
hematopoiesis.23,25,26,28 Similar allosteric effects have been observed in KIX with MLL and a 
different activator, the phosphorylated kinase-inducible domain of CREB (pKID).22,29 In these 
ternary systems, initial binding of KIX and MLL leads to enhancement of binding of either Myb 
or pKID at the other KIX site. With DSF, we hypothesize that these effects could be observable as 
changes in the melting transition and Tm between the systems. Thus, the ternary systems of 
Myb•KIX•MLL and pKID•KIX•MLL were analyzed using DSF (Figure B.11). As expected, the 
greatest increase in thermal stability was observed for the ternary complex formation in both 
systems. For the pKID system, a similar Tm increase is observed with either MLL or pKID binding, 
0. 8 ± 0.2 °C and 0.7 ± 0.2 °C respectively. For the ternary complex, the Tm increases by 1.5 ± 0.3  
°C, which happens to be the sum of the two individual melting temperature changes. For this 
experiment Myb binding to KIX led to DTm of 0.3 ± 0.5 °C. Notably with the error incorporated 
this is practically no change. Also, this is in contrast to another experiment conducted with Myb 
(Figure B.10) where Myb led to a negative DTm. Because the melt curve flattens with Myb, there 
is a lot of error associated with the determined Tm. MLL binding to KIX here lead to a DTm of 1.0 
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± 0.2 °C and the ternary complex had a DTm of 1.5 ± 0.3 °C. Again, there appears to be an almost 




Figure B.11. DSF with the apo KIX ternary systems. Data was obtained in technical triplicate, and the 
average fluorescence is shown. Tm values were calculated using DSFworld 
(https://gestwickilab.shinyapps.io/dsfworld/). 
 
Previous studies have found that the mutation KIXI660V “turns on” the allosteric 
communication in the pKID ternary system; that is to say that with the I660V mutant, pKID 
binding is enhanced regardless of whether MLL is pre-bound or not.30 Thus, it was hypothesized 
that for this mutant, a larger increase in thermal stability would be observed in the pKID binary 
complex. In agreement with this hypothesis, the DTm of KIXI660V with pKID increased to 1.6 ± 0.2 
°C, which was the exact same DTm for the ternary system. The DTm of KIXI660V with MLL actually 
decreased slightly from 1.0 ± 0.2 °C in the apo system to 0.6 ± 0.2 °C. So, we observe a similar 
enhancement of stabilization KIX with pKID regardless of if MLL is also bound or not, similar to 
the binding enhancement previously observed using this model.  





















































Figure B.12. DSF with the apo KIX and KIXI660V ternary systems. Data was obtained in technical 




Molecule 1-10 has been shown to bind at the MLL site and allosterically inhibit pKID 
binding at the distal site.21,30 The crystal structure of 1-10 Tethered to KIXL664C has been solved 
and 1-10 has been show to thermally stabilize KIXL664C using CD.21 In line with this data, we 
observe a large increase in KIX thermal stability with 1-10 using DSF (Figure B.13). The Tm of 
the modified complex increases the melting temperature by 2.3 ± 0.4 °C in comparison to the apo 
protein and 3.9 ± 0.3  °C in comparison to KIXL664C. The unfolding transition is sharper with the 
molecule bound, as seen in the plot of first derivative of changing fluorescence by temperature, 
that it is for unbound KIXL664C. The increase in thermal melting temperature as determined by CD 
was ~15°C, much larger than that observed with DSF, further illustrating the variability between 
different techniques.  
   
Figure B.13. DSF with the KIXL664C and small molecule stabilizer 1-10. Data was obtained in technical 
triplicate, and the average fluorescence is shown. Tm’s were calculated using DSFworld 
(https://gestwickilab.shinyapps.io/dsfworld/). 
 



























































One issue with KIX DSF experiments is the high background due to dye binding, the max 
fluorescence is actually at the lowest temperatures. KIX is a flexible three helix bundle and with 
abundant hydrophobic surface area, so this is not surprising. However, this leads to an extremely 
small observed melting transition, and much more error in Tm determination than compared to a 
protein with a traditional melt curve such as AcID. For future work with KIX using DSF it will be 
beneficial to explore alternative dyes, hopefully leading to a lower background and more defined 
melting transitions.   
 
B.4 Conclusions 
DSF is a tool that could be applied for HTS of coactivator proteins. Current observations 
suggest a hypothesis that small molecules that bind and decrease Tm are acting allosterically, 
binding to a conformational state other than the native state/altering the distribution of 
conformational states. Known orthosteric molecules increase Tm, although no molecules have led 
to stabilization of Med25 AcID. Individual molecules can have distinct effects not only on Tm but 
on melting curve shape. Current work analyzing dye dependency on thermal melt curves, as well 
as extracting additional thermodynamic parameters such as DS and DH, and looking for trends 
using principle component analysis (PCA) will make DSF an even more invaluable tool for 
dynamic protein inhibitor profiling in future studies. 
 
B.5 Materials and Methods 
Protein expression and purification 
Med25 AcID and CBP KIX were expressed and purified as described in Chapter 2. 
Plasmids for KIX mutants were obtained from Dr. Jean Lodge and expressed and purified using 
the same method as WT (cite paper). All proteins were tested for purity using SDS-page gel (>95% 
pure) and identity was confirmed using mass spectrometry.  
 
DSF protocol 
 Experiments were conducted utilizing 20 µL sample volumes in 96 well PCR plates sealed 
with clear cap strips. To determine Tm, protein (8 µM AcID; 15 µM KIX – unless otherwise noted) 
in the presence of 5X SYPRO orange dye (1:1000 dilution of purchased 5000X stock; Invitrogen) 
was incubated with ligand (5X for small molecules, or 1X for TAD peptides unless otherwise 
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noted) at RT for 30 minutes. An Applied Biosystems StepOnePlus qPCR instrument was utilized 
to obtain melting curves by exciting at 488 nm and monitoring emission at 602 nm over a 
temperature gradient of 25-95°C with a 1°C/min ramp. Raw fluorescence data was converted to 
relative fluorescence units (RFU) by normalizing each individual melt curve to its maximum 
fluorescence. RFU was imported into the online data analysis program, DSFworld, and Tm was 
calculated by determining the maximum of the first derivative (dRFU). For data visualization, both 
RFU and dRFU are plotted as a function of temperature using GraphPad Prism software. The 
maximum of the first derivative is the reported Tm, with DTm of each ligand calculated as the 
difference between the Tm of the protein and the Tm of the protein + ligand. 
 
Gel-based thermal shift assay  
Norstictic acid (dissolved in DMSO) or an equivalent volume of DMSO was added to 
purified Med25 AcID and samples were incubated at RT for 30 minutes. Final concentration of 
DMSO was 0.1% v/v. After incubation, samples were alliquoted into thin-walled PCR tubes (15 
µl per tube). 
 A Labnet Multigene OPTIMAX PCR was used to heat each sample for 3 minutes at various 
temperatures. Contents were transferred to epitubes and centrifuged at 17000 g for 1 minute at 4°C 
to remove precipitated proteins. Contents of each epitube were carefully transferred to a clean 
epitube, leaving precipitated protein behind. LDS loading dye was added and samples were boiled 
for 5 minutes at 95°C. 10 µL of each sample was loaded onto a 4-20% mini-PROTEAN TGX gel 
(BioRad, 4561096); gel was run at 180V for 45 minutes. To visualize protein, the gel was stained 
with Coumassie quick stain and an image was taken using an Azure Biosystems c600 imager in 
the visible light spectrum. Analysis was conducted using ImageJ software. 
 
Synthesis of transcriptional activation domain peptides 
All peptides were synthesized automatically by Dr. Stephen Joy using a Liberty Blue 
peptide synthesizer on Protide resin from CEM.  Peptides were deprotected and cleaved from the 
resin for 4 hours in 90% trifluoroacetic acid (TFA), 5% thioanisole, 3% ethanedithiol (EDT) and 
2% anisole unless otherwise noted.  Crude peptides were filtered to remove resin, dried under 
nitrogen stream, and precipitated from cold ether.  Peptide suspensions were transferred to a 15 
mL falcon tube, centrifuged at 4000 g for 5 minutes at 4 C, and ether decanted.  Pellets were 
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resuspended in 20% acetonitrile, frozen and lyophilized.  Dry, crude peptides were resuspended 
again in 20% acetonitrile, purified via HPLC on an Agilent 1260 analytical HPLC using a semi-
prep C18 column (Phenomenex) over a 10-50% acetonitrile gradient in 0.1% TFA.  Pure fractions 
were collected and lyophilized to afford pure peptides unless otherwise noted.  Analytical traces 
and mass spectra were obtained using an Agilent 6230 LC/TOF and an Agilent 6545 LC/Q-TOF. 
Myb(291-396) was synthesized and purified as described above with no modifications and isolated 
in >98% purity (Figure S7a).   
Myb sequence: Ac-KEKRIKELELLLMSTENELKGQQALW-NH2.   
Myb calculated mass [M+H]+: 3168.74. Mass observed [M+H]+: 3168.76.   
 MLL(840-858) was synthesized as described above but purification was modified slightly.  
Peptide was purified once on a semi-prep C18 column over a 40 min 10-50% acetonitrile gradient 
in 20 mM ammonium acetate to afford a mix of MLL and partially oxidized versions of MLL 
containing both disulfides and methionine oxide products.  MLL and oxidized MLL could not be 
readily separated, and were instead combined, frozen, and lyophilized.  Dried MLL peptides were 
then resuspended in 20% acetonitrile in 50 mM TRIS (pH = 8.0) and 10 mM dithiothreitol (DTT) 
and agitated at room temperature for 2 hours.  The DTT/peptide solution was purified directly on 
10-50% acetonitrile gradient in 0.1% TFA to afford MLL in 98% purity (Figure S7b).   
MLL sequence: Ac-DCGNILPSDIMDFVLKNTPY-NH2.   
MLL calculated mass [M+H]+: 2296.09. Mass observed [M+H]+: 2296.10.   
 pKID(119-147) was synthesized and purified as described above except deprotection and 
resin cleavage was performed for only 2 hours in 95% TFA, 2.5% water and 2.5% 
triisopropylsilane.  HPLC purification afforded pKID in >90% purity (Figure S7c). 
pKID sequence: Ac-TDSQKRREILSRRPS(Phos)YRKILNDLSSDAPG-NH2.   
pKID calculated mass [M+H]+: 3479.78. Mass observed [M+H]+: 3479.81. 
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Techniques Used for in sillico Study of TMPRSS2 
 
This appendix provides additional detail on the computational methodology utilized in Chapter 4 
to study and screen TMPRSS2. This work was conducted by Yujin Wu and Amanda Peiffer, and 
the details in this appendix were reproduced from Peiffer A.L*, Garlick J.M.*, Wu Y., Soellner 
M.B., Brooks C.L. III, Mapp A.K. TMPRSS2 inhibitor discovery facilitated through an in silico 

































Construction of homology model 
The homology model of TMPRSS2 was generated using SWISS-Model based on the serine 
protease Hepsin (PDB 5CE1), which has 34% similarity and 70% coverage of the TMPRSS2 
sequence. Included in the Hepsin structure is a 100 nM inhibitor, 2-[6-(1-
hydroxycyclohexyl)pyridin-2-yl]-1H-indole-5-carboximidamide, which is bound in the active site. 
The inhibitor is utilized as one of the pharmacophore targets in our fastdock protocol. The SWISS-
MODEL structure of TMPRSS2 was further “conditioned” through the application of molecular 
dynamics in an implicit solvent (GBMV) model to facilitate better packing and configurational 
relaxation.1,2,3 
 
Virtual screening to identify preliminary hits for in vitro assays 
Extensive virtual screening was performed to obtain putative hits for follow-up testing via 
in vitro inhibition assays (Figure 4). Over 100,000 molecules were collected from multiple 
databases, including the ZINC database,4 SWEETLEAD,5 and the Center for Chemical Genomics 
(CCG), which were subjected to a hierarchical refinement of docking poses. In the first stage, rigid 
receptor docking was performed exploring two means of initially positioning the small molecules. 
One utilized pharmacophores based on ligands in other bound serine proteases (see Methods), and 
the other initiated from a random generation of molecular conformations and random positioning 
inside the pocket. The second relied upon a novel 3D pharmacophore fastdock framework, which 
has the potential to perform a preliminary screen of millions of compounds by superposing 
pharmacophores onto compounds bound in experimentally solved structures.  
Level 1 screening candidates were subjected to GPU accelerated Flexible-CDOCKER 
methods that were recently developed as part of the CHARMM molecular modeling package 
cite.6–9 This approach utilizes flexible side chains for residues in or near the binding pocket while 
using a grid representation for the remaining receptor. Multiple copies of each set of side chains 
and initial ligand poses are created, which allows for parallel, multiple copy processing of multiple 
flexible ligands-flexible receptor trials simultaneously on GPUs. The flexible docking searching 
algorithm combines molecular dynamics (MD) based simulated annealing and a continuous 
genetic algorithm search protocol to enhance the sampling of differing receptor conformations.  
A novel scoring methodology was utilized, performing conformational clustering of the 
flexible side chains and the ligand, which provided key contributions to the ligand scoring from 
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the entropic variation of the side chains to accommodate various ligand poses. The ligands were 
rescored in the protein binding site a final time using an implicit solvent model that captures 
aspects of the desolvation costs not generally accessible in typical docking methods.10 The 
rescoring was accomplished by minimizing the docked poses from the flexible side chains and 
flexible ligand in the context of the rigid protein, while also considering the total energy of the 
solvated docked and undocked systems.  
 
General flexible docking setup 
The fastdock protocol is a python-based workflow that integrates the align-it software to 
search across our curated library of compounds for 3D pharmacophore matches to an inhibitor 
from a solved structure.11,12 The fastdock ligand templates are taken from the Hepsin structure used 
in the initial generation of the model (PDB 5CE1) as well as from a plasma kallikrein structure 
with the 1 nM inhibitor N-[(6-amino-2,4-dimethylpyridin-3-yl)methyl]-1-({4-[(1H-pyrazol-1-
yl)methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide bound (PDB 6O1G; 43% sequence 
similarity and 51% sequence coverage). Scoring of the pharmacophore matches is based on a 
volumetric Tanimoto value of the target ligand pharmacophore map and the reference ligand map. 
Based on this initial selection of potential ligands for exploration, we harvested 1-10% of the top 
hits.  
The MMTSB tool set was used to cluster binding poses and prepare pdb files.13 Open Babel 
was used to generate ligand random conformations.14 MOE was used to predict the correct 
protonation state for the ligands at pH 7.4.15 ParamChem was used to prepare the ligand topology 
and parameter files with the CGenFF force field.16–18 Clustering used the tool cluster.pl with a 1 Å 
cutoff radius for the K-means clustering. The CHARMM C36 force fields were used and docking 
was performed in CHARMM with the CHARMM/OpenMM parallel simulated annealing 
feature.9,19  
 
Flexible docking setup 
Flexible CDOCKER with a hybrid searching algorithm combining molecular dynamics 
(MD) based simulated annealing and continuous genetic algorithm was used to dock and rank the 
top hits.6 Flexible CDOCKER uses a physics-based scoring function and allows both ligand and 
protein side chains to explore their conformational space simultaneously. The following amino 
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acid side chains are considered flexible : His 296, Tyr 337, Lys 342, Asp 435, Ser 436, Gln 438, 
Ser 441, Thr 459, Trp 461 and Cys 465. 
Each docking measurement represents 500 genes (docking trials). The coordinates of the 
ligand-protein flexible side chains are used to assemble a gene (potential docking pose). Each 
ligand in the dataset is first aligned to the pharmacophore model with align-it. In the initial 
generation, half of the genes have the ligand starting with the aligned position. The rest of the 
genes are constructed by generating a random conformation of the ligand with Open Babel and 
centering at the binding pocket. A random translation (within a volume with a 2 Å edge length) 
and rotation (maximum 360○) are performed on ligands in each gene. An energy cutoff is applied 
to avoid potential collision between ligand atoms and protein atoms due to the random translation 
and rotation. The protein flexible side chains are initialized with the coordinates from the input 
homology model. Then these genes are optimized by an MD based simulated annealing algorithm. 
Detailed values for softness parameter Emax used in flexible receptor docking are summarized in 
Table C.1.  
 
Table C.1: Soft-core potentials used in flexible receptor docking 
name E*max(vdw) E*max(att) E*max(rep) 
Soft-core potential I 15.0 -120.0 -2.0 
Soft-core potential II 3.0 -20.0 40.0 
Soft-core potential III 10000 -10000 10000 
* Emax(vdw), Emax(att) and Emax(rep) in the unit of kcal/mol are parameters for the Van der Waals, 
electrostatic attractive, and electrostatic repulsive interactions, respectively. 
 
The docking poses (optimized genes) are then K-means clustered based on ligand heavy 
atom RMSD with a radius cutoff of 1 Å. We then select the best individuals (minimum energy 
pose) from the top 10 largest clusters to construct the second generation. In our previous study, we 
show that using two generations is adequate and the average computer time for each docking 
measurement is around 30~45 mins. After the second generation, the docking poses are clustered 
and the best individuals from the top 15 largest clusters are saved. These docking poses are then 
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